inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading document false lly lly lly lly lly lly gaap commonclassamember lly gaap segmentdiscontinuedoperationsmember gaap segmentdiscontinuedoperationsmember gaap segmentcontinuingoperationsmember gaap segmentcontinuingoperationsmember gaap segmentdiscontinuedoperationsmember gaap segmentcontinuingoperationsmember gaap additionalpaidincapitalmember gaap retainedearningsmember gaap additionalpaidincapitalmember gaap accumulatedothercomprehensiveincomemember gaap commonstockmember gaap treasurystockmember gaap trustforbenefitofemployeesmember gaap treasurystockmember gaap accumulatedothercomprehensiveincomemember gaap treasurystockmember gaap retainedearningsmember gaap commonstockmember gaap commonstockmember gaap treasurystockmember gaap retainedearningsmember gaap additionalpaidincapitalmember gaap retainedearningsmember gaap accumulatedothercomprehensiveincomemember gaap commonstockmember gaap retainedearningsmember gaap commonstockmember gaap treasurystockmember gaap commonstockmember gaap noncontrollinginterestmember gaap noncontrollinginterestmember gaap accumulatedothercomprehensiveincomemember gaap accumulatedothercomprehensiveincomemember gaap accumulatedothercomprehensiveincomemember gaap treasurystockmember gaap accumulatedothercomprehensiveincomemember gaap retainedearningsmember gaap noncontrollinginterestmember gaap additionalpaidincapitalmember gaap noncontrollinginterestmember gaap noncontrollinginterestmember gaap commonstockmember gaap retainedearningsmember gaap treasurystockmember gaap noncontrollinginterestmember gaap additionalpaidincapitalmember gaap additionalpaidincapitalmember gaap trustforbenefitofemployeesmember gaap retainedearningsmember gaap noncontrollinginterestmember gaap trustforbenefitofemployeesmember gaap additionalpaidincapitalmember gaap trustforbenefitofemployeesmember gaap accumulatedothercomprehensiveincomemember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly elancoanimalhealthincorporatedmember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly elancoanimalhealthincorporatedmember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly elancoanimalhealthincorporatedmember gaap gaap gaap gaap gaap gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember lly erbituxmember gaap nonusmember lly otherneurosciencemember gaap nonusmember lly trulicitymembermember country lly trulicitymembermember gaap nonusmember lly stratteramember gaap nonusmember lly alimtamember gaap nonusmember lly otherproducttotalmember gaap nonusmember lly otherproductmember gaap nonusmember lly humalogmember country lly olumiantmember country lly otherproducttotalmember country lly olumiantmember country lly cialismember gaap nonusmember country lly immunologymember country lly emgalitymember country lly cyramzamember country lly trajentabimember gaap nonusmember lly endocrinologymember gaap nonusmember lly cymbaltamember gaap nonusmember lly cymbaltamember country lly emgalitymember gaap nonusmember lly emgalitymember gaap nonusmember lly cialismember country lly basaglarmember gaap nonusmember lly otheroncologymember country lly otheroncologymember country lly humulinmember country lly cyramzamember country lly neurosciencemember country lly verzeniomember gaap nonusmember lly olumiantmember gaap nonusmember lly trulicitymembermember country lly endocrinologymember country lly humalogmember gaap nonusmember lly basaglarmember country lly oncologymember country lly immunologymember country gaap nonusmember lly stratteramember gaap nonusmember lly taltzmember gaap nonusmember lly trajentabimember gaap nonusmember lly alimtamember gaap nonusmember lly otherproductmember country lly cymbaltamember country lly neurosciencemember gaap nonusmember lly otheroncologymember gaap nonusmember lly verzeniomember gaap nonusmember lly humulinmember country lly alimtamember country lly jardiancemember country country lly erbituxmember country lly otherendocrinologymember country lly otherendocrinologymember gaap nonusmember lly stratteramember country lly neurosciencemember gaap nonusmember lly basaglarmember country lly otheroncologymember gaap nonusmember country lly jardiancemember gaap nonusmember lly cialismember gaap nonusmember lly otherproductmember country lly alimtamember country lly emgalitymember country lly verzeniomember country lly trajentabimember country lly zyprexamember gaap nonusmember lly forteomember country lly otherendocrinologymember country gaap nonusmember lly forteomember gaap nonusmember lly stratteramember country lly taltzmember country lly otheroncologymember country lly emgalitymember country lly taltzmember country lly otherendocrinologymember gaap nonusmember lly jardiancemember gaap nonusmember lly trulicitymembermember gaap nonusmember lly erbituxmember country lly basaglarmember gaap nonusmember lly neurosciencemember country lly emgalitymember gaap nonusmember lly olumiantmember gaap nonusmember lly otherproductmember country lly otherproducttotalmember gaap nonusmember lly trajentabimember gaap nonusmember lly otherproducttotalmember country lly stratteramember country lly otherendocrinologymember gaap nonusmember lly trulicitymembermember country lly cymbaltamember country lly humalogmember gaap nonusmember lly erbituxmember gaap nonusmember lly alimtamember country lly cyramzamember gaap nonusmember lly verzeniomember country lly immunologymember gaap nonusmember lly endocrinologymember country lly endocrinologymember gaap nonusmember lly immunologymember country lly neurosciencemember gaap nonusmember lly zyprexamember country gaap nonusmember lly otherneurosciencemember country lly forteomember gaap nonusmember lly endocrinologymember country lly trajentabimember country lly olumiantmember country lly cialismember country lly oncologymember gaap nonusmember lly stratteramember gaap nonusmember lly basaglarmember gaap nonusmember lly verzeniomember country lly olumiantmember gaap nonusmember lly jardiancemember country lly verzeniomember gaap nonusmember lly forteomember gaap nonusmember lly trajentabimember country lly oncologymember gaap nonusmember lly erbituxmember country lly zyprexamember gaap nonusmember lly zyprexamember country lly alimtamember gaap nonusmember lly otherneurosciencemember country lly endocrinologymember gaap nonusmember lly otheroncologymember gaap nonusmember lly zyprexamember country lly forteomember country lly erbituxmember gaap nonusmember lly taltzmember country lly basaglarmember country lly jardiancemember country lly cyramzamember gaap nonusmember lly oncologymember gaap nonusmember lly immunologymember gaap nonusmember lly taltzmember gaap nonusmember lly otherproductmember gaap nonusmember lly humalogmember country lly oncologymember country lly cialismember country lly humulinmember gaap nonusmember lly zyprexamember gaap nonusmember lly otherproducttotalmember country lly humalogmember country lly otherproducttotalmember gaap nonusmember lly oncologymember country lly otherendocrinologymember country lly cymbaltamember gaap nonusmember lly humulinmember gaap nonusmember lly humalogmember gaap nonusmember lly otherneurosciencemember gaap nonusmember lly taltzmember gaap nonusmember lly cialismember gaap nonusmember lly humulinmember gaap nonusmember lly immunologymember gaap nonusmember lly cyramzamember gaap nonusmember lly trulicitymembermember gaap nonusmember lly jardiancemember gaap nonusmember lly cyramzamember country lly otherproductmember gaap nonusmember lly neurosciencemember country lly otherneurosciencemember country lly cymbaltamember gaap nonusmember lly humulinmember country lly forteomember country lly otherneurosciencemember gaap nonusmember country jp country jp lly otherforeigncountriesmember lly otherforeigncountriesmember country jp srt europemember lly otherforeigncountriesmember srt europemember srt europemember gaap productmember gaap productmember lly collaborationandotherrevenuemember lly collaborationandotherrevenuemember lly collaborationandotherrevenuemember gaap productmember gaap royaltymember country gaap salesreturnsandallowancesmember lly threelargestwholesalesmember srt maximummember gaap accountsreceivablemember country gaap salesreturnsandallowancesmember gaap royaltymember lly threelargestwholesalesmember srt minimummember gaap salesrevenuenetmember lly threelargestwholesalesmember srt minimummember gaap accountsreceivablemember lly threelargestwholesalesmember srt maximummember gaap salesrevenuenetmember gaap royaltymember srt maximummember gaap accountsreceivablemember srt maximummember gaap salesrevenuenetmember srt minimummember gaap salesrevenuenetmember srt minimummember gaap accountsreceivablemember srt maximummember gaap salesrevenuenetmember srt minimummember gaap salesrevenuenetmember lly loxooncologyinc member lly animabiotechmember lly aurkapharmamember lly sigatechnologiesmember lly nektarsphaseiimmunologicaltherapymember lly immunextinc member lly curevacagmember lly nextcureinc member lly centrexiontherapeuticscorporationmember lly hydrabiosciencesmember lly sigilontherapeuticsmember lly aviditybiosciencesinc member lly dicernapharmaceuticalsmember lly keybiosciencesdualamylincalcitoninreceptoragonistsmember lly chugaipharmaceuticalcompanymember lly colucidpharmaceuticalsmember lly acimmunesamember lly armobiosciencesinc member lly eddingpharmmember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember lly eddingpharmmember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember lly lly loxooncologyinc member lly loxooncologyinc member lly loxooncologyinc member gaap contractbasedintangibleassetsmember lly eddingpharmmember gaap disposalgroupdisposedofbysalenotdiscontinuedoperationsmember lly legacyantibioticmedicinesandamanufacturingfacilityinsuzhouchinamember lly acimmunesamember lly dermirainc member gaap subsequenteventmember lly loxooncologyinc member lly acimmunesamember lly basaglarmember lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativemember lly trajentabimember lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativemember lly jardiancemember lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativemember lly olumiantmember gaap royaltyagreementtermsmember lly olumiantmember lly milestonepaymentssalesbasedmember lly olumiantmember lly researchanddevelopmentexpmember lly tanezumabmember lly milestonepaymentsdevelopmentandregulatorymember lly olumiantmember lly milestonepaymentsdevelopmentandregulatorymember lly tanezumabmember lly milestonepaymentssalesbasedmember lly olumiantmember lly olumiantmember lly olumiantmember lly olumiantmember lly milestonepaymentsdevelopmentandregulatoryexpensedmember lly olumiantmember srt europemember lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredmember lly olumiantmember lly milestonepaymentsdevelopmentandregulatoryexpensedmember lly olumiantmember country jp lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredmember lly olumiantmember country lly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredmember lly basaglarmember lly trajentabimember lly jardiancemember lly jardiancemember lly trajentabimember lly basaglarmember lly jardiancemember lly trajentabimember lly basaglarmember country pr lly outsideunitedstatesmember lly loxooncologyinc member country country country gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap foreignexchangecontractmember gaap netinvestmenthedgingmember gaap interestrateswapmember gaap cashflowhedgingmember gaap netinvestmenthedgingmember gaap crosscurrencyinterestratecontractmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap interestrateswapmember gaap cashflowhedgingmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap netinvestmenthedgingmember gaap foreignexchangecontractmember gaap netinvestmenthedgingmember gaap foreignexchangecontractmember gaap interestrateswapmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap carryingreportedamountfairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap estimateoffairvaluefairvaluedisclosuremember gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap carryingreportedamountfairvaluedisclosuremember gaap commercialpapermember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap estimateoffairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap commercialpapermember gaap carryingreportedamountfairvaluedisclosuremember gaap carryingreportedamountfairvaluedisclosuremember gaap commercialpapermember lly swapswissfrancstou dollarsmember lly buyswissfrancssellusdollarmember gaap interestrateswapmember lly buyusdollarselljapaneseyenmember lly buyusdselleuromember lly buygbpsellusdmember lly buyeurosellusdollarmember gaap interestrateswapmember gaap cashflowhedgingmember gaap designatedashedginginstrumentmember lly foreigncurrencydenominateddebtmember gaap currencyswapmember lly foreigncurrencydenominateddebtmember gaap carryingreportedamountfairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember lly equitymethodandotherinvestmentsmember gaap portionatotherthanfairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember lly marketablesecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap carryingreportedamountfairvaluedisclosuremember lly equitymethodandotherinvestmentsmember gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap portionatotherthanfairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember lly otherequitysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly marketablesecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap mortgagebackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember lly otherequitysecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember lly otherequitysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap corporatedebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap otherdebtsecuritiesmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap assetbackedsecuritiesmember gaap carryingreportedamountfairvaluedisclosuremember lly marketablesecuritiesmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap carryingreportedamountfairvaluedisclosuremember gaap nondesignatedmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap carryingreportedamountfairvaluedisclosuremember gaap nondesignatedmember gaap foreignexchangecontractmember gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap cashflowhedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap carryingreportedamountfairvaluedisclosuremember gaap nondesignatedmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap cashflowhedgingmember gaap carryingreportedamountfairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap foreignexchangecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap cashflowhedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap nondesignatedmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap netinvestmenthedgingmember gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap fairvaluehedgingmember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap designatedashedginginstrumentmember gaap crosscurrencyinterestratecontractmember gaap designatedashedginginstrumentmember gaap foreignexchangecontractmember gaap nondesignatedmember gaap foreignexchangecontractmember gaap nondesignatedmember gaap foreignexchangecontractmember gaap nondesignatedmember lly hedgedfixedratedebtmember gaap designatedashedginginstrumentmember lly hedgedfixedratedebtmember gaap designatedashedginginstrumentmember lly hedgedfixedratedebtmember gaap designatedashedginginstrumentmember srt maximummember gaap otherintangibleassetsmember gaap developedtechnologyrightsmember gaap otherintangibleassetsmember gaap inprocessresearchanddevelopmentmember gaap developedtechnologyrightsmember gaap inprocessresearchanddevelopmentmember srt minimummember srt maximummember gaap equipmentmember srt maximummember gaap buildingmember lly otherforeigncountriesmember country ie lly unitedstatesandpuertoricomember lly otherforeigncountriesmember lly unitedstatesandpuertoricomember country ie srt minimummember gaap buildingmember srt minimummember gaap equipmentmember lly gaap seniornotesmember lly gaap seniornotesmember lly gaap notespayabletobanksmember lly gaap seniornotesmember gaap notespayabletobanksmember lly gaap seniornotesmember lly lly lly gaap seniornotesmember lly gaap seniornotesmember lly gaap notespayabletobanksmember gaap seniornotesmember lly gaap seniornotesmember gaap notespayabletobanksmember gaap notespayabletobanksmember lly gaap seniornotesmember srt maximummember srt minimummember gaap performancesharesmember lly shareholdervalueawardsmember gaap restrictedstockunitsrsumember gaap performancesharesmember gaap restrictedstockunitsrsumember gaap restrictedstockunitsrsumember gaap performancesharesmember lly shareholdervalueawardsmember lly shareholdervalueawardsmember gaap restrictedstockunitsrsumember gaap performancesharesmember lly shareholdervalueawardsmember lly lly lly carryforwardmember lly gaap internalrevenueserviceirsmember lly designatedunusablemember lly lly gaap stateandlocaljurisdictionmember lly designatedunusablemember lly noexpirationmember lly lly gaap foreigncountrymember lly designatedunusablemember lly gaap definedbenefitpostretirementhealthcoveragemember gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsemergingmarketsmember gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesusmember gaap pensionplansdefinedbenefitmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesnonusmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap fixedincomefundsmember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsrepurchasedagreementsmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsemergingmarketsmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap fixedincomefundsmember gaap pensionplansdefinedbenefitmember lly fixedincomefundsrepurchasedagreementsmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap hedgefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap othercontractmember gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesusmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap equityfundsmember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly definebenefitplanothermember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesnonusmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly definebenefitplanothermember gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanrealestatemember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesnonusmember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap hedgefundsmember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap equityfundsmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap gaap pensionplansdefinedbenefitmember gaap pensionplansdefinedbenefitmember gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanrealestatemember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitpostretirementhealthcoveragemember gaap pensionplansdefinedbenefitmember gaap pensionplansdefinedbenefitmember gaap pensionplansdefinedbenefitmember gaap definedbenefitpostretirementhealthcoveragemember gaap pensionplansdefinedbenefitmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitpostretirementhealthcoveragemember gaap contractterminationmember lly gaap fixedincomefundsmember gaap definedbenefitplanequitysecuritiesmember gaap contractterminationmember lly gaap segmentdiscontinuedoperationsmember gaap equityfundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsrepurchasedagreementsmember gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap equityfundsmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsemergingmarketsmember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly definebenefitplanothermember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap hedgefundsmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap equityfundsmember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsrepurchasedagreementsmember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly definebenefitplanothermember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap hedgefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember lly fixedincomefundsemergingmarketsmember gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap pensionplansdefinedbenefitmember lly fixedincomefundsemergingmarketsmember gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap othercontractmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesnonusmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesusmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap pensionplansdefinedbenefitmember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesusmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly definebenefitplanothermember gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap othercontractmember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanequitysecuritiesnonusmember gaap pensionplansdefinedbenefitmember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanrealestatemember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesnonusmember gaap definedbenefitpostretirementhealthcoveragemember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanrealestatemember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap definedbenefitplanrealestatemember gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember gaap fixedincomefundsmember gaap pensionplansdefinedbenefitmember lly fixedincomefundsrepurchasedagreementsmember gaap gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap fixedincomefundsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesusmember gaap gaap pensionplansdefinedbenefitmember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap fixedincomefundsmember gaap definedbenefitpostretirementhealthcoveragemember lly fixedincomefundsemergingmarketsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap fixedincomefundsmember gaap pensionplansdefinedbenefitmember gaap othercontractmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap hedgefundsmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap pensionplansdefinedbenefitmember lly definebenefitplanothermember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember lly fairvalueretirementbenefitsinvestmentsvaluedatnetassetvaluemember gaap pensionplansdefinedbenefitmember gaap hedgefundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap pensionplansdefinedbenefitmember gaap definedbenefitplanrealestatemember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap definedbenefitplanequitysecuritiesnonusmember gaap gaap definedbenefitpostretirementhealthcoveragemember gaap equityfundsmember gaap gaap definedbenefitpostretirementhealthcoveragemember lly japaneseadministrativeproceedingsmember lly emgalitypatentlitigationmember srt scenarioforecastmember lly drreddyslabmember lly employeelitigationmember country br lly emgalitypatentlitigationmember lly emgalitypatentlitigationmember gaap subsequenteventmember lly employeelitigationmember country br lly employeelitigationmember country br lly insulinpricinglitigationandproceedingshouseofrepresentativescommitteeonenergyandcommercemember lly employeelitigationmember country br lly emgalitypatentlitigationmember gaap subsequenteventmember lly drreddyslabmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetgainlossincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember lly accumulatednetgainlossfromcashflowhedgesandforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember lly accumulatednetgainlossfromcashflowhedgesandforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember lly accumulatednetgainlossfromcashflowhedgesandforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetgainlossincludingportionattributabletononcontrollinginterestmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulateddefinedbenefitplansadjustmentnetgainlossincludingportionattributabletononcontrollinginterestmember gaap aociattributabletononcontrollinginterestmember gaap accumulatedothercomprehensiveincomemember gaap aociattributabletononcontrollinginterestmember gaap aociattributabletononcontrollinginterestmember gaap aociattributabletononcontrollinginterestmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap segmentdiscontinuedoperationsmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap segmentcontinuingoperationsmember gaap aociincludingportionattributabletononcontrollinginterestmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap accumulatednetgainlossfromcashflowhedgesincludingportionattributabletononcontrollinginterestmember gaap accumulatedforeigncurrencyadjustmentincludingportionattributabletononcontrollinginterestmember gaap accumulatednetinvestmentgainlossincludingportionattributabletononcontrollinginterestmember gaap accumulateddefinedbenefitplansadjustmentincludingportionattributabletononcontrollinginterestmember lly elancoanimalhealthincorporatedmember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember lly elancoanimalhealthincorporatedmember gaap ipomember lly elancoanimalhealthincorporatedmember lly termfacilitymember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember lly elancoanimalhealthincorporatedmember lly elancoanimalhealthincorporatedmember lly elancoanimalhealthincorporatedmember gaap ipomember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember gaap discontinuedoperationsdisposedofbysalemember lly elancoanimalhealthincorporatedmember lly elancoanimalhealthincorporatedmember lly termfacilitymember lly medicine usd xbrli share xbrli pure xbrli share usd jpy eur gbp chf brl lly case lly request lly patent lly lawsuit lly demand united statessecurities and exchange commissionwashington annual report pursuant to section or of the security exchange act of the fiscal year ended december commission file number lilly and company anindianacorporation employer identification no corporate center indianapolis indiana security registered pursuant to section of the exchange act title of each classtrading symbol name of each exchange on which registeredcommon stock no par value llynew york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangeindicate by check mark if the registrant is well known seasoned issuer defined in rule the security act yes no oindicate by check mark if the registrant is not required to file report pursuant to section or of the exchange act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the exchange act the preceding month and ha been subject to filing requirement for the past day yes no oindicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant required to submit such file yes no oindicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule under the exchange act large accelerated filer accelerated fileronon accelerated filero smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act oindicate by check mark whether the registrant is shell company defined in rule of the act yes no aggregate market value of the common equity held by non affiliate computed by reference to the price at which the common equity wa last sold of the last business day of the registrant recently completed second fiscal quarter common stock approximately number of share of common stock outstanding of february of the registrant proxy statement to be filed on or about march have been incorporated by reference into part iii of this report security registered pursuant to section of the exchange act lilly and companyform kfor the year ended december table of content pagepart item business risk factor unresolved staff comment property legal proceeding mine safety disclosure part ii item market for the registrant common equity related stockholder matter and issuer purchase of equity security selected financial data management discussion and analysis of result of operation and financial condition quantitative and qualitative disclosure about market risk financial statement and supplementary data change in and disagreement with accountant on accounting and financial disclosure control and procedure other information part iii item director executive officer and corporate governance executive compensation security ownership of certain beneficial owner and management and related stockholder matter certain relationship and related transaction and director independence principal accountant fee and service exhibit and financial statement schedule form summary looking statementsthis annual report on form includes forward looking statement within the meaning of section of the security act of section of the security exchange act of exchange act and the private security litigation reform act of forward looking statement include all statement that not relate solely to historical or current fact and can generally be identified by the use of word such may believe will expect project estimate intend anticipate plan continue or similar expression in particular information appearing under business risk factor and management discussion and analysis of result of operation and financial condition includes forward looking statement forward looking statement inherently involve many risk and uncertainty that could cause actual result to differ materially from those projected in these statement in any forward looking statement express an expectation or belief to future result or event it is based on management current plan and expectation expressed in good faith and believed to have reasonable basis however we can give no assurance that any such expectation or belief will result or will be achieved or accomplished the following include but not all of the factor that could cause actual result or event to differ materially from those anticipated uncertainty in the pharmaceutical research and development process including with respect to the timing of anticipated regulatory approval and launch of new product market uptake of recently launched product competitive development affecting current product and pipeline the expiration of intellectual property protection for certain of our product our ability to protect and enforce patent and other intellectual property the impact of action of governmental and private payer affecting pricing of reimbursement for and access to pharmaceutical regulatory compliance problem or government investigation regulatory action regarding currently marketed product unexpected safety or efficacy concern associated with our product issue with product supply stemming from manufacturing difficulty or disruption regulatory change or other development change in patent law or regulation related to data package exclusivity litigation investigation or other similar proceeding involving past current or future product or commercial activity we are largely self insured unauthorized disclosure misappropriation or compromise of trade secret or other confidential data stored in our information system network and facility or those of third party with we share our data change in tax law including the impact of united state tax reform legislation enacted in december and related guidance or event that differ from our assumption related to tax position change in foreign currency exchange rate interest rate and inflation asset impairment and restructuring charge change in accounting and reporting standard promulgated by the financial accounting standard board and the security and exchange commission acquisition and business development transaction and related integration cost information technology system inadequacy or operating failure reliance on third party relationship and outsourcing arrangement and the impact of global macroeconomic condition investor not place undue reliance on forward looking statement you should carefully read the factor described in the risk factor section of this annual report on form for description of certain risk that could among other thing cause our actual result to differ from these forward looking statement forward looking statement speak only of the date of this report and are expressly qualified in entirety by the cautionary statement included in this report except is required by law we expressly disclaim any obligation to publicly release any revision to forward looking statement to reflect event the date of this report iitem businesseli lilly and company the company or registrant or lilly wa incorporated in in indiana to succeed to the drug manufacturing business founded in indianapolis indiana in by colonel eli lilly we discover develop manufacture and market product in single business segment human pharmaceutical product our purpose is to unite caring with discovery to create medicine that make life better for people around the world most of the product we sell today discovered or developed by our scientist and our success depends to great extent on our ability to continue to discover or acquire develop and bring to market innovative new medicine in september elanco animal health incorporated elanco an animal health business previously wholly owned by the company completed an initial public offering of it common stock which trade on the new york stock exchange and in march we completed the disposition of our remaining ownership of elanco common stock for more information on the exchange offer see item management discussion and analysis result of operation executive overview we manufacture and distribute our product through facility in the united state puerto rico and other country our product are sold in approximately country productsour product include diabetes and other endocrinology product including baqsimi glucagon nasal powder formulation for the treatment of severe hypoglycemia in patient with diabetes approved in the and europe in basaglar insulin glargine injection long acting human insulin analog for the treatment of diabetes launched in japan and europe under the trade name abasaglar forteo for the treatment of osteoporosis in postmenopausal woman and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal woman humalog humalog mix humalog humalog humalog mix and insulin lispro insulin analog for the treatment of diabetes humatrope for the treatment of human growth hormone deficiency and certain pediatric growth condition humulin humulin humulin humulin and humulin human insulin of recombinant dna origin for the treatment of diabetes jardiance for the treatment of type diabetes and to reduce the risk of cardiovascular death in adult patient with type diabetes and established cardiovascular disease trajenta for the treatment of type diabetes trulicity for the treatment of type diabetes immunology product including olumiant for the treatment of adult with moderately to severely active rheumatoid arthritis approved in europe and japan in and in the in taltz for the treatment of moderate to severe plaque psoriasis active psoriatic arthritis approved in the in and in europe in and ankylosing spondylitis approved in the in neuroscience product including cymbalta for the treatment of major depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to emgality once monthly subcutaneously injected calcitonin gene related peptide cgrp antibody for migraine prevention approved in the and europe in and the treatment of episodic cluster headache approved in the in reyvow an oral medicine for the acute treatment of migraine launched in the in strattera for the treatment of attention deficit hyperactivity disorder zyprexa for the treatment of schizophrenia acute mixed or manic episode associated with bipolar disorder and bipolar maintenanceoncology product including alimta for the first line treatment in combination with another agent of advanced non small cell lung cancer nsclc for patient with non squamous cell histology for the second line treatment of advanced non squamous nsclc monotherapy for the maintenance treatment of advanced non squamous nsclc in patient whose disease ha not progressed immediately following chemotherapy treatment and in combination with another agent for the treatment of malignant pleural mesothelioma cyramza for use single agent or in combination with another agent second line treatment of advanced or metastatic gastric cancer or gastro esophageal junction adenocarcinoma in combination with another agent second line treatment of metastatic nsclc in combination with another agent second line treatment of metastatic colorectal cancer single agent second line treatment of hepatocellular carcinoma approved in the in and in combination with another agent first line treatment of adult patient with metastatic nsclc with activating epidermal growth factor receptor egfr mutation approved in europe in erbitux indicated both single agent and in combination with another chemotherapy agent for the treatment of certain type of colorectal cancer and single agent in combination with chemotherapy or in combination with radiation therapy for the treatment of certain type of head and neck cancer verzenio for use single agent and in combination with endocrine therapy for the treatment of certain type of metastatic breast cancer approved in the in and in europe and japan in other product including cialis for the treatment of erectile dysfunction and benign prostatic hyperplasiamarketingwe sell most of our product worldwide we adapt our marketing method and product emphasis in various country to meet local customer need in the most of our product are distributed through wholesaler that serve pharmacy physician and other health care professional and hospital in and three wholesale distributor in the mckesson corporation amerisourcebergen corporation and cardinal health inc each accounted for percent and percent of our consolidated total revenue no other distributor accounted for more percent of our consolidated total revenue in any of those year we promote our major product in the through sale representative call upon physician and other health care professional we also promote to healthcare provider in medical journal and on line health care channel distribute literature and sample of certain product to physician and exhibit at medical meeting in addition we advertise certain product directly to consumer in the and we maintain website with information about our major product we supplement our employee sale force with contract sale organization to leverage our own resource we maintain special business group to service wholesaler pharmacy benefit manager managed care organization group purchasing organization government and long term care institution hospital and certain retail pharmacy we enter into arrangement with these organization providing for discount or rebate on our product the outside the we promote our product to healthcare provider primarily through sale representative and on line health care channel the product marketed vary from country to country diabetes and other endocrinology product constitute the largest single group in consolidated revenue distribution pattern vary from country to country in most country in which we operate we maintain our own sale organization but in some smaller country we market our product through independent distributor marketing collaborationscertain of our product are marketed in arrangement with other pharmaceutical company including the following we and boehringer ingelheim have global agreement to develop and commercialize portfolio of diabetes product including trajenta jentadueto jardiance glyxambi synjardy trijardy xr and basaglar for additional information see item financial statement and supplementary data note collaboration and other arrangement competitionour product compete globally with product of many other company in highly competitive market important competitive factor include effectiveness safety and ease of use price and demonstrated cost effectiveness marketing effectiveness and research and development of new product process and us most new product that we introduce must compete with other branded or generic product already on the market or product that are later developed by competitor if competitor introduce new product or delivery system with therapeutic or cost advantage our product can be subject to decreased sale progressive price reduction or both we believe our long term competitive success depends upon discovering and developing either alone or in collaboration with others or acquiring innovative cost effective product that provide improved outcome and deliver value to payer and continuously improving the productivity of our operation in highly competitive environment there can be no assurance that our effort will result in commercially successful product and it is possible that our product will be or become uncompetitive from time to time result of product developed by our competitor generic pharmaceuticalsone of the biggest competitive challenge we face is from generic pharmaceutical in the and europe the regulatory approval process for pharmaceutical other than biological product biologics exempts generic from costly and time consuming clinical trial to demonstrate their safety and efficacy allowing generic manufacturer to rely on the safety and efficacy of the innovator product therefore generic manufacturer generally invest far le than we do in research and development and can price their product much lower than our branded product accordingly when branded non biologic pharmaceutical loses it market exclusivity it normally face intense price competition from generic form of the product public and private payer typically encourage the use of generic alternative to brand name drug in their healthcare program law in the generally allow and in many case require pharmacist to substitute generic drug that have been rated under government procedure to be essentially equivalent to brand name drug where substitution is mandatory it must be made unless the prescribing physician expressly forbids it in many country outside the intellectual property protection is weak and we must compete with generic or counterfeit version of our product biosimilarsseveral of our current product including cyramza emgality erbitux taltz and trulicity and many of the new molecular entity nmes in our research pipeline are biologics competition for lilly biologics may be affected by the approval of follow on biologics also known biosimilars biosimilar is subsequent version of an approved innovator biologic that due to it functional and structural similarity to the innovator biologic is approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic globally most government have developed regulatory pathway to approve biosimilars alternative to innovator developed biologics but the patent and regulatory exclusivity for the existing innovator biologic must expire in given market biosimilars may enter that market the extent to which biosimilar once approved will be substituted for the innovator biologic in way that is similar to traditional generic substitution for biologic product is not yet entirely clear and will depend on number of regulatory and marketplace factor that are still developing biosimilars may present both competitive challenge and opportunity for example competitor company ha developed version of insulin lispro which competes with our product humalog on the other hand with our partner boehringer ingelheim we developed basaglar new insulin glargine product which ha the amino acid sequence product currently marketed by competitor and ha launched follow on biologic in the and biosimilar in europe and japan in march the regulatory status of all of our insulin product will transition to become regulated biologics rather than drug based on recent food and drug administration fda draft guidance this change may lower the requirement for competitor biosimilar product to enter the market some of which could be designated interchangeable and therefore substituted for our insulin product at pharmacy private sector dynamicsin the private sector consolidation and integration among healthcare provider is also major factor in the competitive marketplace for pharmaceutical health plan and pharmacy benefit manager have been consolidating into fewer larger entity thus enhancing their purchasing strength and importance for example in cv health large pharmacy benefit manager and pharmacy chain acquired aetna large national insurer and cigna corporation acquired express script in similar transaction more recently in december express script signed three year partnership agreement with another pharmacy benefit manager prime therapeutic payer typically maintain formulary which specify coverage the condition under which drug are included on plan formulary and reimbursement the associated of pocket cost to the consumer formulary placement can lead to reduced usage of drug for the relevant patient population due to coverage restriction such prior authorization and formulary exclusion or due to reimbursement limitation which result in higher consumer out of pocket cost such non preferred co pay tier increased co insurance level and higher deductible consequently pharmaceutical company compete for formulary placement not only on the basis of product attribute such efficacy safety profile or patient ease of use but also by providing rebate value based agreement where pricing is based on achievement or not of specified outcome are another tool which may be utilized between payer and pharmaceutical company formulary placement and pricing are negotiated price is an increasingly important factor in formulary decision particularly in treatment area in which the payer ha taken the position that multiple branded product are therapeutically comparable these downward pricing pressure are expected to continue to negatively affect our future consolidated result of operation patent trademark and other intellectual property rightsoverviewintellectual property protection is critical to our ability to successfully commercialize our life science innovation and invest in the search for new medicine we own have applied for or are licensed under large number of patent in the and many other country relating to product product us formulation and manufacturing process in addition discussed below for some product we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory law the patent protection anticipated to be of most relevance to pharmaceutical is provided by national patent claiming the active ingredient the compound patent particularly those in major market such the various european country and japan these patent may be issued based upon the filing of international patent application usually filed under the patent cooperation treaty pct patent application covering compound are generally filed during the discovery phase of the drug discovery process which is described in the research and development section below in general national patent in each relevant country are available for period of year from the filing date of the pct application which is often year prior to the launch of commercial product further patent term adjustment and restoration may extend the original patent term patent term adjustment is statutory right available to all patent applicant to provide relief in the event that patent grant is delayed during examination by the united state patent and trademark office uspto patent term restoration is statutory right provided to patent holder that claim invention subject to review by the fda to make for portion of the time invested in clinical trial and the fda review single patent for pharmaceutical product may be eligible for patent term restoration patent term restoration is limited by formula and can not be calculated product approval due to uncertainty about the duration of clinical trial and the time it take the fda to review an application there is five year cap on any restoration and no patent expiration date may be extended beyond year from fda approval some country outside the also offer form of patent term restoration for example supplementary protection certificate are available to extend the life of european patent up to an additional five year subject to year cap from european medicine agency ema approval similarly in japan south korea and australia patent term can be extended up to five year depending on the length of regulatory review and other factor loss of effective patent protection for pharmaceutical especially for non biologic product typically result in the loss of effective market exclusivity for the product which often result in severe and rapid decline in revenue for the product however in some case the innovator company may be protected from approval of generic biosimilar or other follow on version of new medicine beyond the expiration of the compound patent through manufacturing trade secret later expiring patent on manufacturing process method of use or formulation or data protection that may be available under pharmaceutical regulatory law change to the law and regulation governing these protection could result in earlier loss of effective market exclusivity the primary form of data protection are follows regulatory authority in major market generally grant data package protection for period of year following new drug approval in recognition of the substantial investment required to complete clinical trial data package protection prohibits other manufacturer from submitting regulatory application for marketing approval based on the innovator company regulatory submission data for the drug the base period of data package protection depends on the country for example the period is generally five year in the year for new biologics described below effectively year in europe and eight year in japan the period begin on the date of product approval and run concurrently with the patent term for any relevant patent under the biologics price competition and innovation act of the bpci act the fda ha the authority to approve biosimilars competitor seeking approval of biosimilar must file an application to show it molecule is highly similar to an approved innovator biologic and include certain amount of safety and efficacy data that the fda will consider on case by case basis under the data protection provision of this law the fda can not approve biosimilar application until year after initial marketing approval of the innovator biologic subject to certain condition the bpci act is part of the affordable care act the constitutionality of which is currently litigated in the the fda ha the authority to grant additional data protection for approved drug where the sponsor conduct specified testing in pediatric or adolescent population within specified time period if granted this pediatric exclusivity provides an additional six month of exclusivity which is added to the term of data protection well to the term of any relevant patent to the extent these protection have not already expired while the term of the pediatric exclusivity attache to the term of any relevant patent pediatric exclusivity is regulatory exclusivity bar to generic approval not patent right under the orphan drug law specific use of drug or biologic can receive orphan designation if it is intended to treat disease or condition affecting fewer than people in the or affecting more than people but not reasonably expected to recover it development and marketing cost through sale among other benefit orphan designation entitles the particular use of the drug to seven year of market exclusivity meaning that the fda can not with limited exception approve another marketing application for the same drug for the same indication until expiration of the seven year period unlike pediatric exclusivity the orphan exclusivity period is independent of and run in parallel with any applicable patent outside the major market the adequacy and effectiveness of intellectual property protection for pharmaceutical varies widely and in number of these market we are unable to patent our product or to enforce the patent we receive for our product under the trade related aspect of intellectual property agreement trip administered by the world trade organization more than country have agreed to provide non discriminatory protection for most pharmaceutical invention and to assure that adequate and effective right are available to patent owner certain developing country limit protection for biopharmaceutical product under their interpretation of flexibility allowed under the agreement thus some type of patent such those on new us of compound or new form of molecule are not available in certain developing country further many developing country and some developed country do not provide effective data package protection even though it is specified in trip intellectual property portfoliowe consider intellectual property protection for certain product process us and formulation particularly with respect to those product discussed below to be important to our operation in addition to the data protection and patent identified below we may hold patent on manufacturing process formulation device or us that extend exclusivity beyond the date shown below the most relevant patent protection or data protection and associated expiry date for our top selling or recently launched patent protected marketed product are follows alimta is protected by vitamin regimen patent plus pediatric exclusivity may baqsimi is protected by data protection july cyramza is protected by compound patent and biologics data protection emgality is protected by compound patent jardiance and the related combination product glyxambi and synjardy are protected by compound patent not including possible patent extension olumiant is protected by compound patent not including possible patent extension reyvow is protected by compound patent not including possible patent extension taltz is protected by compound patent not including possible patent extension and by biologics data protection trajenta and jentadueto are protected by compound patent not including possible patent extension trulicity is protected by compound patent verzenio is protected by compound patent not including possible patent extension outside the important patent protection or data protection includes alimta is protected by vitamin regimen patent in major european country june and by patent covering use to treat cancer concomitantly with vitamin in japan june cyramza is protected by compound patent in major european country and japan emgality in is protected by compound patent in major european country and japan not including possible patent extension olumiant is protected by compound patent in major european country not including possible patent extension and japan taltz is protected by compound patent in major european country and japan trulicity is protected by compound in major european country and japan verzenio is protected by compound in major european country and japan baqsimi ha been submitted for regulatory review in japan where it is expected to be protected by data protection upon approval year flortaucipir ha been submitted for regulatory review in the for use positron emission tomography pet imaging agent and is protected by compound patent not including possible patent extension selpercatinib ha been submitted for regulatory review in the for the treatment of cancer in certain patient and is protected by compound patent not including possible patent extension tanezumab ha been submitted for regulatory review in the for the treatment of osteoarthritis pain and is expected to be protected by data protection upon approval year worldwide we sell all of our major product under trademark for name and unique product appearance the appearance of our trulicity autoinjector which we consider in the aggregate to be important to our operation trademark protection varies throughout the world with protection continuing in some country long the mark is used and in other country long it is registered registration are normally for fixed but renewable term trademark protection often extends beyond the patent and data protection for product licensesmost of our major product are not subject to significant license agreement for information on our license and collaboration agreement with incyte corporation related to olumiant see item financial statement and supplementary data note collaboration patent challenge in the the drug price competition and patent term restoration act of commonly known the hatch waxman act authorizes the fda to approve generic version of innovative pharmaceutical other than biologics when the generic manufacturer ha not conducted safety and efficacy study but file an abbreviated new drug application anda in an anda the generic manufacturer must demonstrate only bioequivalence between the generic version and the new drug application nda approved drug not safety and efficacy establishing bioequivalence is generally straightforward and inexpensive for the generic company absent patent challenge the fda can not approve an anda until after certain of the innovator patent expire however after the innovator ha marketed it product for four year generic manufacturer may file an anda alleging that one or more or all of the patent listed in the innovator nda are invalid or not infringed this allegation is commonly known paragraph iv certification if the innovator responds by filing suit the generic manufacturer the fda is prohibited from approving the generic company application for month period which can be shortened or extended by the trial court judge hearing the patent challenge if one or more of the nda listed patent are challenged the first filer of paragraph iv certification may be entitled to day period of market exclusivity over all other generic manufacturer generic manufacturer use paragraph iv certification extensively to challenge patent on innovative pharmaceutical in addition generic company have shown willingness to launch at risk after receiving anda approval but before final resolution of their patent challenge we are currently in hatch waxman litigation involving alimta with five generic manufacturer for more information on hatch waxman litigation involving the company see item financial statement and supplementary data note contingency and item legal proceeding under the bpci act the fda can not approve biosimilar application until data protection expires year after initial marketing approval of the innovator biologic however the bpci act doe provide mechanism for competitor to challenge the validity of an innovator patent early four year after initial marketing approval of the innovator biologic the patent litigation scheme under the bpci act is complex and court have held that biosimilar applicant are not required to engage in it patent holder still have the right to bring suit under normal patent law procedure if biosimilar applicant attempt to commercialize product prior to patent expiration in addition there is procedure in patent law known inter partes review ipr which allows any member of the public to file petition with the uspto seeking the review of any issued patent for validity iprs are conducted before administrative patent judge in the uspto using lower standard of proof than used in federal district court in addition the challenged patent are not accorded the presumption of validity they are in federal district court generic drug company and even some investment firm have engaged in the ipr process in attempt to invalidate our patent outside the the legal doctrine and process by which pharmaceutical patent can be challenged vary widely in recent year we have experienced an increase in patent challenge from generic manufacturer in many country outside the for more information on administrative challenge and litigation involving our alimta patent in europe and japan see item financial statement and supplementary data note contingency government regulation of our operationsour operation are regulated extensively by numerous national state and local agency the lengthy process of laboratory and clinical testing data analysis manufacturing development and regulatory review necessary for governmental approval is extremely costly and can significantly delay product introduction promotion marketing manufacturing and distribution of pharmaceutical product are extensively regulated in all major market we conduct extensive post marketing surveillance of the safety of the product we sell in addition our operation are subject to complex federal state local and foreign law and regulation concerning the environment occupational health and safety and privacy compliance with the law and regulation affecting the manufacture and sale of current product and the discovery development and introduction of new product will continue to require substantial effort expense and capital investment particular importance to our business is the fda in the pursuant to the federal food drug and cosmetic act the fda ha jurisdiction over all of our product and device in the and administers requirement covering the testing safety effectiveness manufacturing quality control distribution labeling marketing advertising dissemination of information and post marketing surveillance of those product the fda extensively regulates all aspect of manufacturing quality for pharmaceutical under it current good manufacturing practice cgmp regulation outside the our product and operation are subject to similar regulatory requirement notably by the ema in europe and the ministry of health labor and welfare in japan specific regulatory requirement vary from country to country we make substantial investment of capital and operating expense to implement comprehensive company wide quality system in our manufacturing product development and process development operation in an effort to ensure sustained compliance with cgmp and similar regulation however in the event we fail to adhere to these requirement in the future we could be subject to interruption in production fine and penalty and delay in new product approval certain of our product are manufactured by third party and their failure to comply with these regulation could adversely affect through failure to supply product to or delay in new product approval the marketing promotional and pricing practice of pharmaceutical manufacturer well the manner in which manufacturer interact with purchaser prescribers and patient are subject to various other federal and state law including the federal anti kickback statute and the false claim act and state law governing kickback false claim unfair trade practice and consumer protection these law are administered by among others the department of justice doj the office of inspector general of the department of health and human service the federal trade commission the office of personnel management and state attorney general over the past several year state and federal government have increased their oversight enforcement activity and intra agency coordination with respect to pharmaceutical company several claim brought by these agency against and other company under these and other law have resulted in corporate criminal sanction and substantial civil settlement the foreign corrupt practice act of fcpa prohibits certain individual and entity including publicly traded company from promising offering or giving anything of value to foreign official with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage the fcpa also imposes specific recordkeeping and internal control requirement on publicly traded company noted outside the our business is heavily regulated and therefore involves significant interaction with foreign official additionally in many country outside the the health care provider who prescribe pharmaceutical are employed by the government and the purchaser of pharmaceutical are government entity therefore our interaction with these prescribers and purchaser are subject to regulation under the fcpa in addition to the application and enforcement of the fcpa the various jurisdiction in which we operate and supply our product have law and regulation aimed at preventing and penalizing corrupt and anticompetitive behavior in recent year several jurisdiction including china brazil and the united kingdom have enhanced their law and regulation in this area increased their enforcement activity and or increased the level of cross border coordination and information sharing we are and could in the future become subject to administrative and legal proceeding and action which could include claim for civil penalty including treble damage under the false claim act criminal sanction and administrative remedy including exclusion from federal and other health care program it is possible that an adverse outcome in future action could have material adverse impact on our consolidated result of operation liquidity and financial position regulation and private payer action affecting pharmaceutical pricing reimbursement and access in the we are required to provide rebate to the federal government and respective state government on their purchase of our pharmaceutical under state medicaid and medicaid managed care program minimum of percent plus adjustment for price increase over time and rebate to private payer who cover patient in certain type of health care facility that serve low income and uninsured patient known facility no rebate are required at this time in the medicare part physician and hospital outpatient program where reimbursement is set on an average selling price plus percent formula additionally an annual fee is imposed on pharmaceutical manufacturer and importer that sell branded prescription drug to specified government program since the bipartisan budget act ha required manufacturer of brand name drug biologics and biosimilars to provide discount of percent of the cost of branded prescription drug for medicare part participant who are in the doughnut hole the coverage gap in medicare prescription drug coverage up from the previous percent discount are also negotiated in the private sector we give rebate to private payer who provide prescription drug benefit to senior covered by medicare and to private payer who provide prescription drug benefit to their customer these rebate are affected by the introduction of competitive product and generic in the same class in the white house signed into law targeted amendment to the medicaid drug rebate program statute well the fair and accurate medicaid pricing act which wa part of the continuing appropriation act we do not believe either will have material impact to our business several state have passed importation legislation including colorado florida maine and vermont specifically the state of florida is working with the administration to implement an importation program from canada early we are currently reviewing the state legislation well corresponding proposed federal rulemaking and guidance recently published by the department of health and human service and the fda the impact of which is uncertain at this time in most international market we operate in an environment of government mandated cost containment program which may include price control international reference pricing to other country price discount and rebate therapeutic reference pricing to other often generic pharmaceutical choice restriction on physician prescription level and mandatory generic substitution globally public and private payer are increasingly restricting access to pharmaceutical based on assessment of comparative effectiveness and value including through the establishment of formal health technology assessment process in addition third party organization including professional association academic institution and non profit entity associated with payer are conducting and publishing comparative effectiveness and cost benefit analysis on medicine the impact of which are uncertain at this time we can not predict the extent to which our business may be affected by these or other potential future legislative regulatory or payer development however in general we expect that state federal and international legislative and regulatory development could have further negative effect on pricing and reimbursement for our product research and developmentour commitment to research and development date back more than year we invest heavily in research and development we believe it is critical to our long term competitiveness at the end of we employed approximately people in pharmaceutical research and development activity including substantial number of physician scientist holding graduate or postgraduate degree and highly skilled technical personnel our internal pharmaceutical research focus primarily on the area of oncology diabetes neurodegeneration immunology and pain we believe that we have strong biotechnology research program with more than half of our clinical stage pipeline currently consisting of biologics in addition to discovering and developing nmes we seek to expand the value of existing product through new us formulation and therapeutic approach that provide additional value to patient to supplement our internal effort we collaborate with others including academic institution and research based pharmaceutical and biotechnology company we use the service of physician hospital medical school and other research organization worldwide to conduct clinical trial to establish the safety and effectiveness of our pharmaceutical product we actively invest in external research and technology that we believe complement and strengthen our own effort these investment can take many form including licensing arrangement co development and co marketing agreement co promotion arrangement joint venture and acquisition development is time consuming expensive and risky on average only one out of many thousand of molecule discovered by researcher ultimately becomes an approved medicine the process from discovery to regulatory approval can take over decade drug candidate can fail at any stage of the process and even late stage drug candidate sometimes fail to receive regulatory approval or achieve commercial success the rate of innovation cycle leading to medical improvement over initial invention is accelerating which ha increased the risk that we opt not to develop late stage asset or that new product fail to achieve commercial success due to technical obsolescence displacement by follow on competitor product before the period of exclusivity ha ended after approval and launch of product we expend considerable resource on post marketing surveillance and additional clinical study to collect data and understand the benefit and potential risk of medicine they are used therapeutic consistent with their purpose these study have the potential to identify information about problem with product safety or efficacy that result in product withdrawal the following describes in more detail the research and development process for pharmaceutical product phase of new drug development discovery phasethe earliest phase of new drug research and development the discovery phase can take many year scientist identify design and synthesize promising molecule screening ten of thousand of molecule for their effect on biological target that appear to play an important role in one or more disease target can be part of the body such protein receptor or gene or foreign such virus or bacteria some target have been proven to affect disease process but often the target is unproven and may later prove to be irrelevant to the disease or to yield insufficient clinical benefit molecule that have the desired effect on the target and meet other design criterion become candidate molecule and move to the next phase of development the probability of any one candidate molecule becoming commercial product is extremely low early development phasethe early development phase involves refining candidate molecule understanding to manufacture them efficiently and completing initial testing for safety and efficacy safety testing is done first in laboratory test and animal necessary to identify toxicity and other potential safety issue that would preclude use in human in general the first human test often referred to phase are conducted in small group of healthy volunteer or patient to ass safety and find the potential dosing range after safe dose range ha been established the drug is typically administered to small population of patient phase ii to look for initial sign of efficacy in treating the targeted disease or biomarkers of the disease and to continue to ass safety in parallel scientist work to identify safe effective and economical manufacturing process long term animal study continue to test for potential safety issue of the molecule that enter the early development phase approximately percent move on to the product phase the early development phase can take several year to complete product phaseproduct phase phase iii molecule have met initial safety requirement and typically shown initial evidence of efficacy result these molecule generally have higher likelihood of success the molecule are tested in much larger patient population to demonstrate efficacy to predetermined level of statistical significance and to continue to develop the safety profile these trial are generally global in nature and are designed to generate the data necessary to submit the molecule to regulatory agency for marketing approval the potential new drug is generally compared with existing competitive therapy placebo or both the resulting data is compiled and may be submitted to regulatory agency around the world phase iii testing varies by disease state but can often last from three to four year submission phaseonce molecule is submitted to regulatory agency the time to final marketing approval can vary from several month to several year depending on variable such the disease state the strength and complexity of the data presented the novelty of the target or compound and the time required for the agency to evaluate the submission there is no guarantee that potential medicine will receive marketing approval or that decision on marketing approval or indication will be consistent across geographic area believe our investment in research both internally and in collaboration with others have been rewarded by the large number of new molecule and new indication for existing molecule that we have in all stage of development we currently have approximately drug candidate across all stage of human testing and larger number of project in preclinical development among our new investigational molecule currently in the product phase of development or awaiting regulatory approval or launch are potential therapy for various cancer alzheimer disease pain migraine cluster headache diabetes obesity and autoimmune disease including alopecia areata systemic lupus erythematosus psoriasis atopic dermatitis crohn disease and ulcerative colitis we are studying many other drug candidate in the earlier stage of development in our chosen priority area we are also developing new us formulation or delivery method for many of these molecule well several currently marketed product see item management discussion and analysis result of operation executive overview late stage pipeline for more information on certain of our product candidate raw material and product supplymost of the principal material we use in our manufacturing operation are available from more than one source however we obtain certain raw or intermediate material primarily from only one source we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply could be implemented in the event one of these supplier wa unable to provide the material or product however in the event of an extended failure of supplier it is possible that we could experience an interruption in supply until we established new source or in some case implemented alternative process the majority of our revenue come from product produced in our own facility our principal active ingredient manufacturing occurs at site we own in the ireland and puerto rico finishing operation including formulation filling assembling delivery device manufacturing and packaging take place at number of site throughout the world we utilize third party for certain active ingredient manufacturing and finishing operation we manage our supply chain including our own facility contracted arrangement and inventory in way that is intended to allow to meet all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to change in supply and demand to maintain stable supply of our product we use variety of technique including comprehensive quality system inventory management and back up site however pharmaceutical production process are complex highly regulated and vary widely from product to product shifting or adding manufacturing capacity can be very lengthy process requiring significant capital expenditure process modification and regulatory approval accordingly if we were to experience unplanned plant shutdown at one of our own facility significant failure of contract supplier or significant unanticipated increase in demand we could experience an interruption in supply of certain product or product shortage until production could be resumed or expanded quality assuranceour success depends in great measure upon customer confidence in the quality of our product and in the integrity of the data that support their safety and effectiveness product quality arises from total commitment to quality in all part of our operation including research and development purchasing facility planning manufacturing distribution and dissemination of information about our medicine quality of production process involves strict control of ingredient equipment facility manufacturing method packaging material and labeling we perform test at various stage of production process and on the final product in an effort to assure that the product meet all regulatory requirement and lilly internal standard these test may involve chemical and physical chemical analysis microbiological testing testing in animal or combination thereof additional assurance of quality is provided by corporate quality assurance group that audit and monitor all aspect of quality related to pharmaceutical manufacturing procedure and system in company operation and at third party supplier executive officer of the companythe following table set forth certain information regarding our executive officer except otherwise noted all executive officer have been employed by the company in management or executive position during the last five year the term of office for each executive officer expires on the date of the annual meeting of the board of director to be held on may in connection with the company annual shareholder meeting or on the date or successor is chosen and qualified no director or executive officer ha family relationship with any other director or executive officer of the company that term is defined for purpose of this disclosure requirement there is no understanding between any executive officer or director and any other person pursuant to which the executive officer wa selected nameageoffices and business experiencedavid chief executive officer director since january and board chair since june melissa vice president enterprise risk management and chief ethic and compliance officer since january stephen vice president human resource and diversity since february anat vice president and general counsel since february prior to joining lilly hakim wa executive vice president general counsel and secretary of wellcare health plan managed care company prior to joining wellcare served divisional vice president and associate general counsel at abbott laboratory health care company patrik vice president and president lilly bio medicine since september michael mason vice president and president lilly diabetes since january johna vice president global quality since april myles vice president and president manufacturing operation since january leigh ann vice president corporate affair and communication since june prior to joining lilly pusey served president and ceo of the american insurance association aarti shah ph vice president and chief information and digital officer since january daniel skovronsky ph vice president chief scientific officer and president lilly research laboratory since june joshua vice president and chief financial officer since january anne vice president and president lilly oncology since september alfonso vice president and president lilly international since january employeesat the end of we employed approximately people including approximately employee outside the substantial number of our employee have long record of continuous service information available on our websiteour company website is http www lilly com none of the information accessible on or through our website is incorporated into this form we make available through the website free of charge our company filing with the security and exchange commission sec soon reasonably practicable after we electronically file them with or furnish them to the sec these include our annual report on form quarterly report on form current report on form proxy statement registration statement and any amendment to those document the company website link to our sec filing is http investor lilly com financial information sec filing in addition the corporate governance portion of our website includes our corporate governance guideline board and committee information including committee charter and our article of incorporation and bylaw the link to our corporate governance information is http www lilly com about corporate governance page corporate governance aspx we will provide paper copy of our sec filing free of charge upon request to the company secretary at the address listed on the front of this form risk factorsin addition to the other information contained in this form the following risk factor should be considered carefully in evaluating our company it is possible that our business financial condition liquidity cash flow or result of operation could be materially adversely affected by any of these risk certain of these risk could also adversely affect the company reputation pharmaceutical research and development is very costly and highly uncertain we may not succeed in developing or acquiring commercially successful product sufficient in number or value to replace revenue of product that have lost or will soon lose intellectual property protection or are displaced by competing product or therapy there are many difficulty and uncertainty inherent in pharmaceutical research and development and the introduction of new product there is high rate of failure inherent in new drug discovery and development to bring drug from the discovery phase to market can take over decade and often cost in excess of billion failure can occur at any point in the process including in later stage after substantial investment result most fund invested in research program will not generate financial return new product candidate that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concern inability to obtain or maintain necessary regulatory approval or payer reimbursement or coverage limited scope of approved us change in the relevant treatment standard or the availability of new or better competitive product difficulty or excessive cost to manufacture or infringement of the patent or intellectual property right of others regulatory agency continue to establish increasingly high hurdle for the efficacy and safety of new product delay and uncertainty in drug approval process can result in delay in product launch and lost market opportunity in addition it can be very difficult to predict revenue growth rate of new product we can not state with certainty when or whether our product under development will be approved or launched whether if initially granted such approval will be maintained whether we will be able to develop license or otherwise acquire additional product candidate or product or whether our product once launched will be commercially successful we must maintain continuous flow of successful new product and successful new indication or brand extension for existing product sufficient both to cover our substantial research and development cost and to replace revenue that are lost profitable product lose intellectual property exclusivity or are displaced by competing product or therapy failure to do in the short term or long term would have material adverse effect on our business result of operation cash flow and financial position see item management discussion and analysis result of operation executive overview late stage pipeline for more detail we depend on product with intellectual property protection for most of our revenue cash flow and earnings we have lost or will lose effective intellectual property protection for many of those product in the next several year which ha resulted and is likely to continue to result in rapid and severe decline in revenue number of our top selling product have recently lost or will lose in the next several year significant patent protection and or data protection in the well key country outside the illustrated in the table below productu revenue in million percent of worldwide revenue patent data protection alimta vitamin regimen patent plus pediatric exclusivity will expire in may formulation and related process patent expired in december and use patent expired in august outside in million percent of worldwide revenue patent data protection major europe japanalimta major european country vitamin regimen patent will expire in june use patent to treat cancer concomitantly with vitamin will expire in june japan data package protection expired in july formulation and use patent expired in august japan data package protection expired in january certain other significant product no longer have effective exclusivity through patent protection or data protection for non biologic product loss of exclusivity whether by expiration of legal right or by termination thereof consequence of litigation typically result in the entry of one or more generic competitor leading to rapid and severe decline in revenue especially in the historically outside the the market penetration of generic following loss of exclusivity ha not been rapid or pervasive in the however generic market penetration is increasing in many market outside the including japan europe and many country in the emerging market for biologics such humalog humulin erbitux cyramza trulicity taltz and emgality loss of exclusivity may or may not result in the near term entry of competitor version biosimilars due to many factor including development timeline manufacturing challenge and or uncertainty in the regulatory pathway for approval of the competitor version there is no assurance that the patent we are seeking will be granted or that the patent we hold will be found valid and enforceable if challenged moreover patent relating to particular product us formulation or process do not preclude other manufacturer from employing alternative process or marketing alternative product or formulation that compete with our patented product in addition competitor or other third party may assert claim that our activity infringe patent or other intellectual property right held by them or allege third party right of ownership in our existing intellectual property see item management discussion and analysis result of operation executive overview other matter patent matter and item business patent trademark and other intellectual property right for more detail our long term success depends on intellectual property protection if our intellectual property right are invalidated circumvented or weakened our business will be adversely affected our long term success depends on our ability to continually discover or acquire develop and commercialize innovative new pharmaceutical product without strong intellectual property protection we would be unable to generate the return necessary to support the enormous investment in research and development and capital well other expenditure required to bring new drug to the market intellectual property protection varies throughout the world and is subject to change over time depending on local law and regulation change to such law and regulation could reduce protection for our innovative product in the in addition to the process for challenging patent set forth in the bpci act which applies to our biologic product the hatch waxman act provides generic company powerful incentive to seek to invalidate our other pharmaceutical patent result we expect that our patent on major pharmaceutical product will continue to be routinely challenged in litigation and may not be upheld in addition separate ipr process allows competitor to request review of issued patent by the uspto without the protection of the hatch waxman act our patent may be invalidated via this review process although such decision can be appealed to the court in certain circumstance loss in such proceeding could result in competitor entering the market while win provides no precedential value the same patent can still be challenged by other competitor we face many generic manufacturer challenge to our patent outside the well the entry of generic competitor typically result in rapid and severe decline in revenue in addition competitor or other third party may claim that our activity infringe patent or other intellectual property right held by them if successful such claim could result in our being unable to market product in particular territory or being required to pay significant damage for past infringement or royalty on future sale see item business patent trademark and other intellectual property right item legal proceeding and item financial statement and supplementary data note contingency for more detail our business is subject to increasing government price control and other public and private restriction on pricing reimbursement and access for our drug which could have material adverse effect on our reputation or business public and private payer are taking increasingly aggressive step to control their expenditure for pharmaceutical by placing restriction on pricing and reimbursement for and patient access to our medication these pressure could continue to negatively affect our future revenue and net income we expect pricing reimbursement and access pressure from both government and private payer inside and outside the to become more severe for more detail see item business regulation and private payer action affecting pharmaceutical pricing reimbursement and access and item management discussion and analysis result of operation executive overview other matter trend affecting pharmaceutical pricing reimbursement and access we face intense competition from multinational pharmaceutical company biotechnology company and lower cost generic and biosimilar manufacturer and such competition could have material adverse effect on our business we compete with large number of multinational pharmaceutical company biotechnology company and generic pharmaceutical company to compete successfully we must continue to deliver to the market innovative cost effective product that meet important medical need our product revenue can be adversely affected by the introduction by competitor of branded product that are perceived superior by the marketplace by generic or biosimilar version of our branded product and by generic or biosimilar version of other product in the same therapeutic class our branded product regulation of generic and biosimilar product varies around the world particularly for biosimilars change to such regulation could make it easier le expensive and le time consuming for competitor product to enter the market some of which could be substituted for our product at the pharmacy our revenue can also be adversely affected by treatment innovation that eliminate or minimize the need for treatment with our drug see item business competition and business research and development for more detail change in foreign currency rate or devaluation of foreign currency can materially affect our revenue cost of sale and operating expense global company with substantial operation outside the we face foreign currency risk exposure from fluctuating currency exchange rate while we seek to manage portion of these exposure through hedging and other risk management technique significant fluctuation in currency rate can have material impact either positive or negative on our revenue cost of sale and operating expense in the event of an extreme devaluation of local currency the price of our product could become unsustainable in the relevant market see item management discussion and analysis financial condition for more detail unanticipated change in our tax rate or exposure to additional tax liability could increase our income tax and decrease our net income we are subject to income tax in the and numerous foreign jurisdiction and in the course of our business we make judgment about the expected tax treatment of various transaction and event including the separation of elanco change in the relevant tax law regulation administrative practice principle and interpretation well event that differ from our expectation could adversely affect our future effective tax rate the enacted tax reform legislation significantly revising the tax law effective january and number of other country are actively considering or enacting tax change modification to key element of the or international tax framework could have material adverse effect on our consolidated operating result and cash flow see item management discussion and analysis result of operation executive overview other matter tax matter and item financial statement and supplementary data note income tax for more detail lilly ha taken the position on the separation from elanco based on an opinion of tax counsel that the divestiture of elanco common stock qualifies transaction that is tax free for federal income tax purpose if any fact assumption representation and undertaking from lilly and elanco regarding the past and future conduct of their respective business and other matter are incorrect or not otherwise satisfied the divestiture may not qualify for tax free treatment which could result in significant federal income tax liability for both lilly and it shareholder who exchanged their stock for elanco stock failure inadequacy or breach of our information technology system infrastructure and business information or violation of data protection law could result in material harm to our business and reputation great deal of confidential information owned by both and our business partner is stored in our information system network and facility or those of third party this includes valuable trade secret and intellectual property clinical trial information corporate strategic plan marketing plan customer information and personally identifiable information such employee and patient information collectively confidential information we also rely to large extent on the efficient and uninterrupted operation of complex information technology system infrastructure and hardware together it system some of which are within the company control and some of which are within the control of third party to accumulate process store and transmit large amount of confidential information and other data we are subject to variety of continuously evolving and developing law and regulation around the world related to privacy data protection and data security maintaining the confidentiality integrity and availability of our it system and confidential information is vital to our business it system are vulnerable to system inadequacy operating failure service interruption or failure security breach malicious intrusion or cyber attack from variety of source cyber attack are growing in their frequency sophistication and intensity and are becoming increasingly difficult to detect mitigate or prevent cyber attack come in many form including the deployment of harmful malware exploitation of vulnerability denial of service attack the use of social engineering and other mean to compromise the confidentiality integrity and availability of our it system confidential information and other data breach resulting in the compromise disruption degradation manipulation loss theft destruction or unauthorized disclosure or use of confidential information or the unauthorized access to disruption of or interference with our product and service can occur in variety of way including but not limited to negligent or wrongful conduct by employee or others with permitted access to our system and information or wrongful conduct by hacker competitor certain government or other current or former company personnel our third party partner face similar risk the failure or inadequacy of our it system the compromise disruption degradation manipulation loss theft destruction or unauthorized disclosure or use of confidential information or the unauthorized access to disruption of or interference with our product and service that rely on it system could impair our ability to secure and maintain intellectual property right result in product manufacturing interruption or failure or in the interruption or failure of product or service that rely on it system damage our operation customer relationship or reputation and cause to lose trade secret or other competitive advantage unauthorized disclosure of personally identifiable information could expose to significant sanction for violation of data privacy law and regulation around the world and could damage public trust in our company to date system inadequacy operating failure unauthorized access service interruption or failure security breach malicious intrusion cyber attack and the compromise disruption degradation manipulation loss theft destruction or unauthorized disclosure or use of confidential information have not material impact on our consolidated result of operation we maintain cyber liability insurance however this insurance may not be sufficient to cover the financial legal business or reputational loss that may result from an interruption or breach of our it system we continue to implement measure in an effort to protect detect respond to and minimize or prevent these risk and to enhance the resiliency of our it system however these measure may not be successful if they are not successful any of these event could result in material financial legal business or reputational harm to our business significant economic downturn or international trade disruption or dispute could adversely affect our business and operating result while pharmaceutical have not generally been sensitive to overall economic cycle prolonged economic slowdown could lead to decreased utilization of our product affecting our sale volume declining tax revenue attributable to economic downturn increase the pressure on government to reduce health care spending leading to increasing government effort to control drug price and utilization additionally some customer including government or other entity reliant upon government funding may be unable to pay in timely manner for our product also if our customer supplier or collaboration partner experience financial difficulty we could experience slower customer collection greater bad debt expense and performance default by supplier or collaboration partner similarly in the event of significant economic downturn we could have difficulty accessing credit market significant portion of our business are conducted in europe including the asia and other international geography trade dispute and interruption in international relationship including pandemic disease such the coronavirus could result in change to regulation governing our product and our intellectual property or otherwise affect our ability to do business while we do not expect either circumstance to materially affect our business in direct manner these and similar event could adversely affect or our business partner or customer pharmaceutical product can develop unexpected safety or efficacy concern which could have material adverse effect on revenue income and reputation pharmaceutical product receive regulatory approval based on data obtained in controlled clinical trial of limited duration after approval the product are used for longer period of time by much larger number of patient we and others including regulatory agency and private payer collect extensive information on the efficacy and safety of our marketed product by continuously monitoring the use of our product in the marketplace in addition we or others may conduct post marketing clinical study on efficacy and safety of our marketed product new safety or efficacy data from both market surveillance and post marketing clinical study may result in product label change or other measure that could reduce the product market acceptance and result in declining sale serious safety or efficacy issue that arise after product approval could result in voluntary or mandatory product recall or withdrawal from the market safety issue could also result in costly product liability claim we face litigation and investigation related to our product and our pricing practice and are self insured we could face large number of claim in the future which could adversely affect our business we are subject to substantial number of product liability claim involving actos axiron byetta cialis and cymbalta among other product well litigation and investigation related to the pricing of our product see item financial statement and supplementary data note contingency and item legal proceeding for more information on our current product liability litigation well pricing litigation investigation and inquiry because of the nature of pharmaceutical product we are and could in the future become subject to large number of product liability claim for these or other product or to further litigation or investigation into pricing or other commercial practice such matter require substantial expenditure to resolve and if involving marketed product could adversely affect sale of the product due to very restrictive market for liability insurance we are self insured for product liability loss for all our currently marketed product well for litigation or investigation related to our pricing practice or other similar matter regulatory compliance problem could be damaging to the company the marketing promotional and pricing practice of pharmaceutical manufacturer well the manner in which manufacturer interact with purchaser prescribers and patient are subject to extensive regulation many company including have been subject to claim related to these practice asserted by federal state and foreign governmental authority private payer and consumer these claim have resulted in substantial expense and other significant consequence to we are and could in the future become subject to such investigation the outcome of which could include criminal charge and fine penalty or other monetary or non monetary remedy including exclusion from federal and other health care program in addition regulatory issue concerning compliance with cgmp regulation and comparable foreign regulation for our product can lead to product recall and seizure fine and penalty interruption of production leading to product shortage and delay in the approval of new product pending resolution of the issue see item business government regulation of our operation for more detail manufacturing difficulty or disruption could lead to product supply problem pharmaceutical manufacturing is complex and highly regulated manufacturing difficulty at our facility or contracted facility or the failure or refusal of contract manufacturer to supply contracted quantity could result in product shortage leading to lost revenue such difficulty or disruption could result from quality or regulatory compliance problem natural disaster or pandemic disease mechanical or information technology system vulnerability such system inadequacy operating failure service interruption or failure security breach malicious intrusion or cyber attack from variety of source or inability to obtain sole source raw or intermediate material in addition given the difficulty in predicting sale of new product and the very long lead time necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity it is possible that we could have difficulty meeting unanticipated demand for new product see item business raw material and product supply for more detail reliance on third party relationship and outsourcing arrangement could adversely affect our business we rely on third party including supplier distributor alliance with other pharmaceutical and biotechnology company and third party service provider for selected aspect of product development manufacture commercialization support for information technology system product distribution and certain financial transactional process for example we outsource the day to day management and oversight of our clinical trial to contract research organization outsourcing these function involves the risk that the third party may not perform to our standard or legal requirement may not produce reliable result may not perform in timely manner may not maintain the confidentiality integrity and availability of our confidential and proprietary information may experience disruption or fail to perform due to information technology system vulnerability breach or cyber attack or may fail to perform at all failure of these third party to meet their contractual regulatory confidentiality privacy security or other obligation to could have material adverse effect on our business item unresolved staff commentsnone propertiesour principal domestic and international executive office are located in indianapolis at december we owned production and distribution site in the and puerto rico together with the corporate administrative office these facility contain an aggregate of approximately million square foot of floor area dedicated to production distribution and administration major production site include indianapolis indiana carolina puerto rico and branchburg new jersey we own production and distribution site in country outside the and puerto rico containing an aggregate of approximately million square foot of floor area major production site include facility in ireland france spain italy and china in the our research and development facility contain an aggregate of approximately million square foot of floor area primarily consisting of owned facility located in indianapolis we also lease smaller site in san diego california and new york city new york outside the we own smaller research and development facility in the and spain and lease smaller site in singapore we believe that none of our property is subject to any encumbrance easement or other restriction that would detract materially from it value or impair it use in the operation of the business the building we own are of varying age and in good condition item legal proceedingswe are party to various currently pending legal action government investigation and environmental proceeding and we anticipate that such action could be brought against in the future the most significant of these matter are described below or noted in item financial statement and supplementary data note contingency while it is not possible to determine the outcome of the legal action investigation and proceeding brought against we believe that except otherwise specifically noted in item financial statement and supplementary data note contingency the resolution of all such matter will not have material adverse effect on our consolidated financial position or liquidity but could be material to our consolidated result of operation in any one reporting period legal proceeding described in note to the consolidated financial statementssee item financial statement and supplementary data note contingency for information on various legal proceeding including but not limited to the patent litigation and administrative proceeding involving alimta jardiance taltz and emgality the product liability litigation involving cymbalta the litigation related to the cosmopolis facility in brazil and pricing litigation investigation and inquiry that information is incorporated into this item by reference other product liability litigationwe are named along with takeda chemical industry ltd and takeda affiliate collectively takeda defendant in four purported product liability class action in canada related to actos which we commercialized with takeda in canada until including one in ontario casseres et al takeda pharmaceutical north america inc et al one in quebec whyte et al eli lilly et al one in saskatchewan weiler takeda canada inc et al and one in alberta epp takeda canada inc et al in general plaintiff in these action alleged that actos caused or contributed to their bladder cancer we believe these lawsuit are without merit and we and takeda are defending against them vigorously we are named defendant in approximately byetta product liability lawsuit in the involving approximately plaintiff approximately of these lawsuit covering about plaintiff are filed in california state court and coordinated in los angeles superior court approximately of the lawsuit covering about plaintiff are filed in federal court the majority of which are coordinated in multi district litigation mdl in the district court for the southern district of california three lawsuit representing approximately four plaintiff have also been filed in various state court approximately of the lawsuit approximately plaintiff contain allegation that byetta caused or contributed to the plaintiff cancer primarily pancreatic cancer or thyroid cancer most others allege byetta caused or contributed to pancreatitis in addition two suit involving approximately nine plaintiff allege that byetta caused or contributed to renal injury and one case alleges that byetta caused or contributed to ampullary cancer the federal and state trial court granted summary judgment in favor of and our co defendant on the claim alleging pancreatic cancer the plaintiff appealed those ruling in november the court of appeal for the ninth circuit reversed the district court grant of summary judgment based on that court discovery ruling and remanded the case for further proceeding in november the california court of appeal reversed the state court grant of summary judgment based on that court discovery ruling and remanded for further proceeding we are aware of approximately additional claimant who have not yet filed suit these additional claim allege damage for pancreatic cancer or thyroid cancer we believe these lawsuit are without merit and are defending against them vigorously we are named defendant in approximately axiron personal injury product liability lawsuit in the involving approximately plaintiff in some of the case other manufacturer of testosterone are named co defendant all of these lawsuit have been consolidated in federal mdl in the district court for the northern district of illinois the case generally allege cardiovascular and related injury we have reached agreement on settlement framework that provides for comprehensive resolution of all of these personal injury claim alleging cardiovascular and related injury from axiron treatment we have also been engaged in litigation with medical mutual of ohio mmo which filed class action complaint against multiple manufacturer of testosterone product including lilly in the district court for the northern district of illinois on behalf of third party payer who paid for those product and is seeking damage under the federal racketeer influenced and corrupt organization act mmo motion for class certification wa denied and in february the district court granted summary judgment in favor of defendant dismissing mmo lawsuit with prejudice in november the court of appeal for the seventh circuit affirmed the district court ruling concluding this case we are named defendant in approximately cialis product liability lawsuit in the these case many of which were originally filed in various federal court contain allegation that cialis caused or contributed to the plaintiff cancer melanoma in december the judicial panel on multidistrict litigation jpml granted the plaintiff petition to have filed case and an unspecified number of future case coordinated into federal mdl in the district court for the northern district of california alongside an existing coordinated proceeding involving viagra the jpml ordered the transfer of the existing case to the now renamed multidistrict litigation in viagra sildenafil citrate and cialis tadalafil product liability litigation we believe these lawsuit are without merit and are defending against them vigorously other patent litigationin canada several generic company previously challenged the validity of our zyprexa compound patent in the canadian federal court of appeal denied appeal of the lower court decision that certain patent claim were invalid for lack of utility in our petition for leave to appeal the decision to the supreme court of canada wa denied apotex inc and apotex pharmachem inc collectively apotex pursued claim for damage arising from our enforcement of the patent under canadian regulation apotex claim seek compensation based on novel legal theory under the statute of monopoly trade mark act and common law we believe these claim are without merit and are defending against them vigorously trial is scheduled to begin in april other matterswe are named defendant in litigation filed by research corporation technology inc rct in the district court for the district of arizona rct is seeking damage for breach of contract unjust enrichment and conversion related to process used to manufacture certain product including humalog and humulin trial date ha not been set we believe this lawsuit is without merit and are defending against it vigorously we are named defendant in lawsuit in the district court for the eastern district of texas seeking damage under the federal anti kickback statute and state and federal false claim act for certain patient support program related to our product humalog humulin and forteo in september the district court granted the doj motion to dismiss the relator second amended complaint in january the relator appealed the district court dismissal to the court of appeal for the fifth circuit we believe this lawsuit is without merit and are defending against it vigorously competition authority in china ha investigated our distributor pricing practice in china in connection with broader inquiry into pharmaceutical industry pricing we have cooperated with this investigation we along with another pharmaceutical manufacturer are named co defendant in united state et al ex rel streck takeda pharm inc et al which wa unsealed in the district court for the northern district of illinois the complaint alleges that the defendant should have treated certain credit from distributor retroactive price increase and included such increase in calculating average manufacturer price we believe these claim are without merit and are defending against them vigorously under the comprehensive environmental response compensation and liability act commonly known superfund we have been designated one of several potentially responsible party with respect to the cleanup of fewer than site under superfund each responsible party may be jointly and severally liable for the entire amount of the cleanup we are also defendant in other litigation and investigation including product liability patent employment and premise liability litigation of character we regard normal to our business item mine safety disclosuresnot applicable iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity securitiesyou can find information relating to the principal market for our common stock and related stockholder matter at item selected financial data unaudited item management discussion and analysis of result of operation and financial condition and item financial statement and supplementary data note selected quarterly data unaudited that information is incorporated by reference the following table summarizes the activity related to repurchase of our equity security during the fourth quarter ended december periodtotal number ofshares purchased in thousand average price paidper sharetotal number of sharespurchased part ofpublicly announcedplans or program in thousand approximate dollar valueof share that may yet bepurchased under theplans or program dollar in million october during the three month ended december we repurchased million of share under the billion share repurchase program authorized in june graphthis graph compare the return on lilly stock with that of the standard poor stock index and our peer group for the year through the graph assumes that on december person invested each in lilly stock the stock index and the peer group collective common stock the graph measure total shareholder return which take into account both stock price and dividend it assumes that dividend paid by company are reinvested in that company stock value of invested on last business day of comparison of five year cumulative total return among lilly stock index peer group and peer group previous lilly peer group peer group previous we constructed the peer group the industry index for this graph it is comprised of the following company in the pharmaceutical and biotech industry abbvie inc allergan plc amgen inc astrazeneca plc biogen inc bristol myers squibb company gilead science inc glaxosmithkline plc johnson johnson merck co inc novartis ag novo nordisk pfizer inc roche holding ag sanofi and takeda pharmaceutical company limited the peer group used for performance benchmarking aligns with the peer group used for executive compensation purpose for other than our peer group for performance benchmarking excludes celgene corporation and shire plc they were acquired in our previous peer group is the same the peer group except that allergan plc novo nordisk and takeda pharmaceutical company limited were added to and baxter international inc and medtronic plc were removed from the peer group our peer group previous excludes celgene corporation and shire plc they were acquired in the peer group previous total shareholder return is not presented in the graph above the graph substantially overlapped the peer group total shareholder return selected financial data unaudited eli lilly and company and subsidiary dollar in million except revenue per employee and per share data revenue of and selling and before income tax income loss from continuing income loss loss per share from continuing operation loss per share diluted declared per average number of share outstanding diluted thousand financial position total asset term supplementary data return on total equity return on asset revenue per employee of of shareholder of on march we completed the disposition of our remaining percent ownership of elanco animal health elanco common stock through tax free exchange offer result elanco ha been presented discontinued operation in our consolidated financial statement for all period presented see note to the consolidated financial statement for discussion regarding discontinued operation other includes acquired in process research and development asset impairment restructuring and other special charge and other net income expense see note to the consolidated financial statement for discussion regarding in process research and development charge see note to the consolidated financial statement for discussion regarding asset impairment restructuring and other special charge see note to the consolidated financial statement for discussion regarding income tax the increase wa primarily driven by gain of approximately billion related to the disposition of elanco the increase in earnings loss per share and return on equity were also driven by the reduction of common stock related to the disposition of elanco see note to the consolidated financial statement for discussion regarding discontinued operation management discussion and analysis of result of operation and financial conditionresults of operation table present dollar in million except per share data generalmanagement discussion and analysis of result of operation and financial condition is intended to assist the reader in understanding and assessing significant change and trend related to the result of operation and financial position of our consolidated company this discussion and analysis should be read in conjunction with the consolidated financial statement and accompanying footnote in item of part ii of this annual report on form certain statement in this item of part ii of this annual report on form constitute forward looking statement various risk and uncertainty including those discussed in forward looking statement and item risk factor may cause our actual result financial position and cash generated from operation to differ materially from these forward looking statement executive overviewthis section provides an overview of our financial result recent product and late stage pipeline development and other matter affecting our company and the pharmaceutical industry earnings per share eps data are presented on diluted basis on march we completed the disposition of our remaining percent ownership of elanco animal health incorporated elanco common stock through tax free exchange offer result we recognized gain on the disposition of approximately billion in the first quarter of and now operate single segment see note to the consolidated financial statement for further discussion financial resultsthe following table summarizes our key operating result year endeddecember percent change revenue margin percent of operating expense in process research and asset impairment restructuring and other special nmincome before income income from continuing nmeps from continuing nmnm not meaningfulrevenue increased in driven by increased volume partially offset by lower realized price and the unfavorable impact of foreign exchange rate operating expense increased in reflecting higher late stage development expense and increased marketing expense for recently launched product partially offset by lower marketing expense for late life cycle product the increase in net income and eps in were driven primarily by the gain recognized on the disposition of elanco and to lesser extent lower acquired in process research and development ipr charge in addition to the increase in net income eps in significantly benefited from lower weighted average share outstanding result of the elanco exchange offer and share repurchase following highlighted item affect comparison of our and financial result ipr note to the consolidated financial statement we recognized acquired ipr charge of million primarily related to collaboration with ac immune sa ac immune centrexion therapeutic corporation centrexion immunext inc immunext and avidity bioscience inc avidity asset impairment restructuring and other special charge note to the consolidated financial statement we recognized charge of million primarily associated with the accelerated vesting of loxo oncology inc loxo employee equity award result of the closing of the acquisition of loxo and to lesser extent charge associated with the decision to close and sell research and development facility located in the united kingdom other net income expense note to the consolidated financial statement we recognized gain of million on the sale of the company antibiotic business in china we recognized debt extinguishment loss of million related to the repurchase of debt net income from discontinued operation note to the consolidated financial statement we recognized gain related to the disposition of elanco of approximately billion acquired ipr note to the consolidated financial statement we recognized acquired ipr charge of billion primarily related to the acquisition of armo bioscience inc armo and the collaboration with dicerna pharmaceutical inc dicerna asset impairment restructuring and other special charge note to the consolidated financial statement we recognized charge of million primarily associated with asset impairment related to the sale of the posilac rbst brand and the related sale of the augusta georgia manufacturing site and with expense related to our effort to reduce our cost structure income tax note to the consolidated financial statement we recognized million of income tax benefit primarily due to measurement period adjustment to the one time repatriation transition tax also known the toll tax and the global intangible low taxed income gilti late stage pipelineour long term success depends to great extent on our ability to continue to discover and develop innovative pharmaceutical product and acquire or collaborate on molecule currently in development by other biotechnology or pharmaceutical company we have approximately potential new drug in human testing or under regulatory review and larger number of project in preclinical research the following new molecular entity nmes have been approved by regulatory authority in at least one of the major geography for use in the condition described the first quarter in which the nmes initially were approved in any major geography for any indication is shown in parenthesis galcanezumab emgality once monthly subcutaneously injected calcitonin gene related peptide cgrp antibody for migraine prevention and for the treatment of episodic cluster headache see note to the consolidated financial statement for discussion of the legal proceeding involving teva pharmaceutical international gmbh and teva pharmaceutical usa inc lasmiditan reyvow an oral agonist for the acute treatment of migraine nasal glucagon baqsimi glucagon nasal powder formulation for the treatment of severe hypoglycemia in patient with diabetes age four year and above following nmes and diagnostic agent have been submitted for regulatory review in at least one of the major geography for potential use in the condition described the first quarter in which each nme and the diagnostic agent initially were submitted in any major geography for any indication is shown in parenthesis flortaucipir positron emission tomography pet tracer intended to image tau or neurofibrillary tangle in the brain which are an indicator of alzheimer disease selpercatinib an oral drug for the treatment of patient with cancer that harbor abnormality in the rearranged during transfection ret kinase specifically thyroid cancer and lung cancer tanezumab an anti nerve growth factor monoclonal antibody for the treatment of osteoarthritis pain in collaboration with pfizer inc pfizer ultra rapid lispro an ultra rapid insulin for the treatment of type and type diabetes the following nmes are currently in phase iii clinical trial testing for potential use in the condition described below but have not yet been submitted for regulatory approval for any indication the first quarter in which each nme initially entered phase iii for any indication is shown in parenthesis mirikizumab monoclonal antibody designed for the treatment of autoimmune disease solanezumab an anti amyloid beta monoclonal antibody for the treatment of preclinical alzheimer disease tirzepatide long acting combination therapy of glucose dependent insulinotropic polypeptide gip and glucagon like peptide for the treatment of type diabetes and obesity biologic molecule subject to the united state biologics price competition and innovation act diagnostic agentthe following table reflects the status of the recently approved product nmes and diagnostic agent set forth above well certain other development to our late stage pipeline since january compoundindicationu europejapandevelopmentsendocrinologybaqsimisevere hypoglycemialaunchedapprovedsubmittedlaunched in the in third quarter of approved in europe in the fourth quarter of submitted to the japan regulatory authority in tirzepatidetype diabetesphase iiiphase iii trial are ongoing obesityphase iiiphase iii trial were initiated in the fourth quarter of ultra rapid lisprotype and diabetessubmittedsubmitted to regulatory authority in europe and japan in the first quarter of submitted to the food and drug administration fda in the third quarter of in january the european regulatory authority issued positive opinion recommending approval immunologymirikizumabcrohn diseasephase iiiphase iii trial were initiated during the third quarter of psoriasisphase iiiphase iii trial are ongoing ulcerative colitisphase iiiphase iii trial are ongoing europejapandevelopmentsneuroscienceemgalitycluster headachelaunchedsubmittedphase iiisubmitted to european regulatory authority in the first quarter of approved and launched in the in the second quarter of migraine preventionlaunchedsubmittedlaunched in europe in the first quarter of submitted to japanese regulatory authority in january flortaucipiralzheimer disease diagnosticsubmittedphase iiisubmitted to the fda in the third quarter of reyvowacute treatment of migrainelaunchedphase iiiapproved by the fda in the fourth quarter of received schedule classification from the drug enforcement agency and launched in the in january solanezumabpreclinical alzheimer diseasephase iiiannounced in february that phase iii trial for people with dominantly inherited alzheimer disease diad not meet the primary endpoint we do not plan to pursue submission for diad phase iii trial is ongoing for anti amyloid treatment in asymptomatic alzheimer tanezumabosteoarthritis painsubmittedphase iiiin the third quarter of and the first quarter of announced multiple phase iii trial met several primary endpoint in the second quarter of announced the result of the long term phase iii study in which the dose met two of the three co primary endpoint and the dose did not meet any of the three co primary endpoint in partnership with pfizer we submitted to the fda in the fourth quarter of and are pursuing submission in europe and japan in chronic low back painphase iiiin the first quarter of announced phase iii trial met primary endpoint for the dose and did not meet primary endpoint on the dose in the third quarter of announced result from phase iii study evaluating long term safety and efficacy in japan in partnership with pfizer announced in the third quarter of that we are not planning regulatory submission we plan to maintain an open dialogue with regulatory authority on potential future regulatory pathway cancer painphase iiiphase iii trial is ongoing europejapandevelopmentsoncologylartruvo soft tissue sarcomawithdrawnwithdrawingnot submittingin the first quarter of announced confirmatory phase iii trial did not meet primary endpoint this trial did not confirm clinical benefit we suspended promotion globally and withdrew the product in the in the third quarter of for country in europe we have withdrawn or are in the process of withdrawing the product pegilodecakinpancreatic cancernot submittingin the fourth quarter of announced phase iii trial did not meet primary endpoint of overall survival phase ii trial for other indication also did not meet primary endpoint we do not plan to initiate any new trial selpercatinib loxo thyroid cancersubmittedphase iiiin the fourth quarter of submitted to the fda and european regulatory authority based on phase ii data granted breakthrough therapy designation granted priority review from the fda in first quarter of phase iii trial were initiated in the fourth quarter of in all major geography lung cancersubmittedphase iii the breakthrough therapy designation is designed to expedite the development and review of potential medicine that are intended to treat serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on clinically significant endpoint priority review is designed to expedite the review of potential medicine that if approved would be significant improvement in the safety or effectiveness of the treatment diagnosis or prevention of serious condition when compared to standard application there are many difficulty and uncertainty inherent in pharmaceutical research and development and the introduction of new product there is high rate of failure inherent in new drug discovery and development to bring drug from the discovery phase to market can take over decade and often cost in excess of billion failure can occur at any point in the process including in later stage after substantial investment result most fund invested in research program will not generate financial return new product candidate that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concern inability to obtain or maintain necessary regulatory approval or payer reimbursement or coverage limited scope of approved us change in the relevant treatment standard or the availability of new or better competitive product difficulty or excessive cost to manufacture or infringement of the patent or intellectual property right of others regulatory agency continue to establish increasingly high hurdle for the efficacy and safety of new product delay and uncertainty in drug approval process can result in delay in product launch and lost market opportunity in addition it can be very difficult to predict revenue growth rate of new product we manage research and development spending across our portfolio of molecule and delay in or termination of any one project will not necessarily cause significant change in our total research and development spending due to the risk and uncertainty involved in the research and development process we can not reliably estimate the nature timing and cost of the effort necessary to complete the development of our research and development project can we reliably estimate the future potential revenue that will be generated from successful research and development project each project represents only portion of the overall pipeline and none is individually material to our consolidated research and development expense while we do accumulate certain research and development cost on project level for internal reporting purpose we must make significant cost estimation and allocation some of which rely on data that are neither reproducible nor validated through accepted control mechanism therefore we do not have sufficiently reliable data to report on total research and development cost by project by preclinical versus clinical spend or by therapeutic category matterspatent matterswe depend on patent or other form of intellectual property protection for most of our revenue cash flow and earnings we lost our patent exclusivity for strattera in the in may and generic version of strattera were approved in the same month following settlement related to the compound patent challenge for effient generic product launched in the in the third quarter of the entry of generic competition for these product ha caused rapid and severe decline in revenue which in the aggregate ha had material adverse effect on our consolidated result of operation and cash flow our compound patent protection for cialis tadalafil and adcirca tadalafil expired in major european market and the in november however in the we were granted pediatric exclusivity through may another later expiring patent october wa the subject of patent litigation and pursuant to settlement agreement related thereto generic tadalafil entered the market in september we have faced and remain exposed to generic competition following the loss of exclusivity which ha rapidly and severely eroded revenue and is likely to continue to erode revenue our formulation patent for forteo expired in december and our use patent expired in august in major european market and the both the formulation patent and the use patent expired in august in japan we expect further volume decline result of the entry of generic and biosimilar competition following the loss of patent exclusivity in these market in the aggregate we expect that the decline in revenue will have material adverse effect on our consolidated result of operation and cash flow the alimta vitamin regimen patent which we expect to provide with patent protection for alimta through june in japan and major european country and through may in the have been challenged in each of these jurisdiction in the we and eagle pharmaceutical inc eagle reached an agreement in december to settle all pending litigation allowing eagle limited initial entry into the market with it product starting february up to an approximate three week supply and subsequent unlimited entry starting april our vitamin regimen patent have also been challenged in other smaller european jurisdiction our compound patent for alimta expired in the in january and expired in major european country and japan in december we are aware that several company have received approval to market generic version of pemetrexed in major european market including germany france and the netherlands and that additional generic competitor may choose to launch at risk although we will continue to seek to remove any such product generic product entry is resulting in some loss in revenue in these jurisdiction we expect that further entry of generic competition for alimta following the loss of effective patent protection will cause rapid and severe decline in revenue for the product which will in the aggregate have material adverse effect on our consolidated result of operation and cash flow see note to the consolidated financial statement for more detailed account of the legal proceeding currently pending in the europe and japan regarding our alimta patent the compound patent for humalog insulin lispro ha expired in major market global regulator have different legal pathway to approve similar version of insulin lispro competitor launched similar version of insulin lispro in certain european market in and in the in the second quarter of while it is difficult to estimate the severity of the impact of insulin lispro product entering the market we do not expect and have not experienced rapid and severe decline in revenue however we expect additional pricing pressure and some loss of market share that would continue over time foreign currency exchange ratesas global company with substantial operation outside the we face foreign currency risk exposure from fluctuating currency exchange rate primarily the dollar against the euro and japanese yen while we manage portion of these exposure through hedging and other risk management technique significant fluctuation in currency rate can have substantial impact either positive or negative on our revenue cost of sale and operating expense while there is uncertainty in the future movement in foreign exchange rate fluctuation in these rate could negatively impact our future consolidated result of operation and cash flow affecting pharmaceutical pricing reimbursement and accessu in the public concern over access to and affordability of pharmaceutical continues to drive the regulatory and legislative debate these policy and political issue increase the risk that tax fee rebate or other cost control measure may be enacted to manage federal and state budget key health policy initiative affecting biopharmaceuticals include foreign reference pricing in medicare and private insurance modification to medicare part and provision that would allow the department of health and human service to negotiate price for biologics and drug in medicare reduction in biologic data exclusivity proposal related to medicaid prescription drug coverage and manufacturer drug rebate proposal that would require biopharmaceutical manufacturer to disclose proprietary drug pricing information and state level proposal related to prescription drug price and reducing the cost of pharmaceutical purchased by government health care program california and several other state have enacted legislation related to prescription drug pricing transparency and it is unclear the effect this legislation will have on our business the bipartisan budget act enacted in february requires manufacturer of brand name drug biologics and biosimilars to pay percent discount in the medicare part coverage gap up from the previous percent discount this increase in coverage gap discount became effective at the beginning of in the white house signed into law targeted amendment to the medicaid drug rebate program statute well the fair and accurate medicaid pricing act which wa part of the continuing appropriation act we do not believe these will have material impact to our business several state passed importation legislation including colorado florida maine and vermont specifically the state of florida is working with the administration to implement an importation program from canada early we are currently reviewing the state legislation well corresponding proposed federal rulemaking and guidance recently published by the department of health and human service and the fda the impact of which is uncertain at this time in the private sector consolidation and integration among healthcare provider is also major factor in the competitive marketplace for pharmaceutical health plan pharmacy benefit manager wholesaler and other supply chain stakeholder have been consolidating into fewer larger entity increasingly through vertical integration thus enhancing their purchasing strength and importance payer typically maintain formulary which specify coverage the condition under which drug are included on plan formulary and reimbursement the associated out of pocket cost to the consumer formulary placement can lead to reduced usage of drug for the relevant patient population due to coverage restriction such prior authorization and formulary exclusion or due to reimbursement limitation that result in higher consumer out of pocket cost such non preferred co pay tier increased co insurance level and higher deductible consequently pharmaceutical company compete for formulary placement not only on the basis of product attribute such greater efficacy fewer side effect or greater patient ease of use but also by providing rebate value based agreement are another tool which may be utilized between payer and pharmaceutical company formulary placement and pricing are negotiated price is an increasingly important factor in formulary decision particularly in treatment area in which the payer ha taken the position that multiple branded product are therapeutically comparable these downward pricing pressure could continue to negatively affect future consolidated result of operation in addition to formulary placement change in insurance design continue to drive greater consumer cost sharing through high deductible plan and higher co insurance or co pay including co pay accumulator and maximizer program we continue to invest in patient affordability solution resulting in lower revenue in an effort to assist patient in affording their medicine main coverage expansion provision of the affordable care act aca are currently in effect through both state based exchange and the expansion of medicaid trend ha been the prevalence of benefit design containing high out of pocket cost for patient particularly for pharmaceutical in addition to the coverage expansion many employer in the commercial market continue to evaluate strategy such private exchange and wider use of consumer driven health plan to reduce their healthcare liability over time federal legislation litigation or administrative action to repeal or modify some or all of the provision of the aca could have material adverse effect on our consolidated result of operation and cash flow at the same time the broader paradigm shift towards performance based reimbursement and the launch of several value based purchasing initiative have placed demand on the pharmaceutical industry to offer product with proven real world outcome data and favorable economic profile internationalinternational operation also are generally subject to extensive price and market regulation cost containment measure exist in number of country including additional price control and mechanism to limit reimbursement for our product such policy are expected to increase in impact and reach given the pressure on national and regional health care budget that come from growing aging population and ongoing economic challenge additional reform are finalized we will ass their impact on future revenue in addition government in many emerging market are becoming increasingly active in expanding health care system offering given the budget challenge of increasing health care coverage for citizen policy may be proposed that promote generic and biosimilars only and reduce current and future access to branded human pharmaceutical product tax matterswe are subject to income tax and various other tax in the and in many foreign jurisdiction therefore change in both domestic and international tax law or regulation could adversely affect our effective tax rate result of operation and cash flow country around the world including the actively consider and enact tax law change further action taken with respect to tax related matter by association such the organisation for economic co operation and development and the european commission could influence tax policy in country in which we operate modification to and foreign tax law or regulation are frequently enacted and could result in material impact to our result of operation and financial position acquisitionswe strategically invest in external research and technology that we believe to complement and strengthen our own effort these investment can take many form including licensing arrangement collaboration and acquisition we view our business development activity an important way to achieve our strategy we seek to bolster our pipeline and enhance shareholder value we continue to evaluate business development transaction that have the potential to strengthen our business in february we acquired all share of loxo for purchase price of billion net of cash acquired under the term of the agreement we acquired pipeline of investigational medicine including selpercatinib loxo an oral ret inhibitor that ha been granted breakthrough therapy designation by the fda and loxo an oral btk inhibitor on january we announced an agreement to acquire dermira inc for purchase price of per share or approximately billion the acquisition will expand our immunology pipeline with the addition of lebrikizumab novel investigational monoclonal antibody designed to bind il with high affinity that is being evaluated in phase iii clinical development program for the treatment of moderate to severe atopic dermatitis lebrikizumab wa granted fast track designation from the fda the fda fast track designation is designed to expedite the development and review of new therapy to treat serious condition and address unmet medical need the acquisition will also expand our portfolio of marketed dermatology medicine with the addition of qbrexza glycopyrronium cloth medicated cloth approved by the fda for the topical treatment of primary axillary hyperhidrosis uncontrolled excessive underarm sweating the transaction is not subject to any financing condition and is expected to close by the end of the first quarter of subject to customary closing condition including receipt of required regulatory approval and the tender of majority of the outstanding share of dermira common stock see note to the consolidated financial statement for further discussion regarding our recent acquisition result revenuethe following table summarizes our revenue activity by region year endeddecember percent changeu may not add due to rounding revenue includes revenue in puerto rico the following are component of the change in revenue compared with the prior year outside price foreign exchange rate percent number may not add due to rounding in the the revenue increase in wa driven by increased volume for trulicity taltz verzenio jardiance emgality and basaglar the increase in revenue wa partially offset by decreased volume for product that have lost exclusivity primarily cialis lower volume for forteo and the impact from the product withdrawal of lartruvo additionally the increase in revenue wa partially offset by lower realized price for several product primarily trulicity outside the the revenue increase in wa primarily driven by increased volume for trulicity olumiant taltz and jardiance the increase in revenue wa partially offset by the unfavorable impact of foreign exchange rate and to lesser extent lower realized price following table summarizes our revenue activity in compared with year endeddecember productu outside total totalpercent changetrulicity cymbalta nmerbitux nmzyprexa nmother revenue may not add due to rounding nm not meaningful revenue includes revenue in puerto rico humalog revenue includes insulin lispro jardiance revenue includes glyxambi and synjardy trajenta revenue includes jentadueto revenue of trulicity treatment for type diabetes increased percent in the driven by higher demand partially offset by lower realized price revenue outside the increased percent primarily driven by increased volume partially offset by the unfavorable impact of foreign exchange rate and to lesser extent lower realized price revenue of humalog an injectable human insulin analog for the treatment of diabetes decreased percent in the primarily driven by lower realized price and decreased demand revenue outside the decreased percent primarily driven by the unfavorable impact of foreign exchange rate included in the revenue of humalog in the is our own insulin lispro authorized generic which wa launched in the second quarter of in order to lower out of pocket cost for patient competitor launched similar version of insulin lispro in certain european market in and in the in the second quarter of while it is difficult to estimate the severity of the impact of similar insulin lispro product entering the market we do not expect and have not experienced rapid severe decline in revenue however due to the impact of competition and due to pricing pressure in the and some international market we expect some price decline and loss of market share to continue over time of alimta treatment for various cancer increased percent in the driven by increased demand partially offset by lower realized price revenue outside the decreased percent driven by lower realized price and to lesser extent the unfavorable impact of foreign exchange rate and lower volume resulting from the entry of generic pemetrexed in germany we have faced and remain exposed to generic entry in multiple country which ha eroded revenue and is likely to continue to erode revenue in those country from current level revenue of forteo an injectable treatment for osteoporosis in postmenopausal woman and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal woman decreased percent in the primarily driven by decreased demand revenue outside the decreased percent driven by decreased volume and to lesser extent the unfavorable impact of foreign exchange rate and lower realized price we expect further volume decline result of competitive dynamic in the and the entry of generic and biosimilar competition following the loss of patent exclusivity in the third quarter of in the japan and major european market see executive overview other matter patent matter for more information revenue of taltz treatment for moderate to severe plaque psoriasis active psoriatic arthritis and ankylosing spondylitis increased percent in the primarily driven by increased demand partially offset by lower realized price revenue outside the increased percent driven by increased volume from recent launch partially offset by the unfavorable impact of foreign exchange rate revenue of humulin an injectable human insulin for the treatment of diabetes decreased percent in the driven by lower realized price partially offset by increased volume revenue outside the decreased percent primarily driven by the unfavorable impact of foreign exchange rate partially offset by increased volume and to lesser extent higher realized price revenue of basaglar long acting human insulin analog for the treatment of diabetes increased percent in the driven by higher realized price and increased demand revenue outside the increased percent driven by increased volume partially offset by the unfavorable impact of foreign exchange rate and to lesser extent lower realized price revenue of jardiance treatment for type diabetes and to reduce the risk of cardiovascular death in adult patient with type diabetes and established cardiovascular disease increased percent in the driven by increased demand revenue outside the increased percent primarily driven by increased volume partially offset by the unfavorable impact of foreign exchange rate revenue of cyramza treatment for various cancer increased percent in the driven by increased demand and to lesser extent higher realized price revenue outside the increased percent primarily due to increased volume partially offset by the unfavorable impact of foreign exchange rate and lower realized price revenue of cialis treatment for erectile dysfunction and benign prostatic hyperplasia decreased percent in the driven by decreased demand due to generic competition revenue outside the decreased percent driven by the unfavorable impact of foreign exchange rate lower volume due to the loss of exclusivity in europe and to lesser extent lower realized price we lost our compound patent protection for cialis in major european market in november and exclusivity ended in late september we have faced and remain exposed to generic competition following the loss of exclusivity which ha eroded revenue and is likely to continue to rapidly and severely erode revenue from current level see result of operation executive overview other matter patent matter for more information gross margin cost and expensesgross margin percent of total revenue wa percent in an increase of percentage point compared with primarily due to the favorable impact of foreign exchange rate on international inventory sold and lower intangible amortization expense partially offset by unfavorable product mix the impact of lower realized price on revenue and charge resulting from the product withdrawal of lartruvo research and development expense increased percent to billion in driven by higher late stage development expense marketing selling and administrative expense increased percent to billion in primarily due to increased marketing expense for recently launched product partially offset by lower expense for late life cycle product recognized acquired ipr charge of million in resulting from business development transaction with ac immune centrexion immunext and avidity in we recognized acquired ipr charge of billion primarily related to the acquisition of armo and the collaboration with dicerna we recognized asset impairment restructuring and other special charge of million in the charge were primarily associated with the accelerated vesting of loxo employee equity award part of the closing of the acquisition of loxo and to lesser extent the charge associated with the decision to close and sell research and development facility located in the in we recognized million of asset impairment restructuring and other special charge primarily associated with asset impairment related to the sale of the posilac rbst brand and the related sale of the augusta georgia manufacturing site and with expense associated with effort to reduce our cost structure other net income expense wa income of million in compared to income of million in primarily driven by higher net gain on investment security and the gain on the sale of the company antibiotic business in china partially offset by the charge related to the repurchase of debt and higher net interest expense our effective tax rate wa percent in compared with percent in the higher effective tax rate in wa primarily due to non deductible acquired ipr charge operating result resultsthe following table summarizes our key operating result year endeddecember percent change revenue margin percent of operating expense acquired in process research and impairment restructuring and other special income before income net income loss from continuing nmnet income loss nmearnings loss per share from continuing nmearnings loss per nmnm not meaningfulrevenue increased in driven by increased volume and to lesser extent the favorable impact of foreign exchange rate partially offset by lower realized price the increase in net income and eps in were driven by lower income tax higher gross margin and lower asset impairment restructuring and other special charge partially offset by higher acquired ipr charge item affect the comparison of our and result the highlighted item are summarized in the result of operation executive overview section the highlighted item are summarized follows acquired ipr note to the consolidated financial statement we recognized acquired ipr charge of billion primarily related to the acquisition of colucid pharmaceutical inc colucid asset impairment restructuring and other special charge note to the consolidated financial statement we recognized charge of billion primarily associated with effort to reduce our cost structure including the voluntary early retirement program income tax note to the consolidated financial statement we recognized provisional tax expense of billion due to the tax cut and job act tax act revenuethe following table summarizes our revenue activity by region year endeddecember percent changeu may not add due to rounding revenue includes revenue in puerto rico the following are component of the change in revenue in compared with outside price foreign exchange rate percent number may not add due to rounding in the the revenue increase in wa driven by increased volume for newer product including trulicity basaglar taltz verzenio and jardiance the increase in revenue wa partially offset by decreased volume for product that have lost exclusivity including cialis effient and strattera well lower realized price for several product including trulicity basaglar forteo and taltz outside the the revenue increase in wa due to increased volume for several newer product primarily driven by trulicity olumiant and taltz and to lesser extent the favorable impact of foreign exchange rate the increase in revenue wa partially offset by lower realized price for several product following table summarizes our revenue activity in compared with year endeddecember productu outside total totalpercent changetrulicity jardiance trajenta other may not add due to rounding revenue includes revenue in puerto rico jardiance revenue includes glyxambi and synjardy trajenta revenue includes jentadueto revenue of trulicity increased percent in the driven by higher demand revenue outside the increased percent primarily driven by increased volume and to lesser extent the favorable impact of foreign exchange rate partially offset by lower realized price revenue of humalog increased percent in the primarily driven by increased demand and to lesser extent higher realized price due to change in estimate to rebate and discount revenue outside the increased percent driven by increased volume and to lesser extent the favorable impact of foreign exchange rate partially offset by lower realized price revenue of alimta increased percent in the driven by increased demand and higher realized price revenue outside the decreased percent driven by lower volume due to competitive pressure and the loss of exclusivity in certain european country including germany and lower realized price partially offset by the favorable impact of foreign exchange rate revenue of cialis decreased percent in the driven by decreased demand primarily due to the entry of generic tadalafil partially offset by higher realized price revenue outside the decreased percent driven by the loss of exclusivity in europe revenue of forteo decreased percent in the driven by decreased demand and to lesser extent lower realized price revenue outside the increased percent driven by increased volume and the favorable impact of foreign exchange rate partially offset by lower realized price revenue of humulin increased percent in the driven by increased volume partially offset by lower realized price primarily due to change in segment mix and to lesser extent the impact of patient affordability program revenue outside the decreased percent primarily driven by decreased volume and to lesser extent lower realized price of taltz increased percent in the primarily driven by increased demand partially offset by lower realized price revenue outside the increased million driven by increased volume from recent launch partially offset by lower realized price revenue of cyramza increased percent in the driven by increased demand and to lesser extent higher realized price revenue outside the increased percent primarily due to increased volume and to lesser extent the favorable impact of foreign exchange rate partially offset by lower realized price revenue of basaglar increased million in the driven by increased demand partially offset by lower realized price due to increased volume in medicare part revenue outside the increased million primarily driven by increased volume revenue of cymbalta treatment for major depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder chronic musculoskeletal pain and the management of fibromyalgia decreased percent in the driven by decreased volume partially offset by higher realized price revenue outside the increased percent driven by increased volume in japan gross margin cost and expensesgross margin percent of total revenue wa percent in an increase of percentage point compared with primarily due to manufacturing efficiency and lower amortization expense offset by the impact of foreign exchange rate on international inventory sold the timing of manufacturing production and the negative impact of price on revenue research and development expense decreased percent to billion in driven by lower development expense for lanabecestat partially offset by higher expense for other late stage asset marketing selling and administrative expense remained flat in compared to both research and development expense and marketing selling and administrative expense benefited during from action taken to reduce our cost structure we recognized acquired ipr charge of billion in primarily related to the acquisition of armo and the collaboration with dicerna in we recognized acquired ipr charge of billion primarily related to the acquisition of colucid we recognized asset impairment restructuring and other special charge of million in the charge are primarily associated with asset impairment related to the sale of the posilac rbst brand and the related sale of the augusta georgia manufacturing site and with expense associated with effort to reduce our cost structure in we recognized billion of asset impairment restructuring and other special charge primarily associated with effort to reduce our cost structure including the voluntary early retirement program and asset impairment related to lower projected revenue for posilac rbst other net income expense wa income of million in compared to income of million in driven by lower net gain on sale of investment during we recorded income tax expense of million while earning billion of income before income tax we recognized million of income tax benefit primarily due to measurement period adjustment to the toll tax and gilti during we recorded income tax expense of billion which included provisional tax charge of billion despite earning billion of income before income tax the provisional tax charge wa result of the tax act including the toll tax conditioncash and cash equivalent decreased to billion of december compared with billion at december net cash provided by operating activity wa billion in compared with billion in net cash provided by operating activity in included approximately million of cash paid to settle the accelerated vesting of loxo employee equity award see note to the consolidated financial statement net cash provided by operating activity in included approximately million of net cash provided by operating activity related to our discontinued operation see note to the consolidated financial statement refer to the consolidated statement of cash flow for additional detail on the significant source and us of cash for the year ended december and in addition to our cash and cash equivalent we held total investment of billion and billion of december and respectively see note to the consolidated financial statement for additional detail in february we completed our acquisition of loxo for per share or approximately billion which wa funded through mixture of cash and debt see note to the consolidated financial statement for additional information of december total debt wa billion an increase of billion compared with billion at december the increase primarily related to the net proceeds of billion from the issuance of senior note in february the proceeds from these note were used to repay commercial paper that wa issued in connection with the acquisition of loxo and for general corporate purpose see note to the consolidated financial statement for additional detail of december we had total of billion of unused committed bank credit facility billion of which is available to support our commercial paper program see note to the consolidated financial statement for additional detail we believe that amount accessible through existing commercial paper market should be adequate to fund any short term borrowing need for the consecutive year we distributed dividend to our shareholder dividend of per share and per share were paid in and respectively in the fourth quarter of effective for the dividend to be paid in the first quarter of the quarterly dividend wa increased to per share resulting in an indicated annual rate for of per share capital expenditure of billion during compared to billion in in we repurchased billion of share under our billion share repurchase program authorized in june of december we had billion remaining under this program see note to the consolidated financial statement for additional detail on march we completed the disposition of our remaining percent ownership of elanco common stock through tax free exchange offer which resulted in reduction in share of our common stock outstanding by approximately million of that date in january we announced an agreement to acquire dermira inc for per share or approximately billion the acquisition will be funded through cash on hand and the issuance of commercial paper see note to the consolidated financial statement for additional information see result of operation executive overview other matter patent matter for information regarding recent and upcoming loss of patent protection we believe cash provided by operating activity along with available cash and cash equivalent should be sufficient to fund our normal operating need including installment payment of the toll tax dividend paid to shareholder share repurchase and capital expenditure both domestically and abroad we continue to monitor the potential impact of the economic environment the creditworthiness of our wholesaler and other customer including foreign government backed agency and supplier the uncertain impact of health care legislation and various international government funding level in the normal course of business our operation are exposed to fluctuation in interest rate and currency value these fluctuation can vary the cost of financing investing and operating we seek to address portion of these risk through controlled program of risk management that includes the use of derivative financial instrument the objective of this risk management program is to limit the impact on earnings of fluctuation in interest and currency exchange rate all derivative activity are for purpose other than trading primary interest rate risk exposure result from change in short term dollar interest rate in an effort to manage interest rate exposure we strive to achieve an acceptable balance between fixed and floating rate debt position and may enter into interest rate derivative to help maintain that balance based on our overall interest rate exposure at december and including derivative and other interest rate risk sensitive instrument hypothetical percent change in interest rate applied to the fair value of the instrument of december and respectively would not have material impact on earnings cash flow or fair value of interest rate risk sensitive instrument over one year period our foreign currency risk exposure result from fluctuating currency exchange rate primarily the dollar against the euro and japanese yen we face foreign currency exchange exposure when we enter into transaction arising from subsidiary trade and loan payable and receivables denominated in foreign currency we also face currency exposure that arises from translating the result of our global operation to the dollar at exchange rate that have fluctuated from the beginning of the period we may enter into foreign currency forward or option derivative contract to reduce the effect of fluctuating currency exchange rate principally the euro and the japanese yen our corporate risk management policy outline the minimum and maximum hedge coverage of such exposure gain and loss on these derivative contract offset in part the impact of currency fluctuation on the existing asset and liability we periodically analyze the fair value of the outstanding foreign currency derivative contract to determine their sensitivity to change in foreign exchange rate hypothetical percent change in exchange rate primarily against the dollar applied to the fair value of our outstanding foreign currency derivative contract of december and would not have material impact on earnings cash flow or financial position over one year period this sensitivity analysis doe not consider the impact that hypothetical change in exchange rate would have on the underlying foreign currency denominated transaction off balance sheet arrangement and contractual obligationswe have no off balance sheet arrangement that have material current effect or that are reasonably likely to have material future effect on our financial condition change in financial condition revenue or expense result of operation liquidity capital expenditure or capital resource we acquire and collaborate on potential product still in development and enter into research and development arrangement with third party that often require milestone and royalty payment to the third party contingent upon the occurrence of certain future event linked to the success of the asset in development milestone payment may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product approval for marketing by the appropriate regulatory agency or upon the achievement of certain sale level if required by the arrangement we may make royalty payment based upon percentage of the sale of the product in the event that regulatory approval for marketing is obtained because of the contingent nature of these payment they are not included in the table of contractual obligation below individually these arrangement are generally not material in any one annual reporting period however if milestone for multiple product covered by these arrangement were reached in the same reporting period the aggregate charge to expense or aggregate milestone payment made could be material to our result of operation or cash flow respectively in that period see note to the consolidated financial statement for additional detail these arrangement often give the discretion to unilaterally terminate development of the product which would allow to avoid making the contingent payment however we are unlikely to cease development if the compound successfully achieves milestone objective we also note that from business perspective we view these payment positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flow from sale of product current noncancelable contractual obligation that will require future cash payment were follows of december payment due by period dollar in million total le year more yearslong term debt including interest payment lease operating lease obligation tax act toll tax long term liability reflected on our balance sheet our long term debt obligation include both our expected principal and interest obligation and our interest rate swap we used the interest rate forward curve at december to compute the amount of the contractual obligation for interest on the variable rate debt instrument and swap we have included the following purchase obligation consisting primarily of all open purchase order of december some of these purchase order may be cancelable however for purpose of this disclosure we have not distinguished between cancelable and noncancelable purchase obligation contractual payment obligation with each of our significant vendor which are noncancelable and are not contingent the tax act provided an election to taxpayer subject to the toll tax to make payment over an eight year period we made this election therefore we have included future toll tax payment accordingly we have included long term liability consisting primarily of our nonqualified supplemental pension funding requirement and other post employment benefit liability we excluded long term income tax payable of billion because we can not reasonably estimate the timing of future cash outflow associated with those liability the contractual obligation table is of december we expect the amount of these obligation to change materially over time new contract are initiated and existing contract are completed terminated or modified application of critical accounting estimatesin preparing our financial statement in accordance with accounting principle generally accepted in the gaap we must often make estimate and assumption that affect the reported amount of asset liability revenue expense and related disclosure some of those judgment can be subjective and complex and consequently actual result could differ from those estimate for any given individual estimate or assumption we make it is possible that other people applying reasonable judgment to the same fact and circumstance could develop different estimate we believe that given current fact and circumstance it is unlikely that applying any such other reasonable judgment would cause material adverse effect on our consolidated result of operation financial position or liquidity for the period presented in this report our most critical accounting estimate have been discussed with our audit committee and are described below revenue recognition and sale return rebate and discount accrualswe recognize revenue primarily from two different type of contract product sale to customer net product revenue and collaboration and other arrangement for product sale to customer provision for return rebate and discount are established in the same period the related product sale are recognized to determine the appropriate transaction price for our product sale at the time we recognize sale to direct customer we estimate any rebate or discount that ultimately will be due to the direct customer and other customer in the distribution chain under the term of our contract significant judgment are required in making these estimate the largest of our sale rebate and discount amount are rebate associated with sale covered by managed care medicare medicaid and chargeback contract in the in determining the appropriate accrual amount we consider our historical rebate payment for these program by product percentage of our historical sale well any significant change in sale trend patent expiry and product launch an evaluation of the current contract for these program the percentage of our product that are sold via these program and our product pricing to note to the consolidated financial statement for further information on revenue recognition and sale return rebate and discount accrual revenue recognized from collaboration and other arrangement will include our share of profit from the collaboration well royalty upfront and milestone payment we receive under these type of contract financial statement impactwe believe that our accrual for sale return rebate and discount are reasonable and appropriate based on current fact and circumstance our global rebate and discount liability are included in sale rebate and discount on our consolidated balance sheet our global sale return liability is included in other current liability and other noncurrent liability on our consolidated balance sheet of december percent change in our global sale return rebate and discount liability would have led to an approximate million effect on our income before income tax the portion of our global sale return rebate and discount liability resulting from sale of our product in the wa approximately percent of december and the following represents roll forward of our most significant sale return rebate and discount liability balance including managed care medicare and medicaid dollar in million return rebate and discount liability beginning of year of net sale payment sale return rebate and discount liability end of year adjustment of the estimate for these return rebate and discount to actual result were approximately percent of consolidated net sale for each of the year presented product litigation liability and other contingenciesbackground and uncertaintiesproduct litigation liability and other contingency are by their nature uncertain and based upon complex judgment and probability the factor we consider in developing our product litigation liability reserve and other contingent liability amount include the merit and jurisdiction of the litigation the nature and the number of other similar current and past matter the nature of the product and the current assessment of the science subject to the litigation and the likelihood of settlement and current state of settlement discussion if any in addition we accrue for certain product liability claim incurred but not filed to the extent we can formulate reasonable estimate of their cost based primarily on historical claim experience and data regarding product usage we accrue legal defense cost expected to be incurred in connection with significant product liability contingency when both probable and reasonably estimable we also consider the insurance coverage we have to diminish the exposure for period covered by insurance in assessing our insurance coverage we consider the policy coverage limit and exclusion the potential for denial of coverage by the insurance company the financial condition of the insurer and the possibility of and length of time for collection due to very restrictive market for product liability insurance we are self insured for product liability loss for all our currently marketed product in addition to insurance coverage we consider any third party indemnification to which we are entitled or under which we are obligated with respect to our third party indemnification right these consideration include the nature of the indemnification the financial condition of the indemnifying party and the possibility of and length of time for collection the litigation accrual and environmental liability and the related estimated insurance recoverables have been reflected on gross basis liability and asset respectively on our consolidated balance sheet acquisitionsbackground and uncertaintiesto determine whether acquisition or licensing transaction should be accounted for business combination or an asset acquisition we make certain judgment which include assessing whether the acquired set of activity and asset would meet the definition of business under the relevant accounting rule the acquired set of activity and asset meet the definition of business asset acquired and liability assumed are required to be recorded at their respective fair value of the acquisition date the excess of the purchase price over the fair value of the acquired net asset where applicable is recorded goodwill if the acquired set of activity and asset doe not meet the definition of business the transaction is recorded an acquisition of asset and therefore any acquired ipr that doe not have an alternative future use is charged to expense at the acquisition date and goodwill is not recorded refer to note to the consolidated financial statement for additional information the judgment made in determining estimated fair value assigned to asset acquired and liability assumed in business combination well estimated asset life can materially affect our consolidated result of operation the fair value of intangible asset including acquired ipr are determined using information available near the acquisition date based on estimate and assumption that are deemed reasonable by management significant estimate and assumption include but are not limited to probability of technical success revenue growth and discount rate depending on the fact and circumstance we may deem it necessary to engage an independent valuation expert to assist in valuing significant asset and liability the fair value of identifiable intangible asset are primarily determined using an income method described in note to the consolidated financial statement impairment of indefinite lived and long lived assetsbackground and uncertaintieswe review the carrying value of long lived asset both intangible and tangible for potential impairment on periodic basis and whenever event or change in circumstance indicate the carrying value of an asset or asset group may not be recoverable we identify impairment by comparing the projected undiscounted cash flow to be generated by the asset or asset group to it carrying value if an impairment is identified loss is recorded equal to the excess of the asset net book value over it fair value and the cost basis is adjusted goodwill and indefinite lived intangible asset are reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value of the intangible asset is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value of the intangible asset to it carrying value is performed to determine the amount of any impairment several method may be used to determine the estimated fair value of acquired ipr all of which require multiple assumption we utilize the income method described in note to the consolidated financial statement for acquired ipr asset the risk of failure ha been factored into the fair value measure and there can be no certainty that these asset ultimately will yield successful product discussed previously in result of operation executive overview late stage pipeline the nature of the pharmaceutical business is high risk and requires that we invest in large number of project to maintain successful portfolio of approved product such it is likely that some acquired ipr asset will become impaired in the future estimate of future cash flow based on we believe to be reasonable and supportable assumption and projection require management judgment actual result could vary materially from these estimate retirement benefit assumptionsbackground and uncertaintiesdefined benefit pension plan and retiree health benefit plan cost include assumption for the discount rate expected return on plan asset and retirement age these assumption have significant effect on the amount reported in addition to the analysis below see note to the consolidated financial statement for additional information regarding our retirement benefit we evaluate the discount rate and the expected return on plan asset in our defined benefit pension and retiree health benefit plan we use an actuarially determined plan specific yield curve of high quality fixed income debt instrument to determine the discount rate in evaluating the expected return on plan asset we consider many factor with primary analysis of current and projected market condition asset return and asset allocation approximately percent of which are growth investment and the view of leading financial adviser and economist we may also review our historical assumption compared with actual result well the discount rate and expected return on plan asset of other company where applicable in evaluating our expected retirement age assumption we consider the retirement age of our past employee eligible for pension and medical benefit together with our expectation of future retirement age annually we determine the fair value of the plan asset in our defined benefit pension and retiree health benefit plan approximately percent of our plan asset are in hedge fund and private equity like investment fund collectively alternative asset we value these alternative investment using significant unobservable input or using the net asset value reported by the counterparty adjusted necessary input include underlying net asset value discounted cash flow valuation comparable market valuation and adjustment for currency credit liquidity and other risk financial statement impactif the discount rate for the defined benefit pension and retiree health benefit plan plan were to change by quarter percentage point income before income tax would change by million if the expected return on plan asset for plan were to change by quarter percentage point income before income tax would change by million if our assumption regarding the expected age of future retiree for plan were adjusted by one year our income before income tax would be affected by million the plan including puerto rico represent approximately percent and percent of the total projected benefit obligation and total plan asset respectively at december adjustment to the fair value of plan asset are not recognized in pension and retiree health benefit expense in the year that the adjustment occur such change are deferred along with other actuarial gain and loss and are amortized into expense over the expected remaining service life of employee income taxesbackground and uncertaintieswe prepare and file tax return based upon our interpretation of tax law and regulation and record estimate based upon these interpretation in the normal course of business our tax return are subject to examination by various taxing authority which may result in future tax interest and penalty assessment inherent uncertainty exist in estimate of many tax position due to change in tax law resulting from legislation and regulation concluded through the various jurisdiction tax court system we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authority based on the technical merit of the position the tax benefit recognized in the financial statement from such position are measured based on the largest benefit that ha greater than percent likelihood of being realized upon ultimate resolution the amount of unrecognized tax benefit is adjusted for change in fact and circumstance for example adjustment could result from change to existing tax law the issuance of regulation by the taxing authority new information obtained during tax examination or resolution of tax examination we believe our estimate for uncertain tax position are appropriate and sufficient to pay assessment that may result from examination of our tax return we recognize both accrued interest and penalty related to unrecognized tax benefit in income tax expense we have recorded valuation allowance against certain of our deferred tax asset primarily those that have been generated from net operating loss and tax credit carryforwards in certain taxing jurisdiction in evaluating whether we would more likely than not recover these deferred tax asset we have not assumed any future taxable income or tax planning strategy in the jurisdiction associated with these carryforwards where history doe not support such an assumption implementation of tax planning strategy to recover these deferred tax asset or future income generation in these jurisdiction could lead to the reversal of these valuation allowance and reduction of income tax expense statement impactas of december percent change in the amount of uncertain tax position and the valuation allowance would result in change in net income of million and million respectively legal and regulatory matter information relating to certain legal proceeding can be found in note to the consolidated financial statement and is incorporated here by reference financial expectation for for the full year of we expect eps to be in the range of to which includes the anticipated impact of the dermira acquisition we anticipate that total revenue will be between billion and billion revenue growth is expected to be driven by volume from trulicity taltz basaglar jardiance verzenio cyramza olumiant emgality baqsimi and the launch of reyvow revenue growth is expected to be partially offset by lower revenue for product that have lost patent exclusivity including the expected entry of generic competition for forteo in the revenue growth is also expected to be partially offset by low single digit net price decline in the driven primarily by rebate and legislated increase to medicare part cost sharing patient affordability program and net price decline in china japan and europe we anticipate that gross margin percent of revenue will be approximately percent in research and development expense are expected to be in the range of billion to billion marketing selling and administrative expense are expected to be in the range of billion to billion other net income expense is expected to be expense in the range of million to million the effective tax rate is expected to be approximately percent item quantitative and qualitative disclosure about market riskyou can find quantitative and qualitative disclosure about market risk interest rate risk at item management discussion and analysis financial condition that information is incorporated in this report by reference financial statement and supplementary dataconsolidated statement of operationseli lilly and company and subsidiary dollar in million and share in thousand except per share data year ended december expense and other cost of sale and development selling and administrative in process research and development note impairment restructuring and other special charge note net income expense note before income tax tax note income loss from continuing operation net income loss from discontinued operation note net income loss earnings loss per share earnings loss from continuing operation basic earnings loss from discontinued operation basic earnings loss per share basic earnings loss from continuing operation diluted earnings loss from discontinued operation diluted earnings loss per share diluted share used in calculation of earnings loss per share basic note to consolidated financial statement statement of comprehensive income loss eli lilly and company and subsidiary dollar in million year ended december income loss other comprehensive income loss from continuing operation change in foreign currency translation gain loss in net unrealized gain loss on security change in defined benefit pension and retiree health benefit plan note change in effective portion of cash flow hedge comprehensive income loss from continuing operation before income tax benefit provision for income tax related to other comprehensive income loss from continuing operation comprehensive income loss from continuing operation net of tax note comprehensive income loss from discontinued operation net of tax note comprehensive income loss net of tax note income loss see note to consolidated financial statement balance sheetseli lilly and company and subsidiary dollar in million share in thousand december current asset cash and cash equivalent note term investment note receivable net of allowance of and receivables note expense and other asset of discontinued operation note current asset note note intangible net note tax asset note and equipment net note lease asset note other noncurrent asset asset of discontinued operation note asset and equity current liability short term borrowing and current maturity of long term debt note payable compensation rebate and discount payable tax payable note current liability liability of discontinued operation note current liability liability long term debt note operating lease liability note accrued retirement benefit note term income tax payable note noncurrent liability tax liability note liability of discontinued operation note other liability and contingency note eli lilly and company shareholder equity note and common stock no par value authorized share issued share and paid in capital earnings benefit trust accumulated other comprehensive loss note cost of common stock in treasury total eli lilly and company shareholder equity interest equity liability and equity note to consolidated financial statement statement of shareholder equity equity of eli lilly and company shareholder eli lilly and company and subsidiary dollar in million share in thousand common stock additionalpaid incapital retainedearnings employee benefit trust accumulated other comprehensive loss common stock in treasury noncontrolling interestshares amountshares amountbalance at january income loss comprehensive income loss net of tax cash dividend declared per share retirement of treasury share purchase of treasury share issuance of stock under employee stock plan stock based compensation reclassification of stranded tax effect note other balance at december income comprehensive income loss net of tax cash dividend declared per share retirement of treasury share purchase of treasury share issuance of stock under employee stock plan stock based compensation adoption of new accounting standard note sale of elanco stock note balance at december income comprehensive income loss net of tax dividend declared per share retirement of treasury share purchase of treasury share issuance of stock under employee stock plan stock based compensation acquisition of common stock in exchange offer deconsolidation of elanco other balance at december note to consolidated financial statement statement of cash flowseli lilly and company and subsidiary dollar in million year ended december flow from operating activity net income loss adjustment to reconcile net income loss to cash flow from operating activity gain related to disposition of elanco note gain on sale of antibiotic business in china note depreciation and amortization in deferred income tax stock based compensation expense in process research and development note non cash operating activity net change in operating asset and liability net of acquisition and divestiture receivables increase decrease inventory increase decrease other asset increase decrease income tax payable increase decrease payable and other liability increase decrease cash provided by operating activity flow from investing activity purchase of property and equipment proceeds from sale and maturity of short term investment of short term investment proceeds from sale of noncurrent investment of noncurrent investment purchase of in process research and development cash paid for acquisition net of cash acquired note and cash distributed to elanco upon disposition cash received for sale of antibiotic business in china other investing activity net net cash provided by used for investing activity cash flow from financing activity dividend paid net change in short term borrowing from issuance of long term debt of long term debt purchase of common stock net proceeds from elanco initial public offering note other financing activity net net cash provided by used for financing activity of exchange rate change on cash and cash equivalent net increase decrease in cash and cash equivalent and cash equivalent at beginning of year includes and of discontinued operation and cash equivalent at end of year includes and of discontinued operation note to consolidated financial statement to consolidated financial statementseli lilly and company and subsidiary table present dollar in million except per share data note summary of significant accounting policy and implementation of new financial accounting standardsbasis of presentationthe accompanying consolidated financial statement have been prepared in accordance with accounting principle generally accepted in the united state gaap the account of all wholly owned and majority owned subsidiary are included in the consolidated financial statement where our ownership of consolidated subsidiary is le than percent the noncontrolling shareholder interest are reflected separate component of equity all intercompany balance and transaction have been eliminated the preparation of financial statement in conformity with gaap requires management to make estimate and assumption that affect the reported amount of asset liability revenue expense and related disclosure at the date of the financial statement and during the reporting period actual result could differ from those estimate we issued our financial statement by filing with the security and exchange commission sec and have evaluated subsequent event up to the time of the filing of our form certain reclassification have been made to prior period in the consolidated financial statement and accompanying note to conform with the current presentation all per share amount unless otherwise noted in the footnote are presented on diluted basis on march we completed the disposition of our remaining percent ownership of elanco animal health incorporated elanco common stock through tax free exchange offer result elanco ha been presented discontinued operation in our consolidated financial statement for all period presented following the completion of the disposition of elanco we now operate single operating segment engaged in the discovery development manufacturing marketing and sale of pharmaceutical product worldwide global research and development organization and supply chain organization are responsible for the discovery development manufacturing and supply of our product regional commercial organization market distribute and sell the product the business is also supported by global corporate staff function our determination that we operate single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purpose of evaluating performance allocating resource setting incentive compensation target and planning and forecasting for future period research and development expense and acquired in process research and development ipr research and development expense include the following research and development cost which are expensed incurred milestone payment obligation incurred prior to regulatory approval of the product which are accrued when the event requiring payment of the milestone occurs acquired ipr expense includes the initial cost of externally developed ipr project acquired directly in transaction other than business combination that do not have an alternative future use earnings per share eps we calculate basic eps based on the weighted average number of common share outstanding and incremental share from potential participating security we calculate diluted eps based on the weighted average number of common share outstanding including incremental share from our stock based compensation program foreign currency translationoperations in our subsidiary outside the united state are recorded in the functional currency of each subsidiary which is determined by review of the environment where each subsidiary primarily generates and expends cash the result of operation for our subsidiary outside the are translated from functional currency into dollar using the weighted average currency rate for the period asset and liability are using the period end exchange rate the dollar effect that arise from translating the net asset of these subsidiary are recorded in other comprehensive income loss advertising expensescosts associated with advertising are expensed incurred and are included in marketing selling and administrative expense advertising expense comprised primarily of television radio print medium and internet advertising totaled approximately billion million and million in and respectively which wa le than percent of revenue each year other significant accounting policiesour other significant accounting policy are described in the remaining appropriate note to the consolidated financial statement implementation of new financial accounting standardseffective january we adopted accounting standard update lease using the modified retrospective approach applied at the beginning of the period of adoption and we elected the package of transitional practical expedient the adoption of this standard resulted in recording of operating lease asset of approximately million which included reclassifying approximately million of deferred rent and lease incentive net of prepaid rent component of the operating lease asset of january the adoption also resulted in recording operating lease liability of approximately million of january our accounting for finance lease remained substantially unchanged the standard did not have an impact on our consolidated statement of operation effective january we adopted accounting standard update revenue from contract with customer and other related update this standard requires entity to recognize revenue to depict the transfer of promised good or service to customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or service we applied this standard to contract for which performance wa not substantially complete of the date of adoption for those contract that were modified prior to the date of adoption we reflected the aggregate effect of those modification when determining the appropriate accounting under the new standard we believe the effect of applying this practical expedient resulted in material difference we applied this standard through cumulative effect adjustment to retained earnings of the beginning of the year of adoption upon adoption the cumulative effect of applying this standard resulted in an increase of approximately million to retained earnings of january revenue presented for period prior to wa accounted for under previous standard and ha not been adjusted revenue and net income for did not differ materially from amount that would have resulted from application of the previous standard effective january we adopted accounting standard update asu financial instrument overall recognition and measurement of financial asset and financial liability this standard requires entity to recognize change in the fair value of equity investment with readily determinable fair value in net income except for investment accounted for under the equity method of accounting or those that result in consolidation of the investee we applied the new standard through cumulative effect adjustment to retained earnings of the beginning of the year of adoption upon adoption we reclassified from accumulated other comprehensive loss the after tax amount of net unrealized gain resulting in an increase to retained earnings of approximately million adoption of this standard did not result in material change in net income in the year of adoption effective january we adopted accounting standard update income tax intra entity transfer of asset other than inventory this standard requires entity to recognize the income tax consequence of intra entity transfer of asset other than inventory at the time of transfer we adopted this standard using modified retrospective approach upon adoption the cumulative effect of applying this standard resulted in an increase of approximately million to retained earnings billion to deferred tax asset and billion to deferred tax liability of january adoption of this standard did not result in material change in net income in the year of adoption we elected to early adopt accounting standard update income statement reporting comprehensive income reclassification of certain tax effect from accumulated other comprehensive income of december which allowed reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effect resulting from the tax cut and job act tax act see note this standard allowed to reclassify the effect of remeasuring deferred tax liability and asset to item within accumulated other comprehensive loss using the then newly enacted percent federal corporate income tax rate the provisional effect of this early adoption wa reclassification from accumulated other comprehensive loss which resulted in an increase to retained earnings of million of december note revenuethe following table summarizes our revenue recognized in our consolidated statement of operation product revenue and other revenue collaboration and other revenue associated with prior period transfer of intellectual property wa million million and million during the year ended and respectively we recognize revenue primarily from two different type of contract product sale to customer net product revenue and collaboration and other arrangement revenue recognized from collaboration and other arrangement will include our share of profit from the collaboration well royalty upfront and milestone payment we receive under these type of contract see note for additional information related to our collaboration and other arrangement collaboration and other revenue disclosed above includes the revenue from the trajenta and jardiance family of product resulting from our collaboration with boehringer ingelheim discussed in note substantially all of the remainder of collaboration and other revenue is related to contract accounted for contract with customer net product revenuerevenue from sale of product is recognized at the point where the customer obtains control of the good and we satisfy our performance obligation which generally is at the time we ship the product to the customer payment term differ by jurisdiction and customer but payment term in most of our major jurisdiction typically range from to day from date of shipment revenue for our product sale ha not been adjusted for the effect of financing component we expect at contract inception that the period between when we transfer control of the product and when we receive payment will be one year or le any exception are either not material or we collect interest for payment made after the due date provision for rebate discount and return are established in the same period the related sale are recognized we generally ship product shortly after order are received therefore we generally only have few day of order received but not yet shipped at the end of any reporting period shipping and handling activity are considered to be fulfillment activity and are not considered to be separate performance obligation we exclude from the measurement of the transaction price all tax assessed by governmental authority that are imposed on our sale of product and collected from customer most of our product are sold to wholesaler that serve pharmacy physician and other health care professional and hospital for the year ended december and our three largest wholesaler each accounted for between percent and percent of consolidated total revenue further they each accounted for between percent and percent of account receivable of december and significant judgment must be made in determining the transaction price for our sale of product related to anticipated rebate discount and return the following describe the most significant of these judgment sale rebate and discount background and uncertainty we initially invoice our customer at contractual list price contract with direct and indirect customer may provide for various rebate and discount that may differ in each contract consequence to determine the appropriate transaction price for our product sale at the time we recognize sale to direct customer we must estimate any rebate or discount that ultimately will be due to the direct customer and other customer in the distribution chain under the term of our contract significant judgment are required in making these estimate the rebate and discount amount are recorded deduction to arrive at our net product revenue sale rebate and discount that require the use of judgment in the establishment of the accrual managed care medicare medicaid chargebacks long term care hospital patient assistance program and various other program we estimate these accrual using an expected value approach the largest of our sale rebate and discount amount are rebate associated with sale covered by managed care medicare medicaid chargeback and patient assistance program in the in determining the appropriate accrual amount we consider our historical rebate payment for these program by product percentage of our historical sale well any significant change in sale trend patent expiry and product launch an evaluation of the current contract for these program the percentage of our product that are sold via these program and our product pricing although we accrue liability for rebate related to these program at the time we record the sale the rebate related to that sale is typically paid up to six month later because of this time lag in any particular period our rebate adjustment may incorporate revision of accrual for several period most of our rebate outside the are contractual or legislatively mandated and are estimated and recognized in the same period the related sale in some large european country government rebate are based on the anticipated budget for pharmaceutical payment in the country an estimate of these rebate updated governmental authority revise budgeted deficit is recognized in the same period the related sale sale return background and uncertainty when product sale occur to determine the appropriate transaction price for our sale we estimate reserve for future product return related to those sale using an expected value approach this estimate is based on several factor including historical return rate expiration date by product on average approximately month after the initial sale of product to our customer and estimated level of inventory in the wholesale and retail channel well any other specifically identified anticipated return due to known factor such the loss of patent exclusivity product recall and discontinuance or changing competitive environment we maintain return policy that allows customer to return product for dating issue within specified period prior to and subsequent to the product expiration date following the loss of exclusivity for patent dependent product we expect to experience an elevated level of product return product inventory remaining in the wholesale and retail channel expires adjustment to the return reserve have been and may in the future be required based on revised estimate to our assumption we record the return amount deduction to arrive at our net product revenue once the product is returned it is destroyed we do not record right of return asset our return policy outside the are generally more restrictive than in the return are not allowed for reason other than failure to meet product specification in many country our reserve for future product return for product sale outside the is not material part of our process to estimate reserve for product return we regularly review the supply level of our significant product sold to major wholesaler in the and in major market outside the primarily by reviewing periodic inventory report supplied by our major wholesaler and available prescription volume information for our product or alternative approach we attempt to maintain wholesaler inventory level at an average of approximately one month or le on consistent basis across our product portfolio cause of unusual wholesaler buying pattern include actual or anticipated product supply issue weather pattern anticipated change in the transportation network redundant holiday stocking and change in wholesaler business operation in the the current structure of our arrangement provides with data on inventory level at our wholesaler however our data on inventory level in the retail channel is more limited wholesaler stocking and destocking activity historically ha not caused any material change in the rate of actual product return actual product return have been le than percent of our net revenue over each of the past three year and have not fluctuated significantly percentage of revenue although fluctuation are more likely in period following loss of patent exclusivity for major product in the market to revenueadjustments to revenue recognized result of change in estimate for the judgment described above for our most significant sale return rebate and discount liability balance for product shipped in previous period were approximately percent and percent of revenue during and respectively collaboration and other arrangementswe recognize several type of revenue from our collaboration and other arrangement which we discus in general term immediately below and more specifically in note for each of our material collaboration and other arrangement our collaboration and other arrangement are not contract with customer but are evaluated to determine whether any aspect of the arrangement are contract with customer revenue related to product we sell pursuant to these arrangement is included in net product revenue while other source of revenue royalty and profit sharing from our partner are included in collaboration and other revenue initial fee and developmental milestone we receive in collaborative and other similar arrangement from the partnering of our compound under development are generally deferred and amortized into income through the expected product approval date profit sharing due from our collaboration partner which is based upon gross margin reported to by our partner is recognized collaboration and other revenue earned royalty revenue from licensee which is based on sale to third party of licensed product and technology is recorded when the third party sale occurs and the performance obligation to which some or all of the royalty ha been allocated ha been satisfied or partially satisfied this royalty revenue is included in collaboration and other revenue for arrangement involving multiple good or service research and development marketing and selling manufacturing and distribution each required good or service is evaluated to determine whether it is distinct if good or service doe not qualify distinct it is combined with the other non distinct good or service within the arrangement and these combined good or service are treated single performance obligation for accounting purpose the arrangement transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation for arrangement that involve variable consideration where we have sold intellectual property we recognize revenue based on estimate of the amount of consideration we believe we will be entitled to receive from the other party subject to constraint these estimate are adjusted to reflect the actual amount to be collected when those fact and circumstance become known significant judgment must be made in determining the transaction price for our sale of intellectual property because of the risk that product in development will not receive regulatory approval we generally do not recognize any contingent payment that would be due to upon or after regulatory approval we have entered into arrangement whereby we transferred right to product and committed to supply for period of time for those arrangement for which we concluded that the obligation were not distinct any amount received upfront are being amortized to revenue net product revenue over the period of the supply arrangement the performance obligation is satisfied contract liabilitiesour contract liability result from arrangement where we have received payment in advance of performance under the contract and do not include sale return rebate and discount change in contract liability are generally due to either receipt of additional advance payment or our performance under the contract the following table summarizes contract liability balance liability contract liability balance disclosed above of december and were primarily related to the remaining license period of symbolic intellectual property and obligation to supply product for defined period of time during the year ended december and revenue recognized from contract liability of the beginning of the year wa not material revenue expected to be recognized in the future from contract liability the related performance obligation are satisfied is not expected to be material in any one year disaggregation of revenue the following table summarizes revenue by product outside to unaffiliated customer endocrinology trulicity alimta erbitux taltz cymbalta other cialis may not add due to rounding revenue includes revenue in puerto rico humalog revenue includes insulin lispro jardiance revenue includes glyxambi and synjardy trajenta revenue includes jentadueto following table summarizes revenue by geographical area to unaffiliated customer foreign country may not add due to rounding revenue is attributed to the country based on the location of the customer acquisition and divestiturein february we completed the acquisition of loxo oncology inc loxo this transaction further discussed in this note below in acquisition of business wa accounted for business combination under the acquisition method of accounting under this method the asset acquired and liability assumed were recorded at their respective fair value of the acquisition date in our consolidated financial statement the determination of estimated fair value required management to make significant estimate and assumption the excess of the purchase price over the fair value of the acquired net asset where applicable ha been recorded goodwill the result of operation of loxo have been included in our consolidated financial statement from the date of acquisition we acquired asset in development in and which are further discussed in this note below in asset acquisition upon acquisition the acquired ipr charge related to these product were immediately expensed because the product had no alternative future use for the year ended december and we recorded acquired ipr charge of million billion and billion respectively acquisition of businessloxo acquisitionoverview of transactionin february we acquired all share of loxo for purchase price of billion net of cash acquired the accelerated vesting of loxo employee equity award wa recognized transaction expense included in asset impairment restructuring and other special charge during the year ended december see note under the term of the agreement we acquired pipeline of investigational medicine including selpercatinib loxo an oral ret inhibitor granted breakthrough therapy designation by the food and drug administration and loxo an oral btk inhibitor asset acquired and liability assumedthe following table summarizes the amount recognized for asset acquired and liability assumed of the acquisition date estimated fair value at february ipr lived intangible income tax other asset and liability net total identifiable net consideration transferred net of cash acquired billion of the acquired ipr relates to selpercatinib loxo contract based intangible primarily related to vitrakvi which are being amortized to cost of sale on straight line basis over their estimated useful life were expected to have weighted average useful life of approximately year from the acquisition date the goodwill recognized from this acquisition is attributable primarily to future unidentified project and product and the assembled workforce for loxo and is not deductible for tax purpose our consolidated statement of operation for the year ended december includes loxo revenue of million primarily due to regulatory approval and sale milestone received we are unable to provide the result of operation for the year ended december attributable to loxo those operation were substantially integrated into our legacy business pro forma information ha not been included because this acquisition did not have material impact on our result of operation for the year ended december and acquisitionsthe following table and narrative summarize our asset acquisition during and counterpartycompound therapy or assetacquisition month phase of development acquired ipr expenseac immune satau aggregation inhibitor small molecule for the potential treatment of alzheimer disease and other neurodegenerative diseasesjanuary september pre clinical inc novel immunometabolism targetmarch pre clinical bioscience inc potential new medicine in immunology and other select indicationsapril pre clinical therapeutic corporationcntx novel small molecule somatostatin receptor type agonistjuly phase sigilon therapeuticsencapsulated cell therapy for the potential treatment of type diabetesapril pre clinical pharma inc ak an aurora kinase inhibitorjune phase bioscience inc armo cancer therapy pegilodecakinjune phase iii biotechtranslation inhibitor for selected neuroscience targetsjuly pre clinical technology inc priority review voucheroctober not applicable pharmaceutical an oral non peptidic glp receptor agonistoctober pre clinical inc immuno oncology cancer therapiesnovember pre clinical pharmaceutical inc cardio metabolic disease neurodegeneration and paindecember pre clinical antagonist program for the potential treatment of chronic pain syndromesdecember pre clinical colucid pharmaceutical inc colucid oral therapy for the acute treatment of migraine lasmiditanmarch phase iii agmultiple molecule for treatment of metabolic disordersjuly phase ii therapeuticsimmunological therapy nktr phase agcancer vaccinesnovember pre clinical the phase of development presented is of the date of the arrangement and represents the phase of development of the most advanced asset acquired where applicable we recognized acquired ipr expense of million in january upon entering into license agreement and million in september upon entering into an amendment to the license agreement this research and development collaboration agreement ha been terminated to be effective march connection with these arrangement our partner may be entitled to future royalty and or commercial milestone based on sale should product be approved for commercialization and or milestone based on the successful progress of compound through the development process divestiturein october we completed transaction in which we sold the right in china for two legacy antibiotic medicine well manufacturing facility in suzhou china to eddingpharm china based specialty pharmaceutical company in connection with the sale we received net cash proceeds of million from eddingpharm in with an additional payment of million due to in we accounted for the transaction the sale of business we recorded gain of million in other net income expense upon closing the transaction in subsequent event dermira inc dermira acquisitionon january we announced an agreement to acquire dermira for purchase price of per share or approximately billion the acquisition will expand our immunology pipeline with the addition of lebrikizumab novel investigational monoclonal antibody designed to bind il with high affinity that is being evaluated in phase iii clinical development program for the treatment of moderate to severe atopic dermatitis lebrikizumab wa granted fast track designation from the food and drug administration fda the fda fast track designation is designed to expedite the development and review of new therapy to treat serious condition and address unmet medical need the acquisition will also expand our portfolio of marketed dermatology medicine with the addition of qbrexza glycopyrronium cloth medicated cloth approved by the fda for the topical treatment of primary axillary hyperhidrosis uncontrolled excessive underarm sweating the transaction is not subject to any financing condition and is expected to close by the end of the first quarter of subject to customary closing condition including receipt of required regulatory approval and the tender of majority of the outstanding share of dermira common stock note collaboration and other arrangementswe often enter into collaborative and other similar arrangement to develop and commercialize drug candidate collaborative activity may include research and development marketing and selling including promotional activity and physician detailing manufacturing and distribution these arrangement often require milestone and royalty or profit share payment contingent upon the occurrence of certain future event linked to the success of the asset in development well expense reimbursement from or payment to the collaboration partner see note for amount of collaboration and other revenue recognized from these type of arrangement operating expense for cost incurred pursuant to these arrangement are reported in their respective expense line item net of any payment due to or reimbursement due from our collaboration partner with such reimbursement being recognized at the time the party becomes obligated to pay each collaboration is unique in nature and our more significant arrangement are discussed below boehringer ingelheim diabetes collaborationwe and boehringer ingelheim have global agreement to jointly develop and commercialize portfolio of diabetes compound currently included in the collaboration are boehringer ingelheim oral diabetes product trajenta jentadueto jardiance glyxambi synjardy and trijardy xr well our basal insulin basaglar jentadueto is included in the trajenta product family glyxambi synjardy and trijardy xr are included in the jardiance product family table below summarizes significant milestone deferred capitalized for the compound included in this collaboration product family milestone deferred capitalized trajenta in connection with the regulatory approval of basaglar in the europe and japan milestone payment received were recorded contract liability and are being amortized through the term of the collaboration to collaboration and other revenue in connection with the regulatory approval of trajenta and jardiance milestone payment made were capitalized intangible asset and are being amortized to cost of sale through the term of the collaboration this represents the cumulative amount that have been deferred or capitalized from the start of this collaboration through the end of the reporting period the collaboration agreement with boehringer ingelheim for trajenta end upon expiration of the compound patent and any supplementary protection certificate or extension thereto the collaboration agreement with boehringer ingelheim for jardiance end upon expiration of the compound patent and any supplementary protection certificate or extension thereto through december in the most significant market we and boehringer ingelheim shared equally the ongoing development cost commercialization cost and agreed upon gross margin for any product resulting from the collaboration we recorded our portion of the gross margin associated with boehringer ingelheim product collaboration and other revenue we recorded our sale of basaglar to third party net product revenue with the payment made to boehringer ingelheim for their portion of the gross margin recorded cost of sale for all compound under this collaboration we recorded our portion of the development and commercialization cost research and development expense and marketing selling and administrative expense respectively each company wa entitled to potential performance payment depending on the sale of the molecule it contributes to the collaboration these performance payment may have resulted in the owner of the molecule retaining greater share of the agreed upon gross margin of that product subject to achieving these threshold in given period our reported revenue for trajenta and jardiance may have been reduced by any performance payment we make related to these product similarly performance payment we may have received related to basaglar effectively reduced boehringer ingelheim share of the gross margin which reduced our cost of sale effective january we and boehringer ingelheim modernized the alliance in the most significant market we and boehringer ingelheim share equally the ongoing development cost and commercialization cost for the jardiance product family we receive royalty on net sale of boehringer ingelheim product in the most significant market and recognize the royalty collaboration and other revenue we pay to boehringer ingelheim royalty on net sale for basaglar in the we record our sale of basaglar to third party net product revenue with the royalty payment made to boehringer ingelheim recorded cost of sale for the jardiance product family we record our portion of the development and commercialization cost research and development expense and marketing selling and administrative expense respectively boehringer ingelheim is entitled to potential performance payment depending on the net sale of the jardiance product family therefore our reported revenue for jardiance may be reduced by any potential performance payment we make related to this product beginning january the royalty received by related to the jardiance product family may also be increased or decreased depending on whether net sale for this product family exceed or fall below certain threshold the following table summarizes our net product revenue recognized with respect to basaglar and collaboration and other revenue recognized with respect to the trajenta and jardiance family of product have worldwide license and collaboration agreement with incyte corporation incyte which provides the development and commercialization right to it janus tyrosine kinase jak inhibitor compound now known olumiant and certain follow on compound for the treatment of inflammatory and autoimmune disease incyte ha the right to receive tiered double digit royalty payment on future global sale with rate ranging up to percent the agreement call for payment by to incyte associated with certain development success based regulatory and sale based milestone the following table summarizes our significant milestone achieved approval in the intangible asset phase iii testing for systemic lupus erythematosus sle approval in europeintangible approval in japanintangible phase iii testing for atopic dermatitisr of december incyte is eligible to receive up to million of additional payment from contingent upon certain development and success based regulatory milestone incyte is also eligible to receive up to million of potential sale based milestone the agreement provided incyte with option to co develop the compound subject to the collaboration on an indication by indication basis by funding percent of the associated development cost from the initiation of phase iib trial through regulatory approval in exchange for increased tiered royalty ranging up to percentage in the high twenty incyte previously exercised it option to co develop olumiant in rheumatoid arthritis atopic dermatitis alopecia areata and sle however it opted out of co development of all indication of january result we will solely fund all further development and pay lower royalty rate to incyte on sale we record our sale of olumiant to third party net product revenue with the royalty payment made to incyte recorded cost of sale the following table summarizes our net product revenue recognized with respect to olumiant have collaboration agreement with pfizer inc pfizer to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain chronic low back pain and cancer pain under the agreement the company share equally the ongoing development cost and if successful in gross margin and certain commercialization expense of december pfizer is eligible to receive up to million in success based regulatory milestone and up to billion in series of sale based milestone contingent upon the commercial success of tanezumab asset impairment restructuring and other special chargesthe component of the charge included in asset impairment restructuring and other special charge in our consolidated statement of operation are described below and post retirement medical charge associated with voluntary early retirement program see note impairment and other special asset impairment restructuring and other special charge cost recognized during the year ended december and were incurred result of action taken to reduce our cost structure severance cost recognized in were primarily associated with the voluntary early retirement program during severance cost recognized in the and outside the were million and million respectively substantially all of the severance cost incurred in and have been paid substantially all of the severance cost incurred during the year ended december are expected to be paid in the next month asset impairment and other special charge recognized during the year ended december consisted of million related to the acquisition of loxo substantially all of which is associated with the accelerated vesting of loxo employee equity award in addition we incurred an asset impairment charge related to our decision to close and sell research and development facility located in the united kingdom the facility wa written to it estimated fair value which wa based primarily on recent sale of similar asset asset impairment and other special charge recognized during the year ended december resulted primarily from asset impairment and other special charge related to the sale of the posilac rbst brand and the associated augusta georgia manufacturing site asset impairment and other special charge recognized during the year ended december resulted primarily from asset impairment related to lower projected revenue for posilac rbst the asset associated with posilac rbst were written down to their fair value which were determined based upon discounted cash flow valuation impairment charge were recorded for the associated fixed asset and intangible asset of million and million respectively in addition we incurred approximately million of cost associated with the temporary shut down of our puerto rico facility following hurricane maria inventorieswe use the last in first out lifo method for the majority of our inventory located in the continental other inventory are valued by the first in first out fifo method fifo cost approximates current replacement cost inventory measured using lifo must be valued at the lower of cost or market inventory measured using fifo must be valued at the lower of cost or net realizable value inventory at december consisted of the following product in material and approximates replacement cost to lifo valued under the lifo method comprised billion and billion of total inventory at december and respectively note financial instrumentsfinancial instrument that potentially subject to credit risk consist principally of trade receivables and interest bearing investment wholesale distributor of life science product account for substantial portion of our trade receivables collateral is generally not required we seek to mitigate the risk associated with this concentration through our ongoing credit review procedure and insurance large portion of our cash is held by few major financial institution we monitor our exposure with these institution and do not expect any of these institution to fail to meet their obligation major financial institution represent the largest component of our investment in corporate debt security in accordance with documented corporate risk management policy we monitor the amount of credit exposure to any one financial institution or corporate issuer we are exposed to credit related loss in the event of nonperformance by counterparties to risk management instrument but do not expect any counterparties to fail to meet their obligation given their high credit rating we consider all highly liquid investment with maturity of three month or le from the date of purchase to be cash equivalent the cost of these investment approximates fair value our equity investment are accounted for using three different method depending on the type of equity investment investment in company over which we have significant influence but not controlling interest are accounted for using the equity method with our share of earnings or loss reported in other net income expense for equity investment that do not have readily determinable fair value we measure these investment at cost le any impairment plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer any change in recorded value is recorded in other net income expense our public equity investment are measured and carried at fair value any change in fair value is recognized in other net income expense we review equity investment other than public equity investment for indication of impairment and observable price change on regular basis our derivative activity are initiated within the guideline of documented corporate risk management policy and are intended to offset loss and gain on the asset liability and transaction being hedged management review the correlation and effectiveness of our derivative on quarterly basis derivative instrument that are designated and qualify fair value hedge the derivative instrument is marked to market with gain and loss recognized currently in income to offset the respective loss and gain recognized on the underlying exposure for derivative instrument that are designated and qualify cash flow hedge gain and loss are reported component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affect earnings for derivative and non derivative instrument that are designated and qualify net investment hedge the foreign currency translation gain or loss due to spot rate fluctuation are reported component of accumulated other comprehensive loss derivative contract that are not designated hedging instrument are recorded at fair value with the gain or loss recognized in earnings during the period of change we may enter into foreign currency forward or option contract to reduce the effect of fluctuating currency exchange rate principally the euro british pound and the japanese yen foreign currency derivative used for hedging are put in place using the same or like currency and duration the underlying exposure forward and option contract are principally used to manage exposure arising from subsidiary trade and loan payable and receivables denominated in foreign currency these contract are recorded at fair value with the gain or loss recognized in other net income expense we may enter into foreign currency forward and option contract and currency swap fair value hedge of firm commitment forward contract generally have maturity not exceeding month at december we had outstanding foreign currency forward commitment to purchase million dollar and sell million euro commitment to purchase billion euro and sell billion dollar commitment to purchase million dollar and sell billion japanese yen commitment to purchase million swiss franc and sell million dollar and commitment to purchase million british pound and sell million dollar which all settled within day foreign currency exchange risk is also managed through the use of foreign currency debt and cross currency interest rate swap our foreign currency denominated note had carrying amount of billion and billion of december and respectively of which billion and billion have been designated and are effective economic hedge of net investment in certain of our euro denominated foreign operation of december and respectively at december we had outstanding cross currency swap with notional amount of billion swapping dollar to euro billion swapping swiss franc to dollar and million swapping dollar to british pound which have settlement date ranging through our cross currency interest rate swap for which majority convert portion of our dollar denominated floating rate debt to foreign denominated floating rate debt have also been designated and are effective economic hedge of net investment in the normal course of business our operation are exposed to fluctuation in interest rate which can vary the cost of financing investing and operating we seek to address portion of these risk through controlled program of risk management that includes the use of derivative financial instrument the objective of controlling these risk is to limit the impact of fluctuation in interest rate on earnings our primary interest rate risk exposure result from change in short term dollar interest rate in an effort to manage interest rate exposure we strive to achieve an acceptable balance between fixed and floating rate debt and investment position and may enter into interest rate swap or collar to help maintain that balance interest rate swap or collar that convert our fixed rate debt to floating rate are designated fair value hedge of the underlying instrument interest rate swap or collar that convert floating rate debt to fixed rate are designated cash flow hedge interest expense on the debt is adjusted to include the payment made or received under the swap agreement cash proceeds from or payment to counterparties resulting from the termination of interest rate swap are classified operating activity in our consolidated statement of cash flow at december substantially all of our total long term debt is at fixed rate we have converted approximately percent of our long term fixed rate note to floating rate through the use of interest rate swap we also may enter into forward starting interest rate swap which we designate cash flow hedge part of any anticipated future debt issuance in order to reduce the risk of cash flow volatility from future change in interest rate the change in fair value of these instrument is recorded part of other comprehensive income loss and upon completion of debt issuance and termination of the swap is amortized to interest expense over the life of the underlying debt of december the total notional amount of forward starting interest rate contract in designated cash flow hedging instrument were billion which have settlement date ranging between and effect of risk management instrument on the consolidated statement of operationsthe following effect of risk management instrument were recognized in other net income expense value hedge effect from hedged fixed rate debt effect from interest rate contract flow hedge effective portion of loss on interest rate contract reclassified from accumulated other comprehensive cross currency interest rate swap net loss on foreign currency exchange contract not designated hedging the year ended december and the amortization of loss related to the portion of our risk management hedging instrument fair value hedge and cash flow hedge that wa excluded from the assessment of effectiveness wa not material during the year ended december net loss related to ineffectiveness well net loss related to the portion of our risk management hedging instrument fair value hedge and cash flow hedge that were excluded from the assessment of effectiveness were not material the effect of risk management instrument on other comprehensive income loss the effective portion of risk management instrument that wa recognized in other comprehensive income loss is follows investment hedge foreign currency denominated note cross currency interest rate foreign currency exchange contract cash flow hedge forward starting interest rate cross currency interest rate swap in we expect to reclassify million of net loss on cash flow hedge from accumulated other comprehensive loss to other net income expense during the year ended december and the amount excluded from the assessment of hedge effectiveness recognized in other comprehensive income loss were not material value of financial instrumentsthe following table summarize certain fair value information at december for asset and liability measured at fair value on recurring basis well the carrying amount and amortized cost of certain other investment fair value measurement using descriptioncarryingamount cost quoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvaluedecember cash equivalent term investment government and agency security debt backed term investment noncurrent investment government and agency security debt backed backed equity investment without readily determinable fair value equity method investment noncurrent investment december cash equivalent term investment government and agency security debt backed term investment noncurrent investment government and agency security debt backed backed equity investment without readily determinable fair value equity method investment noncurrent investment for available for sale debt security amount disclosed represent the security amortized cost fair value disclosure are not applicable for equity method investment and investment accounted for under the measurement alternative for equity investment fair value measurement using descriptioncarryingamount quoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvalueshort term commercial paper borrowing december december long term debt including current portion december december fair value measurement using descriptioncarryingamount quoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvaluedecember risk management instrument interest rate contract designated fair value hedge other noncurrent asset rate contract designated cash flow hedge other noncurrent currency interest rate contract designated net investment hedge other noncurrent other current liability other noncurrent liability cross currency interest rate contract designated cash flow hedge other noncurrent noncurrent liability foreign exchange contract not designated hedging instrument other current liability december risk management instrument interest rate contract designated fair value hedge other noncurrent current liability other noncurrent liability cross currency interest rate contract designated net investment hedge other other noncurrent other current liability cross currency interest rate contract not designated hedging instrument other noncurrent liability foreign exchange contract not designated hedging instrument other current liability risk management instrument above are disclosed on gross basis there are various right of setoff associated with certain of the risk management instrument above that are subject to enforceable master netting arrangement or similar agreement although various right of setoff and master netting arrangement or similar agreement may exist with the individual counterparties to the risk management instrument above individually these financial right are not material we determine our level and level fair value measurement based on market approach using quoted market value significant other observable input for identical or comparable asset or liability or discounted cash flow analysis level fair value measurement for other investment security are determined using unobservable input including the investment cost adjusted for impairment and price from orderly transaction the fair value of equity method investment and investment measured under the measurement alternative for equity investment that do not have readily determinable fair value are not readily available the table below summarizes the contractual maturity of our investment in debt security measured at fair value of december maturity by period total le year year year more than yearsfair value of debt security net unrealized gain loss recognized in our consolidated statement of operation for equity security were million and million for the year ended december and respectively we adjust our equity investment without readily determinable fair value based upon change in the equity instrument value resulting from observable price change in orderly transaction for an identical or similar investment of the same issuer downward adjustment resulting from an impairment are recorded based upon impairment consideration including the financial condition and near term prospect of the issuer general market condition and industry specific factor adjustment recorded for the year ended december and were not material summary of the fair value of available for sale security in an unrealized gain or loss position and the amount of unrealized gain and loss in accumulated other comprehensive loss follows gross gain gross value of security in an unrealized gain value of security in an unrealized loss periodically ass our investment in available for sale security for other than temporary impairment loss other than temporary impairment loss were not material in and there were no other than temporary impairment loss in or for debt security the amount of credit loss are determined by comparing the difference between the present value of future cash flow expected to be collected on these security and the amortized cost factor considered in assessing credit loss include the position in the capital structure vintage and amount of collateral delinquency rate current credit support and geographic concentration of december the available for sale security in an unrealized loss position include primarily fixed rate debt security of varying maturity which are sensitive to change in the yield curve and other market condition approximately percent of the fixed rate debt security in loss position are investment grade debt security of december we do not intend to sell and it is not more likely than not that we will be required to sell the security in loss position before the market value recover or the underlying cash flow have been received and there is no indication of default on interest or principal payment for any of our debt security activity related to our investment portfolio substantially all of which related to equity and available for sale security wa follows from sale gross gain on gross loss on gain and loss on sale of available for sale investment are computed based upon specific identification of the initial cost adjusted for any other than temporary decline in fair value that were recorded in earnings receivable factoring arrangementswe have entered into account receivable factoring agreement with financial institution to sell certain of our non account receivable these transaction are accounted for sale and result in reduction in account receivable because the agreement transfer effective control over and risk related to the receivables to the buyer our factoring agreement do not allow for recourse in the event of uncollectibility and we do not retain any interest in the underlying account receivable once sold we derecognized million and million of account receivable of december and respectively under these factoring arrangement the cost of factoring such account receivable on our consolidated result of operation for the year ended december and were not material note goodwill and other intangiblesgoodwillgoodwill result from excess consideration in business combination over the fair value of identifiable net asset acquired goodwill is not amortized but is reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value to it carrying value is performed to determine the amount of any impairment the change in goodwill during wa primarily related to our acquisition of loxo see note for further discussion no impairment occurred with respect to the carrying value of goodwill for the year ended december and other intangiblesthe component of intangible asset other than goodwill at december were follows gross accumulatedamortization carryingamount net carryingamount gross accumulatedamortization carryingamount netfinite lived intangible asset marketed product finite lived intangible lived intangible asset acquired ipr other intangible product consist of the amortized cost of the right to asset acquired in business combination and approved for marketing in significant global jurisdiction europe and japan and capitalized milestone payment for transaction other than business combination we capitalize milestone payment incurred at or after the product ha obtained regulatory approval for marketing other finite lived intangible consist primarily of the amortized cost of licensed platform technology that have alternative future us in research and development manufacturing technology and customer relationship from business combination acquired ipr consists of the related cost capitalized adjusted for subsequent impairment if any the cost of acquired ipr project acquired directly in transaction other than business combination are capitalized if the project have an alternative future use otherwise they are expensed immediately the fair value of acquired ipr project acquired in business combination if any are capitalized other intangible asset method may be used to determine the estimated fair value of other intangible acquired in business combination we utilize the income method which is level fair value measurement and applies probability weighting that considers the risk of development and commercialization to the estimated future net cash flow that are derived from projected revenue and estimated cost these projection are based on factor such relevant market size patent protection historical pricing of similar product analyst expectation and expected industry trend the estimated future net cash flow are then discounted to the present value using an appropriate discount rate this analysis is performed for each asset independently the acquired ipr asset are treated indefinite lived intangible asset until completion or abandonment of the project at which time the asset are tested for impairment and amortized over the remaining useful life or written off appropriate see note for further discussion of intangible asset acquired in recent business combination and note for additional discussion of recent capitalized milestone payment the increase in marketed product and acquired ipr intangible asset in were primarily related to our acquisition of loxo other indefinite lived intangible asset are reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value of the asset is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value of the intangible asset to it carrying value is performed to determine the amount of any impairment finite lived intangible asset are reviewed for impairment when an indicator of impairment is present when required comparison of fair value to the carrying amount of asset is performed to determine the amount of any impairment when determining the fair value of indefinite lived acquired ipr well the fair value of finite lived intangible asset for impairment testing purpose we utilize the income method discussed above intangible asset with finite life are capitalized and are amortized over their estimated useful life ranging from three to year of december the remaining weighted average amortization period for finite lived intangible asset wa approximately year amortization expense related to finite lived intangible asset wa follows expense estimated amortization expense for each of the next five year associated with our finite lived intangible asset of december is follows amortization expense expense is included in either cost of sale marketing selling and administrative or research and development depending on the nature of the intangible asset being amortized property and equipmentproperty and equipment is stated on the basis of cost provision for depreciation of building and equipment are computed generally by the straight line method at rate based on their estimated useful life to year for building and three to year for equipment we review the carrying value of long lived asset for potential impairment on periodic basis and whenever event or change in circumstance indicate the carrying value of an asset may not be recoverable impairment is determined by comparing projected undiscounted cash flow to be generated by the asset to it carrying value if an impairment is identified loss is recorded equal to the excess of the asset net book value over it fair value and the cost basis is adjusted at december property and equipment consisted of the following in accumulated depreciation property and equipment net expense related to property and equipment wa follows expense interest cost were not material for the year ended december and the following table summarizes long lived asset by geographical area lived asset and puerto rico foreign country lived asset long lived asset consist of property and equipment net operating lease asset and certain other noncurrent asset leaseswe determine if an arrangement is lease at inception we have lease with term up to year for corporate office research and development facility vehicle and equipment including some of which have option to extend and or early terminate the lease we determine the lease term by assuming the exercise of any renewal and or early termination option that are reasonably assured beginning january operating lease right of use asset have been presented in operating lease asset in our consolidated balance sheet and the current and long term portion of operating lease liability are included in other current liability and noncurrent operating lease liability respectively in our consolidated balance sheet short term lease which are deemed at inception to have lease term of month or le are not recorded on the consolidated balance sheet operating lease asset represent our right to use an underlying asset for the lease term and operating lease liability represent our obligation to make lease payment arising from the lease operating lease asset and liability are recognized at commencement date based on the present value of lease payment over the lease term most of our lease do not provide an implicit rate we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payment lease expense for operating lease asset which is recognized on straight line basis over the lease term wa million during the year ended december variable lease payment which represent non lease component such maintenance insurance and tax and which vary due to change in fact or circumstance occurring after the commencement date other than the passage of time are expensed in the period in which the payment obligation is incurred and were not material during the year ended december short term lease expense wa not material during the year ended december supplemental balance sheet information related to operating lease of december wa follows weighted average remaining lease yearsweighted average discount supplemental cash flow information related to operating lease during the year ended december wa follows operating cash flow from operating lease of use asset obtained in exchange for new operating lease annual minimum lease payment of our operating lease liability of december were follows year year lease imputed expense for all lease including contingent rental not material wa million and million for the year ended december and respectively finance lease are included in property and equipment short term borrowing and current maturity of long term debt and long term debt in our consolidated balance sheet finance lease are not material to our consolidated financial statement borrowingsdebt at december consisted of the following term commercial paper borrowing to percent long term note due long term debt issuance cost fair value adjustment on hedged long term current portion long term debt weighted average effective borrowing rate on outstanding commercial paper at december wa percent at december we had total of billion of unused committed bank credit facility which consisted primarily of billion credit facility that expires in december and billion day facility that expires in december both of which are available to support our commercial paper program we have not drawn against the billion and billion facility of the remaining committed bank credit facility the outstanding balance of december and december were not material compensating balance and commitment fee are not material and there are no condition that are probable of occurring under which the line may be withdrawn in february we issued billion of percent fixed rate note due in march million of percent fixed rate note due in march billion of percent fixed rate note due in march and billion of percent fixed rate note due in march with interest to be paid semi annually we used the net proceeds of billion from the offering to repay commercial paper that wa issued in connection with the acquisition of loxo and for general corporate purpose in november we issued euro denominated note consisting of million of percent fixed note due november and billion of percent fixed rate note due in november with interest to be paid annually we paid billion comprised of billion of net cash proceeds from the offering and proceeds from commercial paper to purchase and redeem certain higher interest rate dollar denominated note with an aggregate principal amount of billion and net carrying value of billion resulting in debt extinguishment loss of million this loss wa included in other net income expense in our consolidated statement of operation during the year ended december in november we issued japanese yen denominated note consisting of billion of percent fixed rate note due in november billion of percent fixed rate note due in november and billion of percent fixed rate note due in november with interest to be paid semi annually we used the net cash proceeds from the offering of million for general corporate purpose including to repay outstanding commercial paper the aggregate amount of maturity on long term debt for the next five year are follows on long term debt have converted approximately percent of our long term fixed rate note to floating rate through the use of interest rate swap the weighted average effective borrowing rate based on long term debt obligation and interest rate at december and including the effect of interest rate swap for hedged debt obligation were percent and percent respectively the aggregate amount of cash payment for interest on borrowing net of capitalized interest are follows payment for interest on borrowing accordance with the requirement of derivative and hedging guidance the portion of our fixed rate debt obligation that is hedged fair value hedge is reflected in the consolidated balance sheet an amount to the sum of the debt carrying value plus the fair value adjustment representing change in fair value of the hedged debt attributable to movement in market interest rate subsequent to the inception of the hedge note stock based compensationour stock based compensation expense consists of performance award pa shareholder value award svas and restricted stock unit rsus we recognize the fair value of stock based compensation expense over the requisite service period of the individual grantee which generally equal the vesting period we provide newly issued share of our common stock and treasury stock to satisfy the issuance of pa sva and rsu share stock based compensation expense and the related tax benefit were follows based compensation expense december stock based compensation award may be granted under the lilly stock plan for not more than million additional share performance award programpas are granted to officer and management and are payable in share of our common stock the number of pa share actually issued if any varies depending on the achievement of certain pre established earnings per share target over two year period pa share are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period the fair value of pa granted for the year ended december and were and respectively the number of share ultimately issued for the pa program is dependent upon the eps achieved during the vesting period pursuant to this program approximately million share million share and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested pa wa million which will be amortized over the weighted average remaining requisite service period of month shareholder value award programsvas are granted to officer and management and are payable in share of our common stock the number of share actually issued if any varies depending on our stock price at the end of the three year vesting period compared to pre established target stock price we measure the fair value of the sva unit on the grant date using monte carlo simulation model the model utilizes multiple input variable that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award expected volatility utilized in the model are based on implied volatility from traded option on our stock historical volatility of our stock price and other factor similarly the dividend yield is based on historical experience and our estimate of future dividend yield the risk free interest rate is derived from the treasury yield curve in effect at the time of grant the weighted average fair value of the sva unit granted during the year ended december and were and respectively determined using the following assumption percent dividend risk free interest to this program approximately million share million share and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested svas wa million which will be amortized over the weighted average remaining requisite service period of month stock unitsrsus are granted to certain employee and are payable in share of our common stock rsu share are accounted for at fair value based upon the closing stock price on the date of grant the corresponding expense is amortized over the vesting period typically three year the fair value of rsu award granted during the year ended december and were and respectively the number of share ultimately issued for the rsu program remains constant with the exception of forfeiture pursuant to this program million million and million share were granted and approximately million million and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested rsus wa million which will be amortized over the weighted average remaining requisite service period of month note shareholder equityduring and we repurchased billion billion and million respectively of share associated with our share repurchase program of december we had billion remaining under our billion share repurchase program that our board authorized in june we have million authorized share of preferred stock of december and no preferred stock wa issued we have an employee benefit trust that held million share of our common stock at both december and to provide source of fund to assist in meeting our obligation under various employee benefit plan the cost basis of the share held in the trust wa billion at both december and and is shown reduction of shareholder equity any dividend transaction between and the trust are eliminated stock held by the trust is not considered outstanding in the computation of eps the asset of the trust were not used to fund any of our obligation under these employee benefit plan during the year ended december and note income taxesin december the president of the signed into law the tax act the tax act included significant change to the corporate income tax system such the reduction in the corporate income tax rate from percent to percent transition to territorial tax system change to business related exclusion deduction and credit and modification to international tax provision including one time repatriation transition tax also known the toll tax on unremitted foreign earnings and global intangible low taxed income gilti provision the new minimum tax on the earnings of our foreign subsidiary in we recognized provisional amount of billion which wa included component of income tax expense from continuing operation this amount represented approximately billion attributable to the toll tax partially offset by the change in deferred tax resulting from the transition to territorial system including the re measurement of deferred tax in we recorded million of income tax benefit mainly attributable to measurement period adjustment to the toll tax and gilti deferred tax are recognized for the future tax effect of temporary difference between financial and income tax reporting based on enacted tax law and rate deferred tax related to gilti are also recognized for the future tax effect of temporary difference we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position based on it technical merit will be sustained upon examination by the taxing authority the tax benefit recognized in the financial statement from such position are measured based on the largest benefit that ha greater than percent likelihood of being realized upon ultimate resolution is the composition of income tax expense federal total current tax federal foreign state deferred tax benefit income tax the current tax expense includes million of tax benefit from utilization of net operating loss carryforwards the and current tax expense includes million and billion of tax expense respectively related to effect of the tax act the and deferred tax benefit includes million and billion of tax benefit respectively related to the effect of the tax act significant component of our deferred tax asset and liability of december were follows tax asset purchase of intangible asset and credit carryforwards and loss carryforwards and rebate and lease product return comprehensive loss on hedging gross deferred tax allowance total deferred tax tax liability earnings of foreign subsidiary intangible inventory prepaid employee benefit property and equipment financial instrument operating lease asset total deferred tax liability deferred tax asset net deferred tax asset and related valuation allowance amount for federal and state net operating loss and tax credit shown above have been reduced for difference between financial reporting and tax return filing at december based on filed tax return we have tax credit carryforwards and carrybacks of million available to reduce future income tax million if unused will expire by and million if unused will expire between and the remaining portion of the tax credit carryforwards is to federal tax credit of million international tax credit of million and state tax credit of million all of which are substantially reserved at december based on filed tax return we had net operating loss and other carryforwards for international and federal income tax purpose of million million will expire by million will expire between and and million of the carryforwards will never expire net operating loss and other carryforwards for international and federal income tax purpose are partially reserved deferred tax asset related to state net operating loss of million and other state carryforwards of million are fully reserved of december domestic and puerto rican company contributed approximately percent percent and percent for the year ended december and respectively to consolidated income before income tax we have subsidiary operating in puerto rico under tax incentive grant effective through the end of the tax act introduced international tax provision that fundamentally change the taxation of foreign earnings result substantially all of the unremitted earnings of our foreign subsidiary are considered to not be indefinitely reinvested for continued use in our foreign operation at december we had accrued an immaterial amount of foreign withholding tax and state income tax that would be owed upon future distribution of unremitted earnings of our foreign subsidiary that are not indefinitely reinvested for the amount considered to be indefinitely reinvested it is not practicable to determine the amount of the related deferred income tax liability due to the complexity in the tax law and assumption we would have to make cash payment of federal state and foreign income tax net of refund were follows payment of income tax tax act provided an election to taxpayer subject to the toll tax to make payment over an eight year period we made this election therefore we have included toll tax payment accordingly following is reconciliation of the income tax expense applying the federal statutory rate to income before income tax to reported income tax expense tax at the federal statutory tax rate deduct international operation including puerto rico general business credit non deductible acquired ipr tax act income tax non deductible acquired ipr wa related to armo in and colucid in see note for additional information related to acquisition reconciliation of the beginning and ending amount of gross unrecognized tax benefit is follows balance at january based on tax position related to the current for tax position of prior for tax position of prior year settlement lapse of statute of limitation change related to the impact of foreign currency translation balance at december total amount of unrecognized tax benefit that if recognized would affect our effective tax rate wa billion and billion at december and respectively we file income tax return in the federal jurisdiction and various state local and non jurisdiction we are no longer subject to federal state and local or non income tax examination in most major taxing jurisdiction for year before the examination of tax year began in and certain matter were effectively settled during the second quarter of result our gross uncertain tax position were reduced by approximately million we made cash payment of approximately million and our consolidated result were benefited by an immaterial reduction in tax expense during the fourth quarter of certain matter for tax year were effectively settled upon conclusion of the internal revenue service irs examination which resulted in an immaterial reduction in tax expense and gross uncertain tax position also in the fourth quarter of the irs began it examination of tax year we recognize both accrued interest and penalty related to unrecognized tax benefit in income tax expense we recognized income tax benefit expense related to interest and penalty follows tax benefit expense december and our accrual for the payment of interest and penalty totaled million and million respectively retirement benefitswe use measurement date of december to develop the change in benefit obligation change in plan asset funded status and amount recognized in the consolidated balance sheet at december for our defined benefit pension and retiree health benefit plan which were follows defined benefitpension plan retiree healthbenefit plan in benefit obligation benefit obligation at beginning of year gain benefit paid plan amendment curtailment gain loss currency exchange rate change and other benefit obligation at end of in plan asset fair value of plan asset at beginning of return on plan paid foreign currency exchange rate change and other fair value of plan asset at end of status net actuarial gain prior service benefit net amount recognized recognized in the consolidated balance sheet consisted of other noncurrent asset current liability accrued retirement benefit accumulated other comprehensive income loss before income net amount recognized unrecognized net actuarial loss gain and unrecognized prior service cost benefit have not yet been recognized in net periodic pension cost and were included in accumulated other comprehensive loss at december market variable associated with the remeasurement specifically decrease in the discount rate partially offset by higher return on plan asset were the primary driver for the billion increase in the benefit obligation in in july we announced that we would amend our defined benefit pension and retiree health benefit plan to freeze or reduce benefit for certain employee effective january we remeasured the impacted pension and retiree health plan benefit obligation of july which resulted in net curtailment gain of million which wa recorded in asset impairment restructuring and other special charge market variable associated with this remeasurement specifically an increase in the discount rate were the primary driver for the billion decrease in the benefit obligation in the workforce reduction plan initiated in included curtailment loss of million and special termination benefit of million of which million wa recorded in asset impairment restructuring other special charge and million wa recorded in discontinued operation result of remeasurement of october the special termination benefit related to early retirement incentive offered part of voluntary early retirement program for the plan in the fourth quarter of this program allowed certain employee the opportunity to voluntarily leave the company the following represents our weighted average assumption of december defined benefitpension plan retiree healthbenefit plan percent rate for benefit discount rate for net benefit of compensation increase for benefit rate of compensation increase for net benefit expected return on plan asset for net benefit annually evaluate the expected return on plan asset in our defined benefit pension and retiree health benefit plan in evaluating the expected rate of return we consider many factor with primary analysis of current and projected market condition asset return and asset allocation and the view of leading financial adviser and economist we may also review our historical assumption compared with actual result well the assumption and trend rate utilized by similar plan where applicable given the design of our retiree health benefit plan healthcare cost trend rate do not have material impact on our financial condition or result of operation the following benefit payment which reflect expected future service appropriate are expected to be paid follows benefit pension plan health benefit relating to defined benefit pension plan with projected benefit obligation in excess of plan asset were follows at december benefit obligation value of plan relating to defined benefit pension plan and retiree health benefit plan with accumulated benefit obligation in excess of plan asset were follows at december defined benefitpension plan retiree health benefit plan benefit obligation value of plan the total accumulated benefit obligation for our defined benefit pension plan wa billion and billion at december and respectively pension and retiree health benefit expense included the following component defined benefitpension plan retiree healthbenefit plan of net periodic benefit cost service cost return on plan asset amortization of prior service benefit recognized actuarial gain termination benefit periodic benefit cost the following represents the amount recognized in other comprehensive income loss for the year ended december and defined benefitpension plan retiree healthbenefit plan gain loss arising during period amendment during period curtailment gain loss amortization of prior service benefit cost included in net amortization of net actuarial loss included in net currency exchange rate change and other total other comprehensive income loss during period have defined contribution saving plan that cover our eligible employee worldwide the purpose of these plan is generally to provide additional financial security during retirement by providing employee with an incentive to save our contribution to the plan are based on employee contribution and the level of our match expense under the plan totaled million million and million for the year ended december and respectively we provide certain other postemployment benefit primarily related to disability benefit and accrue for the related cost over the service life of employee expense associated with these benefit plan for the year ended december and were not material benefit plan investmentsour benefit plan investment policy are set with specific consideration of return and risk requirement in relationship to the respective liability and puerto rico plan represent approximately percent of our global investment given the long term nature of our liability these plan have the flexibility to manage an above average degree of risk in the asset portfolio at the investment policy level there are no specifically prohibited investment however within individual investment manager mandate restriction and limitation are contractually set to align with our investment objective ensure risk control and limit concentration we manage our portfolio to minimize concentration of risk by allocating fund within asset category in addition within category we use different manager with various management objective to eliminate any significant concentration of risk global benefit plan may enter into contractual arrangement derivative to implement the local investment policy or manage particular portfolio risk derivative are principally used to increase or decrease exposure to particular public equity fixed income commodity or currency market more rapidly or le expensively than could be accomplished through the use of the cash market the plan utilize both exchange traded and over the counter instrument the maximum exposure to either market or counterparty credit loss is limited to the carrying value of the receivable and is managed within contractual limit we expect all of our counterparties to meet their obligation the gross value of these derivative receivables and payable are not material to the global asset portfolio and their value are reflected within the table below the defined benefit pension and retiree health benefit plan allocation for the and puerto rico currently comprises approximately percent growth investment and percent fixed income investment the growth investment allocation encompasses and international public equity security hedge fund private equity like investment and real estate these portfolio allocation are intended to reduce overall risk by providing diversification while seeking moderate to high return over the long term public equity security are well diversified and invested in and international small to large company across various asset manager and style the remaining portion of the growth portfolio is invested in private alternative investment fixed income investment primarily consist of fixed income security in treasury and agency emerging market debt obligation corporate bond mortgage backed security commercial mortgage backed obligation and any related repurchase agreement hedge fund are privately owned institutional investment fund that generally have moderate liquidity hedge fund seek specified level of absolute return regardless of overall market condition and generally have low correlation to public equity and debt market hedge fund often invest substantially in financial market instrument stock bond commodity currency derivative etc using very broad range of trading activity to manage portfolio risk hedge fund strategy focus primarily on security selection and seek to be neutral with respect to market move common grouping of hedge fund strategy include relative value tactical and event driven relative value strategy include arbitrage when the same asset can simultaneously be bought and sold at different price achieving an immediate profit tactical strategy often take long and short position to reduce or eliminate overall market risk while seeking particular investment opportunity event strategy opportunity can evolve from specific company announcement such merger and acquisition and typically have little correlation to overall market directional movement our hedge fund investment are made through limited partnership interest in fund of fund structure and directly into hedge fund plan holding in hedge fund are valued based on net asset value navs calculated by each fund or general partner applicable and we have the ability to redeem these investment at nav private equity like investment fund typically have low liquidity and are made through long term partnership or joint venture that invest in pool of capital invested in primarily non publicly traded entity underlying investment include venture capital early stage investing buyout special situation private debt and private real estate investment private equity management firm typically acquire and then reorganize private company to create increased long term value private equity like fund usually have limited life of approximately year and require minimum investment commitment from their limited partner our private equity like investment are made both directly into fund and through fund of fund structure to ensure broad diversification of management style and asset across the portfolio plan holding in private equity like investment are valued using the value reported by the partnership adjusted for known cash flow and significant event through our reporting date value provided by the partnership are primarily based on analysis of and judgment about the underlying investment input to these valuation include underlying navs discounted cash flow valuation comparable market valuation and may also include adjustment for currency credit liquidity and other risk applicable the vast majority of these private partnership provide with annual audited financial statement including their compliance with fair valuation procedure consistent with applicable accounting standard real estate is composed of public holding real estate investment in registered investment company that trade on an exchange are classified level on the fair value hierarchy real estate investment in fund measured at fair value on the basis of nav provided by the fund manager are classified such these navs are developed with input including discounted cash flow independent appraisal and market comparable analysis other asset include cash and cash equivalent and mark to market value of derivative cash value of the trust owned insurance contract is primarily invested in investment grade publicly traded equity and fixed income security other than hedge fund private equity like investment and portion of the real estate holding which are discussed above we determine fair value based on market approach using quoted market value significant other observable input for identical or comparable asset or liability or discounted cash flow analysis the fair value of our defined benefit pension plan and retiree health plan asset of december by asset category were follows fair value measurement using asset classtotal quoted price in active market foridentical asset level significantobservable input level significantunobservable input level investment valued at net asset value defined benefit pension plan public equity security income developed market repurchase agreement emerging alternative investment hedge like retiree health benefit plan public equity security income developed alternative investment hedge like value of trust owned insurance real certain investment that are measured at fair value using the nav per share or it equivalent practical expedient have not been classified in the fair value hierarchy no material transfer between level level or level occurred during the year ended december the activity in the level investment during the year ended december wa not material fair value of our defined benefit pension plan and retiree health plan asset of december by asset category were follows fair value measurement using asset classtotal quoted price in active market for identical asset level significant observable input level significant unobservable input level investment valued at net asset value defined benefit pension plan public equity security income developed market repurchase agreement emerging alternative investment hedge like retiree health benefit plan public equity security income developed alternative investment hedge like value of trust owned insurance real certain investment that are measured at fair value using the nav per share or it equivalent practical expedient have not been classified in the fair value hierarchy no material transfer between level level or level occurred during the year ended december the activity in the level investment during the year ended december wa not material in we expect to contribute approximately million to our defined benefit pension plan to satisfy minimum funding requirement for the year additional discretionary contribution are not expected to be significant contingencieswe are party to various legal action and government investigation the most significant of these are described below it is not possible to determine the outcome of these matter and we can not reasonably estimate the maximum potential exposure or the range of possible loss in excess of amount accrued for any of these matter however we believe that except noted below with respect to the alimta patent litigation and administrative proceeding the resolution of all such matter will not have material adverse effect on our consolidated financial position or liquidity but could possibly be material to our consolidated result of operation in any one accounting period litigation accrual environmental liability and the related estimated insurance recoverables are reflected on gross basis liability and asset respectively on our consolidated balance sheet with respect to the product liability claim currently asserted against we have accrued for our estimated exposure to the extent they are both probable and reasonably estimable based on the information available to we accrue for certain product liability claim incurred but not filed to the extent we can formulate reasonable estimate of their cost we estimate these expense based primarily on historical claim experience and data regarding product usage legal defense cost expected to be incurred in connection with significant product liability loss contingency are accrued when both probable and reasonably estimable patent litigationalimta patent litigation and administrative proceedingsa number of manufacturer are seeking approval in the number of country in europe and japan to market generic form of alimta prior to the expiration of our vitamin regimen patent alleging that those patent are invalid not infringed or both we believe our alimta vitamin regimen patent are valid and enforceable against these generic manufacturer however it is not possible to determine the ultimate outcome of the proceeding and accordingly we can provide no assurance that we will prevail an unfavorable outcome in the could have material adverse impact on our future consolidated result of operation liquidity and financial position we expect that loss of exclusivity for alimta in any of the below jurisdiction would result in rapid and severe decline in future revenue for the product in the relevant market patent litigation and administrative proceedingswe filed lawsuit in the district court for the district of delaware against eagle pharmaceutical inc eagle in response to it application to market product using an alternative form of pemetrexed the active ingredient in alimta in december we and eagle reached an agreement to settle all pending litigation allowing eagle limited initial entry into the market with it product starting february up to an approximate three week supply and subsequent unlimited entry starting april alimta is protected by vitamin regimen patent plus pediatric exclusivity through may in june the district court for the southern district of indiana ruled in our favor in two similar case finding dr reddy laboratory dr reddy and hospira inc hospira proposed product would infringe our method of use patent under the doctrine of equivalent the district court also ruled that the use of hospira proposed product would literally infringe our method of use patent in august the court of appeal for the federal circuit affirmed the district court ruling that the use of dr reddy and hospira proposed product would infringe our patent under the doctrine of equivalent but reversed the finding of literal infringement with respect to hospira product in november the court denied dr reddy and hospira petition for rehearing of the court doctrine of equivalent ruling dr reddy and hospira have petitioned the supreme court to review the case we have lawsuit pending alleging infringement against actavis llc actavis and apotex inc apotex in response to their application to market product using alternative form of pemetrexed in december the district court for the southern district of indiana granted our motion for summary judgment of infringement under the doctrine of equivalent and denied apotex motion apotex ha appealed the lawsuit against actavis ha been stayed pending the conclusion of the dr reddy and hospira appeal described above european patent litigationlegal proceeding are ongoing in various national court throughout europe we are aware that several company have received approval to market generic version of pemetrexed in major european market including generic currently on the market at risk in france germany and the netherlands and that additional generic competitor may choose to launch at risk we will continue to seek to remove any generic product launched at risk in european market and seek damage with respect to such launch and defend our patent against validity challenge japanese administrative proceedingsthree separate set of demand for invalidation of our two japanese vitamin regimen patent involving several company have been filed with the japanese patent office jpo the jpo rejected demand for invalidation by sawai pharmaceutical co ltd which wa affirmed on appeal in in july the jpo issued written decision dismissing demand brought by nipro corporation nipro for invalidation of our two japanese vitamin regimen patent in november the ip high court in tokyo affirmed the dismissal of nipro demand for invalidation the jpo scheduled hearing in march concerning the demand brought by hospira if upheld through all challenge these patent would provide intellectual property protection for alimta until june notwithstanding our patent generic version of alimta received regulatory approval in japan starting in february we do not currently anticipate that generic version of alimta will proceed to pricing approval jardiance patent litigationboehringer ingelheim our partner in marketing and development of jardiance initiated patent litigation in the district court of delaware involving jardiance glyxambi and synjardy in accordance with the procedure set out in the drug price competition and patent term restoration act of the hatch waxman act several company submitted abbreviated new drug application seeking approval to market generic version of jardiance prior to the expiration of the relevant patent alleging certain patent including in some allegation the compound patent are invalid or would not be infringed trial is scheduled in april taltz patent litigationwe have been named defendant in litigation filed by genentech inc in the district court for the southern district of california seeking ruling that genentech patent would be infringed by our continued sale of taltz separately the patent and trademark office uspto ha granted our request to initiate post grant review pgr to examine the validity of genentech patent asserted against in the litigation we expect uspto decision on the merit in the fourth quarter of the litigation in the district court for the southern district of california ha been stayed pending the outcome of the pgr we have also been named defendant in litigation filed by genentech in germany asserting infringement of related genentech patent and seeking similar ruling of patent infringement by sale of taltz in germany we expect trial to ass genentech infringement claim could take place in late or early we have ongoing litigation in the in which genentech ha asserted similar claim regarding genentech corresponding patent we believe all of these lawsuit are without merit and we are vigorously defending against them emgality patent litigationwe have been named defendant in litigation filed by teva pharmaceutical international gmbh and teva pharmaceutical usa inc collectively teva in the district court for the district of massachusetts seeking ruling that various claim in nine different teva patent would be infringed by our launch and continued sale of emgality for the prevention of migraine in adult we believe this lawsuit is without merit and are defending against it vigorously separately the uspto granted our request to initiate an inter partes review ipr to reexamine the validity of the nine teva patent asserted against in the litigation in february the uspto ruled in our favor and found that all claim asserted against in six of teva nine patent were invalid we expect the uspto to issue decision on the remaining three teva patent in the second quarter of the litigation in the district court for the district of massachusetts ha been stayed pending the outcome of the uspto decision on all nine of teva patent product liability litigationcymbalta product liability litigationwe were named defendant in purported class action lawsuit in the district court for the central district of california now called strafford et al eli lilly and company involving cymbalta the plaintiff purporting to represent class of person who purchased and or paid for cymbalta asserted claim under the consumer protection statute of california massachusetts missouri and new york and sought declaratory injunctive and monetary relief for various alleged economic injury arising from their purchase the district court denied the plaintiff motion for class certification plaintiff voluntarily dismissed their claim the plaintiff subsequently appealed to the court of appeal for the ninth circuit in november the court of appeal for the ninth circuit dismissed the appeal for lack of jurisdiction in july the district court for the central district of california denied the plaintiff motion to reopen the case the plaintiff appealed this denial to the court of appeal for the ninth circuit and in january the ninth circuit affirmed the district court decision the plaintiff have filed petition for rehearing before the ninth circuit other mattersbrazil litigation cosmopolis facilitylabor attorney litigationour subsidiary in brazil eli lilly do brasil limitada lilly brasil is named in lawsuit brought by the labor attorney for the region in the labor court of paulinia state of sao paulo brazil alleging possible harm to employee and former employee caused by exposure to heavy metal at former lilly brasil manufacturing facility in cosmopolis brazil operated by the company between and in may the labor court judge ruled against lilly brasil ordering it to undertake several action of unspecified financial impact including paying lifetime health coverage for the employee and contractor who worked at the cosmopolis facility more than six month during the affected year and their child born during and after this period we appealed this decision in july the appeal court affirmed the labor court ruling with the total financial impact of the ruling estimated to be approximately million brazilian real approximately million of december the appeal court restricted the broad health coverage awarded by the labor court to health problem that claimant could show arose from exposure to the alleged contamination in august lilly brasil filed an appeal to the superior labor court in september the appeal court stayed number of element of it prior decision including the obligation to provide health coverage for contractor their child and child of employee who worked at the cosmopolis facility pending the determination of lilly brasil appeal to the superior labor court in june the labor attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeal court in it july ruling and requested restriction on lilly brasil asset in brazil in july the labor court issued ruling requiring either freeze of lilly brasil immovable property or alternatively security deposit of million brazilian real approximately million of december lilly brasil filed writ of mandamus challenging this ruling but the court ha stayed it decision on this writ and instead directed the party to attend conciliation hearing process which is ongoing the labor court also stayed the labor attorney application to enforce the previous healthcare coverage ruling until after the appeal court ruled on the various motion pending before it if the conciliation hearing are unsuccessful once concluded we intend to file motion to strike the labor attorney application to enforce the previous healthcare coverage given the appeal court stay in september of number of element of it prior decision described above individual former employee litigationwe are also named in approximately lawsuit filed in the same labor court by individual former employee making similar claim these lawsuit are each at various stage in the litigation process with judgment being handed down in approximately half of the lawsuit nearly all of which are on appeal in the labor court we believe all of these lawsuit are without merit and are defending against them vigorously litigation investigation and inquirieslitigationwe along with sanofi and novo nordisk are named defendant in consolidated purported class action lawsuit in re insulin pricing litigation in the district court of new jersey relating to insulin pricing plaintiff seek damage under various state consumer protection law and the federal racketeer influenced and corrupt organization act federal rico act separately we along with sanofi and novo nordisk are named defendant in msp recovery claim series llc et al sanofi aventis llc et al in the same court seeking damage under various state consumer protection law common law fraud unjust enrichment and the federal rico act also in the same court we along with sanofi and novo nordisk had been named defendant in purported class action lawsuit prof drug co inc fwk holding llc novo nordisk inc et al seeking damage under the federal and new jersey rico act plaintiff in that matter voluntarily dismissed their lawsuit in january the minnesota attorney general office filed complaint against sanofi and novo nordisk state of minnesota sanofi aventis llc et al in the district court of new jersey alleging unjust enrichment and violation of various minnesota state consumer protection law and the federal rico act additionally the kentucky attorney general office filed complaint against sanofi and novo nordisk commonwealth of kentucky novo nordisk inc et al in kentucky state court alleging violation of the kentucky consumer protection law false advertising and unjust enrichment harris county in texas filed complaint against sanofi novo nordisk express script cv optum and aetna county of harris texas eli lilly co et al in federal court in the southern district of texas alleging violation of the federal rico act and rico conspiracy federal and state anti trust law and the state deceptive trade practice consumer protection act harris county also alleges common law claim such fraud unjust enrichment and civil conspiracy this lawsuit relates to our insulin well trulicity we believe all of these claim are without merit and are defending against them vigorously investigation subpoena and inquirieswe have received subpoena from the new york attorney general office and civil investigative demand from the washington new mexico and colorado attorney general office relating to the pricing and sale of our insulin product the office of the attorney general in mississippi washington california florida hawaii and nevada have requested information relating to the pricing and sale of our insulin product we also received interrogatory from the california attorney general office regarding our competition in the long acting insulin market we received two request from the house of representative committee on energy and commerce and request from the senate committee on health education labor and pension seeking certain information related to the pricing of insulin product among other issue we also received request from the house of representative committee on oversight and reform and the senate committee on finance which seek detailed commercial information and business record we are cooperating with all of these aforementioned request and investigation product liability insurancebecause of the nature of pharmaceutical product it is possible that we could become subject to large number of additional product liability and related claim in the future due to very restrictive market for product liability insurance we are self insured for product liability loss for all our currently and previously marketed product other comprehensive income loss the following table summarizes the activity related to each component of other comprehensive income loss continuing operation amount presented net of tax foreign currency translation gain loss unrealized net gain loss on security defined benefit pension and retiree health benefit plan effective portion of cash flow hedge discontinued operation accumulated other comprehensive lossbeginning balance at january other comprehensive income loss before amount reclassified from accumulated other comprehensive other comprehensive income loss of stranded tax effect note balance at december reclassification due to adoption of new accounting standard other comprehensive income loss before reclassification net amount reclassified from accumulated other comprehensive loss other comprehensive income loss at december other comprehensive income loss before reclassification net amount reclassified from accumulated other comprehensive loss other comprehensive income loss ending balance at december accumulated other comprehensive loss of january consists of billion of accumulated other comprehensive loss attributable to controlling interest and million of accumulated other comprehensive income attributable to noncontrolling interest accumulated other comprehensive loss of december consists of billion of accumulated other comprehensive loss attributable to controlling interest and million of accumulated other comprehensive income attributable to noncontrolling interest this reclassification consists of million of accumulated other comprehensive loss attributable to controlling interest and million of accumulated other comprehensive loss attributable to noncontrolling interest refer to note for further detail regarding the reclassification due to the adoption of asu accumulated other comprehensive loss of december consists of billion of accumulated other comprehensive loss attributable to controlling interest and million of accumulated other comprehensive loss attributable to noncontrolling interest tax effect on the net activity related to each component of other comprehensive income loss for the year ended december were follows tax benefit expense currency translation gain loss net gain loss on security benefit pension and retiree health benefit portion of cash flow hedge benefit provision for income tax allocated to other comprehensive income loss item for the tax effect of foreign currency translation gain and loss related to our foreign currency denominated note cross currency interest rate swap and other foreign currency exchange contract designated net investment hedge see note income tax were not provided for foreign currency translation generally the asset and liability of foreign operation are translated into dollar using the current exchange rate for those operation change in exchange rate generally do not affect cash flow therefore resulting translation adjustment are made in shareholder equity rather than in the consolidated statement of operation reclassification out of accumulated other comprehensive loss were follows detail about accumulated other comprehensive loss componentsyear ended december affected line item in the consolidated statement of of retirement benefit item prior service benefit net other net income expenseactuarial net income expensetotal before tax benefit income taxesnet of unrealized gain loss on available for sale security realized gain net other net income expensetax taxesnet of tax other net of tax net income expensereclassifications from continuing operation net of tax reclassification from discontinued operation net of tax income loss from discontinued operationstotal reclassification for the period net of tax other net income expenseother net income expense consisted of the following expense income debt extinguishment loss note gain on sale of antibiotic business in china note retirement benefit other income expense other net income expense for the year ended december and other income wa primarily related to net gain on investment note discontinued operationson september elanco completed it initial public offering ipo resulting in the issuance of million share of it common stock which represented percent of elanco outstanding share at per share in connection with the completion of the ipo through series of equity and other transaction we transferred to elanco the animal health business that formed it business in exchange elanco transferred to consideration of approximately billion which consisted primarily of the net proceeds from the ipo and the net proceeds from billion debt offering and million three year term loan facility entered into by elanco in august the consideration that we received wa used for debt repayment dividend and share repurchase the excess of the net proceeds from the ipo over the net book value of our divested interest wa million and wa recorded in additional paid in capital of december the noncontrolling interest of billion associated with elanco wa reflected in noncontrolling interest in the consolidated balance sheet through march we continued to consolidate elanco we retained control over elanco we completed the disposition of our remaining percent ownership of elanco common stock through tax free exchange offer that closed on on march the disposition date the earnings attributable to the divested noncontrolling interest for the period from the ipo until disposition were not material result of the disposition in the first quarter of we recognized gain related to the disposition of approximately billion and we presented elanco including the gain related to the disposition discontinued operation in our consolidated financial statement for all period presented the following table set summarizes revenue and net income loss from discontinued operation from discontinued operation income loss from discontinued the following table present the major class of asset and liability from discontinued operation at december december current asset asset of discontinued operation goodwill intangible net and equipment net asset asset of discontinued operation current liability of discontinued operation long term debt liability liability of discontinued operation gain related to the disposition of elanco in the consolidated statement of cash flow includes the operating result of elanco through the disposition date which were not material net cash flow of our discontinued operation for operating and investing activity for the year ended december were not material net cash provided by operating activity related to our discontinued operation wa approximately million and million for the year ended december and respectively net cash used by investing activity related to our discontinued operation wa approximately million and million for the year ended december and respectively we entered into transitional service agreement tsa with elanco that is designed to facilitate the orderly transfer of various service to elanco the tsa relates primarily to administrative service which are generally to be provided over month from the disposition date this agreement is not material and doe not confer upon the ability to influence the operating and or financial policy of elanco subsequent to the disposition date selected quarterly data unaudited fourth third second firstrevenue of sale expense ipr impairment restructuring and other special charge before income tax tax income from continuing operation income from discontinued operation income from continuing operation basic from discontinued operation basic basic from continuing operation diluted from discontinued operation diluted diluted paid per share fourth third second firstrevenue of sale expense ipr asset impairment restructuring and other special charge before income tax tax income loss from continuing operation income loss from discontinued operation income loss loss per share from continuing operation basic loss per share from discontinued operation basic loss per share basic loss per share from continuing operation diluted loss per share from discontinued operation diluted loss per share diluted paid per share includes research and development and marketing selling and administrative expense asset impairment restructuring and other special charge in the first quarter of were primarily associated with the accelerated vesting of loxo employee equity award result of the closing of the acquisition of loxo see note for further discussion acquired ipr charge in the second quarter of were primarily due to the armo acquisition see note for further discussion income tax in the fourth quarter of were tax benefit primarily due to adjustment associated with tax reform see note for further discussion our common stock is listed under the ticker symbol lly on the new york stock exchange nyse reportsmanagement report for financial statement eli lilly and company and subsidiariesmanagement of eli lilly and company and subsidiary is responsible for the accuracy integrity and fair presentation of the financial statement the statement have been prepared in accordance with generally accepted accounting principle in the united state and include amount based on judgment and estimate by management in management opinion the consolidated financial statement present fairly our financial position result of operation and cash flow in addition to the system of internal accounting control we maintain code of conduct known the red book that applies to all employee worldwide requiring proper overall business conduct avoidance of conflict of interest compliance with law and confidentiality of proprietary information all employee must take training annually on the red book and are required to report suspected violation hotline number is published in the red book to enable employee to report suspected violation anonymously employee who report suspected violation are protected from discrimination or retaliation by the company in addition to the red book the chief executive officer and all financial management must sign financial code of ethic which further reinforces their ethical and fiduciary responsibility the consolidated financial statement have been audited by ernst young llp an independent registered public accounting firm their responsibility is to examine our consolidated financial statement in accordance with generally accepted auditing standard of the public company accounting oversight board united state ernst young opinion with respect to the fairness of the presentation of the statement is included in item of our annual report on form ernst young report directly to the audit committee of the board of director our audit committee includes five nonemployee member of the board of director all of whom are independent from our company the committee charter which is available on our website outline the member role and responsibility it is the audit committee responsibility to appoint an independent registered public accounting firm subject to shareholder ratification approve both audit and non audit service performed by the independent registered public accounting firm and review the report submitted by the firm the audit committee meet several time during the year with management the internal auditor and the independent public accounting firm to discus audit activity internal control and financial reporting matter including review of our externally published financial result the internal auditor and the independent registered public accounting firm have full and free access to the committee we are dedicated to ensuring that we maintain the high standard of financial accounting and reporting that we have established we are committed to providing financial information that is transparent timely complete relevant and accurate our culture demand integrity and an unyielding commitment to strong internal practice and policy finally we have the highest confidence in our financial reporting our underlying system of internal control and our people who are objective in their responsibility and operate under code of conduct and are subject to the highest level of ethical standard management report on internal control over financial reporting eli lilly and company and subsidiariesmanagement of eli lilly and company and subsidiary is responsible for establishing and maintaining adequate internal control over financial reporting defined in rule and under the security exchange act of we have global financial policy that govern critical area including internal control financial accounting and reporting fiduciary accountability and safeguarding of corporate asset our internal accounting control system are designed to provide reasonable assurance that asset are safeguarded that transaction are executed in accordance with management authorization and are properly recorded and that accounting record are adequate for preparation of financial statement and other financial information staff of internal auditor regularly monitor on worldwide basis the adequacy and effectiveness of internal accounting control the general auditor report directly to the audit committee of the board of director we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission on our evaluation under this framework we concluded that our internal control over financial reporting wa effective of december however because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate the internal control over financial reporting ha been assessed by ernst young llp of december their responsibility is to evaluate whether internal control over financial reporting wa designed and operating effectively david rick joshua smileychairman president and chief executive officer senior vice president and chief financial officerfebruary of independent registered public accounting firmto the board of director and shareholder of eli lilly and companyopinion on the financial statementswe have audited the accompanying consolidated balance sheet of eli lilly and company and subsidiary the company of december and the related consolidated statement of operation comprehensive income loss shareholder equity and cash flow for each of the three year in the period ended december and the related note collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon adoption of accounting standard update asu no discussed in note to the consolidated financial statement the company changed it method of accounting for the recognition of income tax consequence of intra entity transfer of asset other than inventory in due to the adoption of asu no intra entity transfer of asset other than inventory topic using the modified retrospective adoption method basis for opinionthese financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit matter the critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate medicaid managed care and medicare sale rebate accrualsdescription of the matter described in note to the consolidated financial statement under the caption revenue recognition the company establishes provision for sale rebate and discount in the same period the related sale occur at december the company had million in sale rebate and discount accrual large portion of these accrual are rebate associated with sale in the united state for which payment for purchase of the product is covered by medicaid managed care and medicare auditing the medicaid managed care and medicare sale rebate and discount liability is challenging because of the subjectivity of certain assumption required to estimate the rebate liability in calculating the appropriate accrual amount the company considers historical medicaid managed care and medicare rebate payment by product percentage of their historical sale well any significant change in sale trend the lag in payment timing an evaluation of the current medicaid and medicare law and interpretation the percentage of product that are sold via medicaid managed care and medicare and product pricing for medicaid there is significant complexity associated with calculating the legislated medicaid rebate management utilizes employee with legislative experience and knowledge in developing assumption used to calculate medicaid rebate similarly for managed care and medicare given variability in prescription drug cost continued historical year over year increase in enrollee and variability in prescription data historical rebate information may not be predictive for management to estimate the rebate accrual and thus management supplement it historical data analysis with qualitative adjustment based upon current utilization how we addressed the matter in our audit we tested the company control addressing the identified risk of material misstatement related to the valuation of the sale rebate and discount liability this included testing control over management review of the significant assumption used to calculate the medicaid managed care and medicare rebate liability including the significant assumption discussed above this testing also included management control to compare actual activity to forecasted activity and control to ensure the data used to evaluate the significant assumption wa complete and accurate our audit procedure included among others evaluating for reasonableness the significant assumption in light of economic trend product profile and other regulatory factor our testing involved assessing the historical accuracy of management estimate by comparing actual activity to previous estimate and performing analytical procedure based on internal and external data source to evaluate the completeness of the reserve additionally our procedure included reviewing sample of contract testing sample of rebate payment and testing the underlying data used in management evaluation for medicaid we involved our professional with an understanding of the statutory reimbursement requirement to ass the consistency of the company calculation methodology with the applicable government regulation and policy for medicare we evaluated the reasonableness of assumption made by management in estimating the medicare coverage gap liability retirement benefit valuation of alternative investmentsdescription of the matter described in note to the consolidated financial statement under the caption benefit plan investment the company benefit plan investment policy are set with specific consideration of return and risk requirement in relationship to the respective liability at december the company had million in plan asset related to the defined benefit pension plan and retiree health benefit plan approximately of the total pension and retiree asset are in hedge fund and private equity like investment fund alternative investment these alternative investment are valued using significant unobservable input or are valued at net asset value nav reported by the counterparty adjusted necessary auditing the fair value of these alternative investment is challenging because of the higher estimation uncertainty of the input to the fair value calculation including the underlying net asset value navs discounted cash flow valuation comparable market valuation and adjustment for currency credit liquidity and other risk additionally certain information regarding the fair value of these alternative investment is based on unaudited information available to management at the time of valuation we addressed the matter in our audit we tested the company control addressing the risk of material misstatement relating to valuation of alternative investment this included testing management review control over alternative investment valuation which included comparison of return to benchmark and in person or telephonic meeting with investment firm to discus valuation policy and procedure our audit procedure included among others comparing fund return to selected relevant benchmark and understanding variation obtaining the latest audited financial statement and comparing to the company estimated fair value and reconciling any difference we also inquired of management about change to the investment portfolio and or related investment strategy and consideration we assessed the historical accuracy of management estimate by comparing actual activity to previous estimate we evaluated for contrary evidence by confirming the fair value of the investment and ownership interest directly with the trustee and sample of manager at year end valuation of intangible asset related to the loxo oncology loxo acquisitiondescription of the matter described in note to the consolidated financial statement in february the company completed it acquisition of loxo oncology inc loxo for purchase price of billion net of cash acquired result of the acquisition the company acquired pipeline of investigational medicine including loxo an oral ret inhibitor that ha been granted breakthrough therapy designation by the food and drug administration loxo wa accounted for an indefinite lived in process research and development ipr asset and valued at billion auditing the valuation of the loxo ipr asset wa complex because of the significant estimation uncertainty in determining the fair value of the asset the fair value determination is based on discounted cash flow model using certain assumption for which there is high subjectivity such revenue growth probability of technical success and discount rate these significant assumption are forward looking and could be affected by future economic and market condition further the estimated fair value of the ipr asset wa sensitive to change in these assumption how we addressed the matter in our audit we tested the company control addressing the identified risk of material misstatement related to the valuation of the ipr asset for example we tested control over management review of the significant assumption used to calculate the valuation of the intangible asset acquired including forecast of future cash flow and review of the valuation model our audit procedure included among others obtaining an understanding of management approach to developing the probability of technical success and evaluating the reasonableness by comparing to analyst expectation historical result of similar product in development and industry trend to the extent applicable we also evaluated the reasonableness of the projected revenue growth used within the valuation against analyst expectation industry trend market trend other market information and identified contrary evidence we involved our valuation specialist to evaluate the discounted cash flow model used by the company and to test the discount rate utilized in the company valuation lastly we evaluated the appropriateness of the company related disclosure we have served the company auditor since indianapolis indianafebruary of independent registered public accounting firmto the board of director and shareholder of eli lilly and companyopinion on internal control over financial reportingwe have audited eli lilly and company and subsidiary internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion eli lilly and company and subsidiary the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of operation comprehensive income loss shareholder equity and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate indianapolis indianafebruary change in and disagreement with accountant on accounting and financial disclosurenone item control and proceduresdisclosure control and proceduresunder applicable security and exchange commission sec regulation management of reporting company with the participation of the principal executive officer and principal financial officer must periodically evaluate the company disclosure control and procedure which are defined generally control and other procedure designed to ensure that information required to be disclosed by the reporting company in it periodic report filed with the sec such this form is recorded processed summarized and reported on timely basis our management with the participation of david rick president and chief executive officer and joshua smiley senior vice president and chief financial officer evaluated our disclosure control and procedure of december and concluded that they were effective internal control over financial reportingmr rick and mr smiley provided report on behalf of management on our internal control over financial reporting in which management concluded that the company internal control over financial reporting is effective at december in addition ernst young llp the company independent registered public accounting firm provided an attestation report on the company internal control over financial reporting of december you can find the full text of management report and ernst young attestation report in item change in internal controlsduring the fourth quarter of there were no change in our internal control over financial reporting that materially affected or are reasonably likely to materially affect our internal control over financial reporting item other informationnone iiiitem director executive officer and corporate governancedirectors and executive officersinformation relating to our board of director is found in our definitive proxy statement to be dated on or about march the proxy statement under board of director and is incorporated in this report by reference information relating to our executive officer is found at item business executive officer of the company code of ethicsinformation relating to our code of ethic is found in our proxy statement under code of ethic and is incorporated in this report by reference corporate governanceinformation about the procedure by which shareholder can recommend nominee to our board of director is found in our proxy statement under director qualification and nomination process and is incorporated in this report by reference the board ha appointed an audit committee consisting entirely of independent director in accordance with applicable sec and new york stock exchange rule for audit committee information about our audit committee is found in our proxy statement under audit committee and is incorporated in this report by reference section reporting complianceinformation about our compliance with section is found in our proxy statement under other matter delinquent section report and is incorporated in this report by reference item executive compensationinformation on director compensation executive compensation and compensation committee matter can be found in the proxy statement under director compensation committee of the board of director compensation committee compensation discussion and analysis and executive compensation that information is incorporated in this report by reference security ownership of certain beneficial owner and management and related stockholder matterssecurity ownership of certain beneficial owner and managementinformation relating to ownership of the company common stock by management and by person known by the company to be the beneficial owner of more than five percent of the outstanding share of common stock is found in the proxy statement under ownership of company stock that information is incorporated in this report by reference security authorized for issuance under equity compensation plansthe following table present information of december regarding our compensation plan underwhich share of lilly common stock have been authorized for issuance plan category number of security to be issued upon exercise of outstanding option warrant and right weighted average exercise price of outstanding option warrant and right number of security remaining available for future issuance under equity compensation plan excluding security reflected in column equity compensation plan approved by security holder compensation plan not approved by security holder total share are underlying outstanding equity award other than option item certain relationship and related transaction and director independencerelated person transactionsinformation relating to the board policy and procedure for approval of related person transaction can be found in the proxy statement under highlight of the company corporate governance conflict of interest and transaction with related person that information is incorporated in this report by reference director independenceinformation relating to director independence can be found in the proxy statement under director independence and is incorporated in this report by reference item principal accountant fee and servicesinformation related to the fee and service of our principal independent accountant ernst young llp can be found in the proxy statement under item proposal to ratify the appointment of principal independent auditor audit committee report service performed by the independent auditor and independent auditor fee that information is incorporated in this report by reference exhibit and financial statement schedule financial statementsthe following consolidated financial statement of the company and it subsidiary are found at item consolidated statement of operation year ended december and consolidated statement of comprehensive income loss year ended december and consolidated balance sheet december and consolidated statement of shareholder equity year ended december and consolidated statement of cash flow year ended december and note to consolidated financial statement financial statement schedulesthe consolidated financial statement schedule of the company and it subsidiary have been omitted because they are not required are inapplicable or are adequately explained in the financial statement financial statement of interest of percent or le which are accounted for by the equity method have been omitted because they do not considered in the aggregate single subsidiary constitute significant subsidiary agreement and plan of merger dated january among eli lilly and company bowfin acquisition corporation and loxo oncology inc amended article of incorporation bylaw amended indenture with respect to debt security dated of february between eli lilly and company and deutsche bank trust company america successor trustee to citibank trustee agreement dated september appointing deutsche bank trust company america successor trustee under the indenture listed above description of common stock description of the company eur note due eur note due and eur note due description of the company note due description of the company note due description of the company eur note due and eur note due amended and restated lilly stock plan form of performance award under the lilly stock plan form of shareholder value award under the lilly stock plan form of relative value award under the lilly stock plan restricted stock unit award to michael harrington under the lilly stock plan the lilly deferred compensation plan amended the lilly director deferral plan amended the eli lilly and company bonus plan amended the eli lilly and company executive officer incentive plan change in control severance pay plan for select employee amended list of subsidiary consent of independent registered public accounting firm rule certification of david rick chairman president and chief executive officer rule certification of joshua smiley senior vice president and chief financial officer section certification interactive data file cover page interactive data file formatted inline xbrl and contained in exhibit indicates management contract or compensatory plan item form summarynot applicable to exhibitsthe following document are filed part of this report exhibit location agreement and plan of merger dated january among eli lilly and company bowfin acquisition corporation and loxo oncology inc incorporated by reference to exhibit to the current report on form filed by loxo oncology on january amended article of incorporation incorporated by reference to exhibit to the company report on form for the year ended december bylaw amended bylaw amended are incorporated by reference to exhibit to the company report on form dated on december indenture with respect to debt security dated of february between eli lilly and company and deutsche bank trust company america successor trustee to citibank trustee incorporated by reference to exhibit to the company registration statement on form registration no agreement dated september appointing deutsche bank trust company america successor trustee under the indenture listed above incorporated by reference to exhibit to the company report on form for the year ended december description of the company common stock attached description of the company eur note due eur note due and eur note due attached description of the company note due attached description of the company note due attached description of the company eur note due and eur note due attached amended and restated lilly stock plan incorporated by reference to exhibit to the company report on form for the quarter ended june form of performance award under the lilly stock plan attached form of shareholder value award under the lilly stock plan attached form of relative value award under the lilly stock plan attached restricted stock unit award to michael harrington under the lilly stock plan attached the lilly deferred compensation plan amended incorporated by reference to exhibit to the company report on form for the year ended december the lilly director deferral plan amended incorporated by reference to exhibit to the company report on form for the quarter ended june the eli lilly and company bonus plan amended incorporated by reference to exhibit to the company report on form for the year ended december the eli lilly and company executive officer incentive plan incorporated by reference to appendix to the company proxy statement on schedule filed march change in control severance pay plan for select employee amended incorporated by reference to exhibit to the company report on form for the quarter ended september list of subsidiary attached consent of registered independent public accounting firm attached rule certification of david rick chairman president and chief executive officer attached rule certification of joshua smiley senior vice president and chief financial officer attached section certification attached interactive data file attached cover page interactive data file formatted inline xbrl and contained in exhibit to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized eli lilly and companyby david ricksdavid rickschairman president and chief executive officerfebruary to the requirement of the security exchange act of this report ha been signed below on february by the following person on behalf of the registrant and in the capacity indicated signature title david rick chairman president and chief executive officer principal executive officer david rick joshua smiley senior vice president and chief financial officer principal financial officer joshua smiley donald zakrowski vice president finance and chief accounting officer principal accounting officer donald zakrowski ralph alvarez directorralph alvarez katherine baicker ph directorkatherine baicker ph carolyn bertozzi ph directorcarolyn bertozzi ph michael eskew directormichael eskew erik fyrwald directorj erik fyrwald jamere jackson directorjamere jackson william kaelin jr directorwilliam kaelin jr juan luciano directorjuan luciano marschall runge ph directormarschall runge ph kathi seifert directorkathi seifert jackson tai directorjackson tai karen walker directorkaren walker used in this reporttrademarks or service mark owned by eli lilly and company or it affiliate when first used in this report appear with an initial capital and are followed by the symbol or applicable in subsequent us of the mark in the report the symbol may be omitted actos is trademark of takeda pharmaceutical company limited byetta is trademark of amylin pharmaceutical inc glyxambi jardiance jentadueto synjardy trajenta and trijardy are trademark of boehringer ingelheim gmbh posilac is trademark of union agener and elanco inc qbrexza is trademark of dermira inc viagra is trademark of pfizer inc copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next